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A Abstract 
1 Abstract 
When a T cell gets activated by antigen, 1-100 cells per one million T cells give rise to 
a population of antigen-specific effector cells within a few days. The T cells proliferate 
vigorously and induce many physiological changes to fully develop an effector 
phenotype. Two complexes formed by the mammalian/mechanistic target of 
rapamycin, mTORC1 and mTORC2 have been found to be in the center of integrating 
external signals and translating them into cellular changes on the level of transcription, 
translation and cell growth.  
Even though it is known that both RNA Polymerase I and T cell proliferation are 
regulated by mTORC1 a direct correlation between ribosomal RNA synthesis and 
proliferation has not been investigated so far. 
This study asked whether TCR signaling induces mTORC1-dependent ribosomal RNA 
synthesis and thus proliferation in primary T cells. Therefore, in vitro and in vivo studies 
were performed comparing mTORC1 sufficient with deficient T cells, showing a TCR 
induced activation of mTORC1-signaling being highly reduced in mTORC1 deficient T 
cells. This resulted in less proliferation of polyclonal and TCR transgenic mTORC1 
deficient T cells in graft-versus-host responses, a lower response upon transient TCR 
stimuli and lower cell expansion early and late upon a viral infection with the modified 
Vaccinia Ankara virus expressing ovalbumin (MVA-OVA). Furthermore, homeostatic 
survival and lymphopenic proliferation was reduced in the absence of mTORC1. 
In vitro applications with a specific inhibitor of RNA Polymerase I, quarfloxin, 
demonstrated that T cell proliferation requires de novo synthesis of ribosomal RNA at 
both the initial transition from G0 to G1 and the transition from G1 to S phase cell cycle 
checkpoint of the consecutive divisions. Total RNA sequencing and directly assessing 
relative RNA expression by flow cytometry with the dye Pyronin Y revealed that 
mTORC1-signaling is essential for ribosomal as well as global RNA expression in 
primary T cells. 
Our data indicate a major role of ribosomal RNA for the clonal expansion of T cells. 
RNA Polymerase I is being seen as a potential target in cancer therapy. However, its 
inhibition may have side effects that may cause a transient immunodeficiency. 
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Based on previously published data in Rabenstein et al., 2014, in a second project a 
transcriptional repressor, the Krüppel associated box (KRAB) domain, was tested in 
iOVA mice and mice infected with MHV-68_OVA. Since the KRAB domain was fused 
to the DNA-binding domain of the tet-repressor a negative regulation of the expression 
of genes under the control of the tet-operator was detected. In kinetic studies as well 
as functional analysis of antigen-exposed OT-I T cells we showed that the repressing 
function of the KRAB domain did improve the leaky expression of Kb/OVA257-264 under 
the control of the tet-operator in iOVA mice. 
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2 Zusammenfassung 
Wenn eine T-Zelle durch fremdes Antigen aktiviert wird, sind es lediglich wenige 
hundert Zellen unter Millionen aus denen sich eine große Population antigen-
spezifischer Effektorzellen bildet. Dieser Prozess dauert nur wenige Tage und erfordert 
deshalb eine schnelle Expansion und physiologische Anpassung der T-Zellen. Zwei 
Proteinkomplexe, in deren Zentrum sich das mammalian/mechanistic target of 
Rapamycin (mTOR) befindet, mTORC1 und mTORC2, spielen eine tragende Rolle bei 
der Integration und Übersetzung von externen Signalen. Während einer Infektion 
werden diese in zelluläre Prozesse der Transkription, Translation und Wachstum 
umgewandelt.  
Obwohl bekannt ist, dass sowohl die Aktivität der RNA Polymerase I als auch T-Zell 
Proliferation von mTORC1 reguliert wird, wurde der Zusammenhang ribosomaler RNA-
Synthese  mit Proliferation bislang nicht untersucht. 
Ziel dieser Studie ist es, den Zusammenhang von T-Zellrezeptor-induzierter und 
mTORC1-abhängiger ribosomaler RNA-Synthese mit der Proliferation von primären T-
Zellen zu untersuchen. 
In diesem Zusammenhang wurden Experimente sowohl in vitro als auch in vivo mit T-
Zellen aus mTORC1-defizienten und Kontroll-Tieren durchgeführt. Diese zeigten eine 
geringere Zellteilung von adoptiv transferierten mTORC1-defizienten polyklonalen und 
TCR transgenen T-Zellen in Graft-versus-Host Reaktionen auf. Zudem konnte eine 
geringere Reaktion auf transiente TCR-Stimuli und eine reduzierte Zellexpansion als 
Antwort auf eine Infektion mit dem Virus MVA-OVA (Modified Vaccinia Ankara Virus, 
welches Ovalbumin exprimiert) zu frühen und späten Zeitpunkten festgestellt werden. 
Auch war das homöostatische Überleben und die Proliferation unter lymphopenischen 
Bedingungen in diesen Zellen stark reduziert. 
Eine in vitro Behandlung von Wildtyp-T-Zellen mit Quarfloxin, einem Inhibitor gegen die 
Aktivität der RNA Polymerase I, konnte aufzeigen, dass proliferierende T-Zellen stark 
von einer kontinuierlichen Synthese ribosomaler DNA abhängig sind, sowohl beim 
anfänglichen Übergang von G0 zu G1 als auch beim Übergang von G1 zur S-Phase der 
darauffolgenden Zellteilungen. Anhand von Sequenzierungsdaten von Gesamt-RNA, 
und der direkten Visualisierung der relativen RNA-Expression mittels 
Durchflusszytometrie anhand des Farbstoffs Pyronin Y, konnte ein direkter 
Zusammenhang zwischen mTORC1-Aktivität und ribosomaler wie auch globaler RNA-
Expression, ermittelt werden. 
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Unsere Daten deuten auf eine tragende Rolle der ribosomalen RNA bei der klonalen 
Expansion von T-Zellen hin, wobei die RNA-Polymerase I selbst bereits als 
potenzielles Ziel in der Krebstherapie untersucht wird. Mögliche Nebenwirkungen wie 
zum Beispiel vorübergehende Immundefekte können hierbei jedoch nicht 
ausgeschlossen werden. 
 
Ausgehend von einer im Jahr 2014 publizierten Studie von Rabenstein et al., wurde in 
einem weiteren Projekt die Auswirkungen des tet-Repressors KRAB (Krüppel-
associated box) auf die Genexpression von OVA257-264 in iOVA Mäusen bzw. MHV-
68_OVA infizierten Mäusen untersucht. Da die KRAB-Domäne mit der DNA-
Bindedomäne des Tet-Repressors fusioniert war, konnte eine negative Regulation der 
unter dem Tet-Operator exprimierten Gene detektiert werden. In Experimenten 
hinsichtlich der Kinetik von Antigen-Expression sowie funktionelle Analysen von 
Antigen-stimulierten OT-I T-Zellen konnte im Rahmen dieser Arbeit eine Verbesserung 
der Expressionskontrolle des Peptids OVA257-264 gezeigt werden. 
 
 
 
  
B Introduction 
5 
B Introduction 
1 T cells in the context of immune response 
In order to fight pathogens, vertebrates have developed two conceptual systems to 
generate a successful host-pathogen defense – innate and adaptive immunity.  
Whereas innate immune cells show a broad spectrum of recognition mediated via 
pattern recognition receptors (PRRs), cells of the adaptive immune system have high 
antigen specificity, inducing a humoral, antibody-mediated and cellular T and B 
lymphocyte response.  
T cell progenitors originate from the bone marrow and mature in the thymus into single 
positive CD4+ and CD8+ T cells with distinct effector functions. While CD4+ T cells can 
develop into several subsets with distinct T helper cell characteristics (e.g. Th1, Th2, 
Th17, Treg, etc.), CD8+ T cells show a lower level of plasticity and mainly develop a 
cytotoxic function, killing pathogen-infected or neoplastic cells. 
For CD8+ T cells, precursor frequencies between 1 and 100 cells per 106 cells were 
found, whereas the numbers for CD4+ T cells were around five times lower (Jenkins & 
Moon, 2012; Nelson et al., 2015; Obst, 2015). These few antigen-specific T cells 
expand vigorously upon T cell receptor ligation and develop an effector function, which 
enables the clearance of a pathogen within days. What follows is a contraction of 
clones where around 90% of all antigen-specific T cells die. The few survivors remain 
as memory T cells and provide protection in case of a secondary infection with the 
same pathogen (Kaech & Cui, 2012; Masopust & Schenkel, 2013). 
1.1 T cell development 
T cells develop in the thymus. Lymphoid progenitor cells leave the bone marrow and 
migrate into the cortex of the thymus via blood vessels, expressing neither CD4 nor 
CD8 on their surface. These cells are called double negative (DN) thymocytes. DN 
thymocytes can be further distinguished by the expression of CD44 and CD25 on their 
surface. DN1 thymocytes are CD44+ and CD25-. Upon expression of CD25 and 
downregulation of CD44, DN1 thymocytes develop into DN3 cells, passing the DN2 
(CD44+, CD25+) state. In DN3 cells, a RAG1- and RAG2-dependent rearrangement of 
the TCRβ-chain takes place. The successful TCRβ rearrangement, expression and 
pairing with the pTα-chain induces the DN4 stage, including the formation of the pre-
TCR in complex with CD3 molecules. The signaling via the pre-TCR induces cell 
survival and proliferation. With the fixation of the β-chain locus of the TCR, CD4 and 
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CD8 molecules are getting upregulated on the surface of the cell defining them as 
double positive. DP cells rearrange the TCRα-chain loci to build the αβ-TCR. They 
subsequently interact with self-peptide major histocompatibility complex (MHC)-
encoded proteins on thymus-specific antigen-presenting cells, the cortical thymus 
epithelial cells (cTECs). Those cells that bind self-peptide MHC with an appropriate 
affinity get positively selected and enter the medulla of the thymus. Cells that bind with 
a weak or no affinity die of apoptosis (around 85%). In the medulla, cells undergo 
negative selection induced by the interaction with self-peptide MHC on medullar TECs 
(mTECs) or other antigen presenting cells (APCs) such as dendritic cells, B cells and 
macrophages (MΦ). DP cells that interact too strong with self-peptide MHC undergo 
further differentiation or apoptosis, those that survive develop into naïve single positive 
CD4+ or CD8+ T cell, depending to which MHC class the T cell binds (Starr et al., 
2003). 
Most of the T cells in the thymus give rise to αβ T cells. Nevertheless, 5% develop into 
γδ T cells, mainly located in the skin and mucosal tissue (Jameson et al., 2002). This 
thesis focuses on αβ T cells. 
1.2 Antigen recognition by the T cell receptor 
Antigen recognition by T cells is a prerequisite for a successful immune response. It 
induces a cascade of biophysical, biochemical and genetic reactions that enables 
proliferation and thus the clonal expansion of antigen specific T cells. The cell cycle of 
proliferating T cells is perhaps among the fastest cell divisions in adult mammals 
(Mayya & Dustin, 2016; Obst, 2015). 
T cells recognize pathogen-derived antigens in the context of MHC polymorphic 
proteins expressed on the surface of antigen presenting cells via their T cell receptor. 
The MHC genes are organized in a multigenic region called H-2 in mice and Human 
Leucocyte Antigen (HLA) in humans. CD4+ T cells recognize peptides bound to MHC 
class II (MHC-II) proteins (H-2A, H-2E in mice and HLA-DP, -DM, -DOA, -DOB, -DQ 
and -DR in humans), CD8+ T cells respond to peptides in the context of MHC class I 
(MHC-I) proteins (H-2D, H-2K and in some strains H-2L in mice; HLA-A, -B and -C in 
humans).  
MHC-I and -II are structurally different and peptide loading is mediated via different 
mechanisms.  
MHC-I is loaded with peptides from cytosolic proteins e.g. from viral origin, which are 
degraded by the proteasome, transported into the endoplasmatic reticulum (ER) and 
loaded on MHC-I by TAP. Peptides associated with MHC-II originate from extracellular 
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proteins internalized by an APC by endo-, pino- or phagocytosis. Internalized proteins 
are enzymatically processed in the lysosome and loaded on MHC-II in late endosomes, 
in exchange of CLIP (class II-associated invariant chain peptide), which is removed 
from the peptide-binding groove of MHC-II. Whereas MHC-I is expressed on the 
surface of all nucleated cells, MHC-II can only be found on B cells, 
macrophages/monocytes and dendritic cells (Wieczorek et al., 2017). 
1.3 T cell receptor signaling 
The interaction between the TCR and cognate peptide MHC (pMHC) complexes on an 
APC induces the activation of a mature T cell. It requires a stable contact that has to 
last for ~24 hours. It allows the T cell to stop migrating and thus to proliferate at the site 
of infection (Bousso & Robey, 2003; Mempel et al., 2004). 
The TCR is a heterodimer, consisting of a TCRα- and β-chain. It associates with the 
CD3 complex that is formed with one δ-chain, one γ-chain, two ε-chains and two ζ-
chains. The intracellular located immunoreceptor tyrosine based activating motifs 
(ITAMs) of the ε- and ζ-chains are phosphorylated upon TCR ligation. 
Upon T cell receptor stimulation, a cascade of signals is induced. An early event is the 
recruitment of LCK (SRC family kinase) to the cytosolic domain of CD4 and CD8, 
which are associated with the TCR. LCK phosphorylates the ζ-chain of the TCR and 
thus allows ZAP70 to bind. In turn, ZAP70 phosphorylates LAT, which recruits multiple 
adaptor and effector molecules to the TCR and thereby induces three major signaling 
pathways. First, the Ca2+-Calcineurin dependent pathway, which leads to a 
translocation of NFAT into the nucleus, second, the mitogen-activated protein kinase 
(MAPK)-pathway that activates the transcription factors Fos, Jun and AP-1 and third, 
the NFκB signaling pathway. In combination with co-stimulation, T cell proliferation, 
differentiation and effector cell generation is induced (Gaud et al., 2018).  
One of these co-stimulatory signaling molecules is CD28, expressed on the surface of 
T cells. If bound by CD80 or CD83 expressed by an APC, it induces PI3K, which in turn 
can phosphorylate PIP3. PIP3 activates PDK1, which phosphorylates Akt on threonine 
308. Akt phosphorylates TSC2 and thus induces the release of TSC2 from TSC1, 
which in complex negatively regulate RHEB. The release of RHEB allows it to bind and 
activate mTORC1 (Inoki et al., 2003a; Pollizzi & Powell, 2015; Tee et al., 2003; Zoncu 
et al., 2011). Whether Akt is the only kinase upstream of mTORC1 or if there are 
additional pathways inducing it is yet unknown (Finlay et al., 2012).  
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1.4 T cell effector function 
Upon infection, CD4+ and CD8+ T cells become activated in secondary lymphoid 
organs by APCs within days. Both cell types start to proliferate vigorously and show 
highly distinguishable effector functions. Whereas CD8+ T cells develop into cytotoxic T 
lymphocytes (CTLs), CD4+ T cells can differentiate into several distinct T helper (Th) 
cell types. The expression of well-defined key transcription factors and cytokines 
induces the development into different subpopulations of the CD4+ Th cell 
compartment (O'Shea & Paul, 2010).  
Th1 and Th2 cells were the first subsets defined by Mosmann and colleagues in 1986 
(Mosmann & Coffman, 1989). Th1 cells are induced by the expression of the 
transcription factor T-bet and the cytokine IFNγ. As main producers of IFNγ, they 
induce an effective destruction of microbial pathogens by (a) phagocytic cells such as 
macrophages, (b) the cytotoxicity of NK cells and (c) the production of Immunoglobulin 
(Ig) G by B cells. Furthermore, the expression of IL-2 increases the number of effector 
T cells by inducing proliferation (Pipkin et al., 2010; Schroder et al., 2004).  
Th2 cell differentiation occurs in the presence of IL-4 that triggers the expression of the 
transcription factor GATA-3 (Nair et al., 2006). Th2 cells mediate the immune response 
against parasites at epithelial barriers and mucosal tissue by recruiting mast cells or 
inducing a class switch to IgE in B cells (Abbas et al., 1996; Grogan et al., 2001). 
Over one decade later, two additional subpopulations of CD4+ T cells were described, 
regulatory T cells (Tregs) and Th17 cells (Aggarwal et al., 2003; Sakaguchi, 2000). 
Th17 cells show a characteristic production of IL-17A, IL-17E, IL-22 and IL-21. Not only 
do they promote protective immunity against extracellular bacteria and fungi at 
mucosal surfaces, but are also involved in autoimmunity and inflammatory disease. 
They are induced by IL-6 and/or IL-21 and express the transcription factor RorγT. (Lee 
et al., 2009; Miossec et al., 2009). 
Tregs are important to maintain central tolerance by producing IL-10 and TGFβ (von 
Boehmer, 2005). They are characterized by the expression of the transcription factor 
FoxP3 and CD25, the high affinity IL-2Rα-chain. They very strongly rely on IL-2 and 
TGFβ signaling (Josefowicz & Rudensky, 2009; Sakaguchi et al., 2008). 
More recently, T follicular helper (Tfh) cells were described as CD4+ T cells expressing 
CXCR5 and ICOS on their surface. Their key transcription factor is Bcl6. They produce 
high amounts of IL-21 and are involved in promoting germinal center responses and B 
cell class switching (Crotty, 2014; Vinuesa et al., 2016). 
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CD8+ T cells show a lower variety and plasticity regarding their cell fate decision. 
Nevertheless, two different populations can be observed upon activation: The short-
lived effector cells (SLECs) and memory precursor effector cells (MPECs). SLECs give 
rise to cells mainly carrying a cytotoxic function directly eliminating virus infected or 
neoplastic cells and are not very long lasting, whereas MPECs serve as precursors for 
long-lasting memory cells, beside their function as effector cells. Upon TCR stimulation 
CTLs start to produce IFNγ as well as perforin, IL-2 and granzymes (Cruz-Guilloty et 
al., 2009; Joshi et al., 2007). 
1.5 T cell memory formation and causes of exhaustion 
Upon the clearance of a pathogen, T cells enter a phase in which more than 90% of 
the effector T cells generated during clonal expansion die, the phase of clonal 
contraction. Those that survive can remain for months or even years, defined as 
memory T cells (Badovinac et al., 2002). They are characterized by a rapid secondary 
response to pathogens with a high proliferative capacity. Both CD4+ and CD8+ memory 
T cells rely on the presence of IL-7 for long-term maintenance. Furthermore, IL-15 is 
described as being essential for CD8+ memory T cell sustainability (Jameson, 2002; 
Kaech & Cui, 2012; McKinstry et al., 2012). 
In chronic infections and in cancer, specific T cells lose their effector function and fail to 
differentiate into functional memory cells due to exhaustion (Wherry et al., 2007). This 
term is used for the progressive and hierarchical loss of effector function, a sustained 
upregulation and co-expression of multiple inhibitory receptors, an altered expression 
and use of key transcription factors, metabolic derangements and a failure to transit 
into quiescence (Doering et al., 2012; Schietinger & Greenberg, 2014; Wherry, 2011). 
Exhausted T cells were described in mice and humans (Gallimore et al., 1998; 
Schietinger & Greenberg, 2014; Wherry et al., 2003; Zajac et al., 1998). They show a 
differential expression pattern of surface markers such as PD-1, KLRG-1, CD44, Ly6C, 
CD122 and CD127 as well as the transcription factors EOMES and T-bet (Paley et al., 
2012; Wherry et al., 2007). Furthermore, they have a unique transcriptomic and 
epigenetic footprint by which they can be differentiated from effector or memory T cells 
(Crawford et al., 2014; Doering et al., 2012; Wherry et al., 2007; Youngblood et al., 
2011; Zhang et al., 2014a).  
In the past decade, CD8+ T cell exhaustion was extensively studied in chronic 
infections such as LCMV clone 13 in numerous mouse models, but also in pathogen-
free animals. Chronic antigen exposure was found to be the central cause for T cell 
exhaustion (Han et al., 2010; Wherry et al., 2003). It was shown that exhausted T cells 
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very much rely on antigen persistence with a faster turnover than T memory cells (Shin 
et al., 2007).  
Persistent antigen presentation can induce several mechanisms interfering with the 
functionality of a T cell. Among these is the expression of inhibitory receptors on the 
surface of a T cell and the desensitization of co-stimulatory pathways. Inhibitory 
receptors were originally described as negative regulators to prevent from 
autoreactivity and immunopathology (Sharpe et al., 2007). An increased expression 
was also detected in exhausted T cells. Center of several studies became the inhibitory 
receptor PD-1 (Araki et al., 2013; Odorizzi & Wherry, 2012). It is very often co-
expressed with other inhibitory receptors such as LAG-3, 2B4, CD160, TIM3 and 
CTLA-4 (Blackburn et al., 2009). Combined therapies interfering with their signaling 
pathway by monoclonal antibodies were found to have promising effects on tumor 
control (Wolchok et al., 2013). 
Furthermore, soluble mediators such as IL-10, TGFβ, Type I interferons and IL-6 can 
drive and promote exhaustion (Wherry & Kurachi, 2015). Source of such mediators can 
be regulatory T cells (Veiga-Parga et al., 2013). On the other hand a general loss of 
CD4+ T helper cells can lead to an even more severe exhaustion phenotype in CD8+ T 
cells (Matloubian et al., 1994).  
In 2014, Crawford, Wherry and others were able to describe T cell exhaustion in CD4+ 
T cells. They defined CD4+ exhausted T cells as a subset not only distinct from CD4+ T 
effector and memory cells, but also CD8+ exhausted T cell. Nevertheless, some 
common features such as the expression of inhibitory receptors are shared (Brooks et 
al., 2010; Crawford et al., 2014; Han et al., 2010). 
The mechanisms responsible for the shift from memory precursor into exhaustion 
precursor cells were in the focus of more recent studies, showing a high plasticity 
among exhausted T cells (Hashimoto et al., 2018; Im et al., 2016; Utzschneider et al., 
2016; Wu et al., 2016). 
2 Metabolic demands of T cells 
During T cell development, the metabolic requirements and availabilities of nutrients 
change drastically. Thus, metabolic pathways have to be engaged or suppressed in 
order to guide activation and differentiation. The two main pathways that supply 
adenosine triphosphate (ATP) within a cell are glycolysis and oxidative phosphorylation 
(OXPHOS). They are accompanied by fatty acid oxidation (FAO) and glutaminolysis 
(Geltink et al., 2018).  
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Naïve T cells show very low glucose utilization and mainly rely on OXPHOS as their 
energy source. Upon encountering their cognate antigen on an APC, TCR signaling 
induces a metabolic switch from OXPHOS to glycolysis for ATP production in T effector 
cells. Nevertheless mitochondrial metabolism is still active to produce calcium-
dependent reactive oxygen species (ROS), which is essential for T cell activation. 
Although anaerobic glycolysis is less efficient in generating ATP than OXPHOS, a 
switch into this metabolic pathway allows lipids and other amino acids to be redirected 
into the generation of biomass to support cell division (Gerriets & Rathmell, 2012; 
Jones & Thompson, 2007). 
Unlike T effector cells, Treg and Tmem cells show a downregulation of glycolysis and 
more rely on FAO and OXPHOS (Gerriets & Rathmell, 2012). Th17 cells use de novo 
FAO as energy source (Berod et al., 2014).  
The serine/threonine protein kinase mammalian/mechanistic target of rapamycin, short 
mTOR is a central molecule that mediates physiological changes dependent on 
metabolic changes in a cell (Geltink et al., 2018).  
3 The mechanistic target of rapamycin, mTOR 
The mTOR homolog TOR (Target of rapamycin) was first discovered in yeast by 
Heitman, Moova and Hall in 1991 (Heitman et al., 1991). Its name originates from the 
fungal toxin rapamycin, an antifungal, antibiotic product by Streptomyces 
hygroscopicus that was found to block the transition from G1 to S phase in fungi (Singh 
et al., 1979).  
TOR was described as being the functional target of FKBP12-bound rapamycin 
(Cafferkey et al., 1993; Koltin et al., 1991). Two complexes formed by TOR, TORC1 
(TOR1, TOR2, KOG1, LST8) and TORC2 (TOR2, AVO1, AVO2, AVO3, LST8) were 
described, with homologues in mammalian cell lines (Loewith et al., 2002). Their 
differential sensitivity to rapamycin, with only TORC1 being sensitive to this toxin, 
revealed the essential contribution of TORC1 to G1 progression and cell growth (Barbet 
et al., 1996; Helliwell et al., 1994; Kunz et al., 1993; Loewith et al., 2002). 
The mammalian target of rapamycin (mTOR) was described in mammalian cell lines in 
two independent studies. Like TOR in yeast, it is sensitive to FKBP12-rapamycin 
(Brown et al., 1994; Sabatini et al., 1994; Sabers et al., 1995). The application of 
rapamycin in experiments performed in mammalian cell lines allowed for the 
identification of mTOR signaling components. Thus, it was shown that, like in yeast, 
mTOR is part of two distinct protein complexes, mTORC1 and mTORC2. Both 
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complexes have distinct activation signals, molecular targets and functions in mammal 
cells (Hara et al., 2002; Sarbassov et al., 2004).  
3.1 The composition of mTORC1 and mTORC2 
Besides several common components such as the scaffolding protein mLST8, the 
regulatory subunit DEPTOR and the Tti1/Tel2 complex, which is necessary for the 
assembly and stability, each complex also contains distinct components. mTORC1 is 
defined by being associated with the scaffolding protein Raptor as well as the negative 
regulator PRAS40, which is released upon growth factor receptor signaling. Rictor and 
mSin1 are mTORC2 specific components. Rictor mainly mediates mTORC2 assembly, 
stability, substrate identification and localization; mSin1 acts as negative regulator of 
the mTORC2 kinase activity until PI3K signaling induces the recruitment of mSin1 to 
the plasma membrane and release from mTORC2 (Aylett et al., 2016; Sarbassov et al., 
2004; Yang & Chi, 2013) (Fig. B1 A). T cells with deletions of the Rictor and Rptor 
genes were used in this thesis. 
3.2 Downstream targets of mTORC1 
Cell growth and division is accompanied by an increased glucose metabolism and 
synthesis of proteins, lipids and nucleotides but also by the suppression of catabolic 
pathways such as protein turnover and autophagy. mTORC1 is central to processes 
coordinating anabolism and catabolism in proliferating cells (Saxton & Sabatini, 2017) 
(Fig. B1 B). 
Among others, the two molecules S6K1 and 4E-BP1 have been described as direct 
targets of mTORC1. Their phosphorylation at Threonine-389 (S6K1) and Threonine-
36/45 (4E-BP1) and thus activation is sensitive to inhibition by rapamycin (Brown et al., 
1995; Burnett et al., 1998; Hara et al., 2002; Kim et al., 2002).  
Protein synthesis is mainly regulated via these two molecules. Their activity shapes the 
binding of translation elongation factors to 5’ TOP mRNA, including mostly genes 
related to protein synthesis (Saxton & Sabatini, 2017). S6K1 can phosphorylate 
substrates that can either promote or inhibit mRNA translation, therefore inducing their 
activation and degradation, respectively. The positive regulator of 5’ cap binding eIF4F 
complex, eIF4B can be activated by S6K1 (Holz et al., 2005). In contrast, the 
degradation of PDCD4, an inhibitor of this complex, can be facilitated by S6K1 
(Dorrello et al., 2006). The negative regulator of translation, 4E-BP1 is directly 
phosphorylated by mTORC1 and thus dissociates from the eIF4E complex. This allows 
the translation of 5’ cap-dependent mRNA (Brunn et al., 1997; Gingras et al., 1999).  
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The translational activity relies on the synthesis and activity of ribosomes. mTORC1 
can regulate ribosome synthesis via its downstream targets TIF-IA (also known as 
Rrn3) and Ubf. These RNA Polymerase I specific transcription factors play major roles 
controlling the transcriptional and translational machinery by regulating the 
transcription of ribosomal ribonucleic acid (rRNA) (Claypool et al., 2004; Hannan et al., 
2003; Mayer et al., 2004). Upon inhibition of Akt or mTOR in T cells, the binding 
capacity of RNA Polymerase I as well as the processing of pre-rRNA were found to be 
limited, which led to reduced rRNA synthesis and ribosome biogenesis (Chan et al., 
2011).  
Nucleotide synthesis is crucial for DNA replication and ribosome synthesis and 
therefore growth and proliferation of a cell. mTORC1 induces the expression and 
activation of key components of the purine and pyrimidine synthesis (Ben-Sahra et al., 
2016; Robitaille et al., 2013). 
Fatty acid and cholesterol biosynthesis is regulated via the sterol responsive element 
binding protein (SREBP) (Porstmann et al., 2008). mTORC1 phosphorylates Lipin1, a 
negative regulator of SREBP (Duvel et al., 2010; Peterson et al., 2009). Furthermore, 
mTORC1 can induce an increased translation of the transcription factor HIF1a, which 
drives the expression of glycolytic transporters and enzymes (Duvel et al., 2010; 
Powell et al., 2012). 
Another function of mTORC1 is the negative regulation of protein degradation by 
autophagy and ubiquitination. Under conditions where nutrients are available, 
mTORC1 phosphorylates ULK1 and thus prevents its binding to a complex driving the 
autophagosome formation, thereby inhibiting it (Kim et al., 2011). Moreover, mTORC1 
phosphorylates the transcription factor EB (TFEB), which in turn blocks the 
translocation of TFEB to the nucleus and the induction of genes, necessary for the 
autophagy machinery and lysosomal biogenesis (Martina et al., 2012; Roczniak-
Ferguson et al., 2012; Settembre et al., 2011; Settembre et al., 2012).  
It was recently demonstrated that proteasome-dependent proteolysis is associated with 
mTORC1 activity. When mTORC1 is inhibited for a limited time frame, global protein-
ubiquitination and the expression of proteasomal chaperones are increased (Rousseau 
& Bertolotti, 2016; Zhao et al., 2015). However, an increase of proteasomal activity was 
also detected in cells with hyperactivated mTORC1 activity, indicating different 
outcomes of acute versus prolonged inhibition of the mTORC1 signaling pathways 
(Zhang et al., 2014b) (Fig B1 C). 
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3.3 Upstream activators of mTORC1 
A shift from catabolism in the direction of anabolism can be induced by a series of 
growth-promoting, endocrine signals. They are related to the stress and energy status 
of a cell and to the availability of oxygen and amino acids (Ananieva et al., 2014; 
Laplante & Sabatini, 2012; Saxton & Sabatini, 2017; Zoncu et al., 2011).  
mTORC1 is described as downstream mediator of several growth factors via the 
Tuberous Sclerosis Complex (TSC), a negative regulator of mTOR (Saxton & Sabatini, 
2017). TSC functions as GTPase activating protein (GAP). Upstream signaling by 
several growth factors induces the dissociation of TSC from the GTPase Rheb, which 
allows an interaction of Rheb with mTORC1 and thus activates the Serin/Threonine 
kinase activity of mTORC1. Such upstream signals can be insulin or insulin-like growth 
factor-1, Ras, Wnt and TNFα, which induce either PI3K or AMPK dependent signaling 
and thus phosphorylation of the heterodimeric subunits of TSC, TSC1 or TSC2 
(Garami et al., 2003; Inoki et al., 2003a; Inoki et al., 2003b; Long et al., 2005; Manning 
et al., 2002; Menon et al., 2014; Sancak et al., 2010; Sancak et al., 2008; Tee et al., 
2003).  
Furthermore, mTORC1 can respond to signals interfering with cell growth such as low 
ATP levels, hypoxia, DNA damage responses and glucose deprivation. Low ATP levels 
and glucose deprivation regulate mTORC1 via two different mechanisms: through 
inhibition of the Rag GTPase and activation of AMPK (Efeyan et al., 2013; Gwinn et al., 
2008; Inoki et al., 2003b; Kalender et al., 2010; Shaw et al., 2004). In addition, AMPK 
activation and thus mTORC1 inhibition can be induced by hypoxia and DNA damage-
responses (Brugarolas et al., 2004; Feng et al., 2007). 
Amino acids are essential building blocks for proteins and energy source of several 
metabolic pathways (Saxton & Sabatini, 2017). Changes in amino acid provision can 
be sensed by mTORC1-mediated mechanisms, if mTORC1 is translocated to the 
cytosolic side of the lysosome. It was demonstrated that the role of mTORC1 on 
lysosomal function relies on PI3K signaling induced by insulin on the one hand and the 
availability of amino acids on the other hand. If the amino acid arginine gets 
transported into the lysosome by SLC38A9, mTORC1 can bind to the Rag GTPases 
RagC and D, located in the lysosome in a complex formed with RagA/B and the 
guanine nucleotide exchange factor (GEF) Ragulator (Wang et al., 2015). Furthermore, 
mTORC1 induces the phosphorylation of the transcription factor EB (TFEB), which in 
turn blocks the translocation of TFEB to the nucleus and the induction of genes, 
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necessary for autophagy in the lysosome (Settembre et al., 2011; Settembre et al., 
2012).  
Several negative and positive regulators of mTORC1 were defined in studies 
addressing the role of mTORC1 on lysosomal function. PRAS40 binds to mTORC1 if 
not phosphorylated by Akt/PKB and inhibits the phosphorylation of S6K1 and cell 
growth (Sancak et al., 2007). In addition FLCN-FNIP complex was described to bind to 
RagC/D in starved cells and thus blocks the binding of mTORC1 to RagC/D (Tsun et 
al., 2013). GATOR1 and GATOR2 were found to have opposite effects on mTORC1 
with GATOR1 functioning as GTPase activating protein (GAP) for RagA and hence as 
negative regulator of mTORC1 (Bar-Peled et al., 2013). GATOR2 activates mTORC1 
and is recruited by KICSTOR and regulated by CASTOR1 and Sestrine2 if leucin is 
bound (Chantranupong et al., 2014; Saxton et al., 2016; Wolfson et al., 2016; Wolfson 
et al., 2017) (Fig B1 C). 
 
Most of the studies on the function of mTORC1 were performed in yeast or mammalian 
cell lines. Nevertheless, mTORC1 was also found to play a major role in T cell 
activation, differentiation and effector function (Powell et al., 2012). Among the signals 
described above, signaling via the TCR in combination with co-stimulatory molecules 
can induce mTORC1 activity. This upstream signal is unique in T cells (Pollizzi & 
Powell, 2015; Powell et al., 2012).  
3.4 mTORC1 in T cells 
Also in T cells S6K1 and 4E-BP1 were described as downstream targets of the 
serine/threonine kinase activity of mTORC1 (Hukelmann et al., 2016; Yang et al., 2013; 
Zeng et al., 2013).  
One of the main features of mTOR is the induction of the metabolic switch from 
OXPHOS to glycolysis, called Warburg effect (Fox et al., 2005; Jones & Thompson, 
2007; MacIver et al., 2013; van der Windt & Pearce, 2012; Vander Heiden et al., 2009). 
Resting T cells are found to be in a catabolic state. Upon stimulation, T cells become 
anabolic and switch to glycolysis and nutrient uptake.  
PI3K signaling by the co-stimulatory receptor CD28 leads to Akt activation and thus the 
expression of glucose transporters via mTORC1 (Frauwirth et al., 2002; Frauwirth & 
Thompson, 2002, 2004; Macintyre et al., 2014; Powell et al., 2012). 
The question of how mTORC1 signaling affects T cell differentiation was mainly 
addressed by inhibiting mTORC1 signaling with the very potent inhibitor rapamycin or 
in T cells with deleted signaling components of mTORC1.  
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It was found that T cells with abrogated mTORC1 activity proliferated less than 
wildtype cells in response to in vitro stimulation with anti-CD3/28 or cognate peptide as 
well as in vivo upon adoptive transfer into irradiated or RAG-deficient mice (Delgoffe et 
al., 2009a; Delgoffe et al., 2009b; Delgoffe et al., 2011; He et al., 2011; Tan et al., 
2017a; Tan et al., 2017b; Yang et al., 2013; Zeng et al., 2013; Zhang et al., 2011). 
Furthermore, a decrease in cell size was found early upon stimulation, indicating that 
mTORC1 plays a crucial role in T cell growth and proliferation (Pollizzi et al., 2015; 
Yang et al., 2013). 
 
It was shown that mTORC1 and mTORC2 are both critical for T helper cell 
development and fate decision. T cells in mice with mTOR-deficiency were not able to 
develop into Th1, Th2 or Th17 cells. Instead, an increase in the FoxP3+ T cell 
compartment was detected even under normal stimulation conditions (Delgoffe et al., 
2009b). Further studies using mice deficient in the mTORC1 activator Rheb showed 
more specifically that mTORC1 regulates the development of Th1 and Th17 cells in in 
vitro stimulation assays. Adoptively transferred OT-II T cells in mice infected with 
Vaccinia-OVA failed to express IFNγ, IL-17 as well as the transcription factors GATA-3 
and Rorγt. Furthermore, EAE scores and Th17 infiltrates were significantly reduced in 
mice carrying Rheb-deficient T cells. The same study showed that Th2 differentiation 
relies on mTORC2 signaling, since in vitro stimulated Rictor-deficient T cells failed to 
express IL-4 under Th2 skewing conditions (Delgoffe et al., 2011; Lee et al., 2010). 
Nevertheless, in T cells with compromised mTORC1 signaling by Raptor-deficiency, an 
impaired development of the Th2 phenotype was found (Yang et al., 2013). Even 
though mTOR-deficient T cells tend to develop into a regulatory T cell phenotype, the 
same was not true in T cells with abrogated mTORC1 function. In T cells deficient for 
either Rheb or Raptor, Treg cells were found to rely on mTORC1 activity to program 
and maintain their metabolic and suppressive function (Delgoffe et al., 2011; Zeng et 
al., 2013). 
The contribution of mTORC1 on memory formation was mainly studied in in vitro 
stimulated CD8+ T cells. T memory cell numbers were increased upon transient 
mTORC1-inhibition with rapamycin; anergy in turn was decreased (Araki et al., 2009; 
Jenkins, 1992; Pearce et al., 2009; Powell et al., 1999; Rao et al., 2010). Nevertheless, 
long-term inhibition of mTORC1 abrogated memory formation (Li et al., 2012).  
Recent studies developed a correlation between mTORC1 activity and the active 
regulation of the translational activity in T cells. Proteomic analysis of rapamycin-
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treated P14 cells in vitro differentiated into CTLs with cognate peptide, showed lower 
global protein levels. A reduction was mainly found in proteins associated with 
cytotoxicity and glycolysis as well as ribosomal proteins and translation factors 
associated with protein synthesis mainly encoded by 5’ TOP mRNA (Hukelmann et al., 
2016; Thoreen et al., 2012). Similar results were detected in Raptor-deficient T cells 
stimulated in vitro with anti-CD3/28 for 16 hours (Tan et al., 2017a). Moreover, 
signaling from the TCR is crucial for ribosome synthesis and translation as shown in 
OT-I T cells deficient for the TCR signaling molecule Lck, stimulated with cognate 
peptide in vitro (Tan et al., 2017b). A further study on P14 CD8+ T cells, adoptively 
transferred into mice infected with LCMV Armstrong, showed an active regulation of 
translational activity by the increase of mRNA bound to polysomes. When treated with 
rapamycin, less mRNA encoding for ribosomal proteins was bound to polysomes. 
Furthermore, a TCR-dependent increase in polysome-bound mRNA was detected in 
experiments comparing responses to the acute LCMV strain Armstrong versus the 
chronic strain clone 13 on day eight, indicating that antigen persistence affects 
translational regulation (Araki et al., 2017). 
 
 
Figure B1: The mammalian 
Target of Rapamycin - mTOR.  
(A) The structure of mTORC1 
and mTORC2. 
(B) mTORC1 controls the 
balance between catabolism and 
anabolism. 
(C) The major upstream and 
downstream targets of mTORC1. 
Modified from (Saxton & Sabatini, 
2017) 
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4 Cell cycle in T cells 
The cell cycle is a highly regulated, universal and conserved process in eukaryotic cells 
leading to the reproduction of a cell. This event can be divided into the S phase, in 
which the DNA of a cell is replicated and mitosis (M phase), in which the DNA is 
separated and partitioned in two daughter cells. S and M phase are separated by two 
gap phases: G1 before and G2 after S phase. In addition, most cells remain in a 
quiescent state in which they do not proliferate, the G0 phase. Upon activation, these 
cells can enter the cell cycle into G1 phase. The most critical event of a cell cycle is the 
replication and partitioning of the hereditary material, the DNA, during the S phase. A 
quantification of the DNA content of a cell helps to distinguish G1 from S and G2/M 
phase (Nurse, 2000; Pardee, 1989). 
In T cells, the cell cycle and proliferation plays a central role for activation and 
accompanies the differentiation of fully functional effector cells (Kaech & Cui, 2012; 
Masopust & Schenkel, 2013). 
In 1980, Darzynkiewicz et al. demonstrated that not only the DNA, but also the RNA 
content of a cell changes during proliferation (Darzynkiewicz et al., 1980). By 
visualizing DNA and RNA in several cell types including phytohaemagglutinin-
stimulation of blood cells by acridine orange in flow cytometry, a better distinction of 
quiescent cells in G0 and cells in G1 was achieved compared to the forward scatter 
parameter (Darzynkiewicz et al., 1980). One year later, Shapiro described the 
xanthene homolog of acridine orange, Pyronin Y as RNA-staining dye which could 
eliminate technical challenges accompanied with acridine orange staining, allowing 
RNA visualization in intact cells (Shapiro, 1981). Since then, Pyronin Y has 
occasionally been used to study the cell cycle in proliferating cells (Behbehani et al., 
2012; Challen et al., 2009; Challen & Goodell, 2008; Crissman et al., 1985; Cui et al., 
2003; Darzynkiewicz et al., 2004; Janumyan et al., 2003; Nakamura-Ishizu et al., 2014; 
Passegue et al., 2005; Qiu et al., 2013; Schmid et al., 2000). Quiescent, non-
proliferating cells remain in G0, characterized by diploid DNA and low RNA content. 
Upon stimulation, T cells enter G1 still having a diploid DNA content but increased RNA 
expression. From there, cells pass into the S-phase, in which they double their DNA 
content to 4n, but also increase their amount of RNA. The S-Phase is followed by G2 
and than the M phase when the genetic material and other macromolecules are 
distributed the two daughter cell. A critical regulation points in cell cycle that often 
dictates the speed of proliferation is the transition from G1 to S phase (Darzynkiewicz et 
al., 1980; Pardee, 1989; Shapiro, 1981).  
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Later on, specific molecules were defined characteristic for the transition into certain 
cell cycle phases. In this course, c-myc and the retinoblastoma protein were described 
as being critical for transitioning from G1 to S phase (Sage et al., 2000; Schorl & 
Sedivy, 2003; Weinberg, 1995). Furthermore, cyclins and cyclin-dependent kinases 
were defined as universal cell cycle regulators (Nurse, 2000).  
In later studies, Dowling et al. used a transgenic mouse system, the FUCCI mouse, 
containing a red fluorescent reporter expressed during G1 phase and a green 
fluorescent reporter expressed from the beginning of S phase to study the kinetics of 
cell cycle transitions in primary T cells in vitro (Dowling et al., 2014). 
In combination with in vivo performed studies using the cell division-sensitive 
fluorescent vital dye CFSE to asses the cell proliferation, gave closer insights on the 
duration of one cell cycle in a T cell. The time a T cell needs to complete one cell cycle 
is between ten and twelve hours in vitro and quite faster (four to eight hours depending 
on the intensity and duration of the TCR stimulus) in vivo (Dowling et al., 2014; 
Lawrence & Braciale, 2004; Yoon et al., 2010; Yoon et al., 2007).  
5 RNA expression in T cells 
In highly proliferative cells, approximately 80% of transcription is invested into 
ribosome synthesis (Moss et al., 2007; Moss & Stefanovsky, 2002; Warner, 2001). 
Ribosomes consist of 28S, 18S, 5.8S and 5S ribosomal RNA and 92 proteins. 2-300 
proteins are involved in processing and assembly of ribosomes in the nucleolus. The 
first three named rRNAs have a common precursor, the 47S rRNA. The expression of 
this precursor is regulated via RNA Polymerase I. RNA Polymerase III regulates the 
expression of 5S rRNA (Moss et al., 2007; Warner, 2001). The production of ribosomes 
starts at the end of mitosis, increases during G1- and has its maximum during G2-phase 
(Gebrane-Younes et al., 1997). Molecules that drive cell cycle progression are the 
cyclin-dependent kinases (CDKs). Cdk1 negatively regulates the expression of RNA 
Polymerase I at the beginning of mitosis by phosphorylating RNA polymerase I specific 
transcription factors, thus preventing DNA binding (Sirri et al., 1999).  
Metabolism and specific environmental challenges are responsible for the regulation of 
the transcription of rRNA genes (Derenzini et al., 1998; Hannan et al., 1998). The 
MAPK-dependent activation of TIF-IA and UBF are the initial signals to induce RNA 
Polymerase I. In association with fibrillarin and nucleophosmin they serve essential 
functions in rRNA maturation (Grummt & Langst, 2013; Voit et al., 1999). Newly 
synthesized RNA is processed and assembled in subnuclear structures called nucleoli.  
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6 The nucleolus 
The nucleolus is a sub-compartment in the nucleus, which mediates the early steps of 
ribosome biogenesis and the assembly as well as function of non-ribosomal 
ribonucleoprotein complexes. It controls cell cycle progression and senses 
environmental stress. The nucleolar morphology changes depending on the 
transcriptional activity of a cell and in turn dictates nuclear pathways that affect 
transcription, replication and DNA repair. Thus it is a key player regulating cell growth, 
survival, senescence and stress responses (Hutten et al., 2011; Pederson, 2010).  
The nucleolus is composed of three compartments: the fibrillar centers (FC), dense 
fibrillar centers (DFC) and granular components (GC) (Scheer & Hock, 1999). The 
transcription of rRNA genes by RNA Polymerase I occurs at the interface between FCs 
and DFCs, while processing of pre-rRNA and assembly with ribosomal proteins takes 
place in the GC of the DFC (Nemeth & Grummt, 2018; Thiry et al., 2011). The 
mammalian nucleolus is remarkably plastic and reorganizes during each cell cycle. The 
early event of nucleolar assembly starts at the telophase of the mitoses and occurs 
during a relatively long period of the cell cycle. It depends on the coordination between 
the transcription of rDNA and the expression of RNA processing complexes. During S-
Phase, RNA Polymerase I is transiently released from rDNA to prevent collision with 
the replication machinery. With entry of the mitotic metaphase, the nucleolus 
disassembles which allows nucleolar proteins to associate with the surface of 
metaphase chromosomes (Hernandez-Verdun et al., 2002; Smirnov et al., 2016). 
7 Aims of this thesis 
It has been shown that mTORC1 serves as a mediator of extracellular signals and cell 
functionality. In T cells, T cell receptor stimulation induces mTORC1 activity, which is 
indispensable for rapid T cell proliferation. Furthermore, mTORC1 regulates the 
expression of transcription factors associated with RNA Polymerase I activity and thus 
the expression of ribosomal RNA. If this also affects proliferation in T cells is not fully 
understood, yet. This study addresses the question whether there is a direct correlation 
between mTORC1-dependet RNA Polymerase I activity and thus ribosomal RNA 
biosynthesis and proliferation in T cells. This hypothesis was tested, by (I) analyzing 
the requirement of mTORC1 activity for T cell proliferation in vivo, (II) the global and 
ribosomal RNA synthesis in mTORC1-deficient T cells in vitro and (III) showing a direct 
correlation between RNA Polymerase I activity and proliferation.  
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In a second project, the Krüppel-associated box KRAB, fused to the DNA-binding 
domain of the tet-repressor was used to improve the leaky peptide expression in iOVA 
mice, a new model for transient antigen expression in vivo. Thus, functional analysis of 
OT-I T cells in response to cognate antigen expression was tested in the presence of 
the KRAB repressor. Furthermore, a doxycycline-inducible OVA257-264 expressing virus 
was created and tested under the absence or presence of the Krüppel-associated box-
domain. With these approaches, the influence of persistent antigen-presentation in 
comparison to transient antigen-stimuli on CD8+ T cell development was tested under 
non-inflammatory conditions. 
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C Material and Methods 
1 Material 
1.1 Chemicals and Solutions 
2-Deoxy-D-Glucose Sigma-Aldrich, St. Louis, MO, USA now: Merck, 
Kenilworth, NJ, USA 
2-Mercaptoethanol  Carl Roth, Arlesheim, Switzerland  
Actinomycin D Hölzel Diagnostika GmbH, Köln, Germany 
Agarose Peqlab, Erlangen, Germany 
Antibiotic/antimycotic GE Healthcare, Chalfont St Giles, UK  
Brefeldin A Sigma-Aldrich, St. Louis, MO, USA now: Merck, 
Kenilworth, NJ, USA 
Casy ton Roche, Basel, Switzerland 
4′,6-diamidino-2-phenylindole 
(DAPI) 
Invitrogen, Carlsbad, CA, USA 
DMEM (Powderly et al.) AppliChem, Darmstadt, Germany 
DMSO Sigma-Aldrich, St. Louis, MO, USA now: Merck, 
Kenilworth, NJ, USA 
dNTPs Peqlab, Erlangen, Germany 
Doxycycline AppliChem, Darmstadt, Germany 
EDTA (Gibco) Life Technologies, Carlsbad, CA, USA 
Ethanol Diagonal, Münster, Germany 
Ethidium bromide (1% solution) AppliChem, Darmstadt, Germany 
FCS (Gibco) Life Technologies, Carlsbad, CA, USA 
Ficoll (PAA) GE Healthcare, Chalfont St Giles, UK  
FVD (eIFlour450, eIFlour660, 
eIFluor780)  
eBioscience, San Diego, CA, USA  
Gelatin Sigma-Aldrich, St. Louis, MO, USA now: Merck, 
Kenilworth, NJ, USA 
Gene ruler (Fermentas) Thermo Fisher Scientific, Waltham, MA, USA  
Glycerin AppliChem, Darmstadt, Germany 
HEPES (PAA) GE Healthcare, Chalfont St Giles, UK    
Ionomycin Diagonal, Münster, Germany 
Isopropanol Diagonal, Münster, Germany 
L-Glutamine (PAA) GE Healthcare, Chalfont St Giles, UK 
H2O AppliChem, Darmstadt, Germany 
Orange G Sigma-Aldrich, St. Louis, MO, USA now: Merck, 
Kenilworth, NJ, USA 
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OVA257-264 Peptides & Elephants, Potsdam, Germany  
Paraformaldehyde Diagonal, Münster, Germany 
PCR Buffer Peqlab, Erlangen, Germany 
PCR Enhancer Peqlab, Erlangen, Germany 
Perm Buffer III BD Phosphoflow BD, Franklin Lakes, NJ, USA 
PMA Diagonal, Münster, Germany 
Proteinase K Diagonal, Münster, Germany 
Pyronin Y Sigma-Aldrich, St. Louis, MO, USA now Merck, 
Kenilworth, NJ, USA 
Quarfloxin Hölzel Diagnostika GmbH, Köln, Germany 
RBC Lysis Buffer   Biolegend, San Diego, CA, USA 
RPMI 1640 +  GlutaMAX 
Supplement 
Life Technologies, Carlsbad, CA, USA 
RPMI 1640 Methionin-free Life Technologies, Carlsbad, CA, USA 
Streptavidin (APC-Cy7, PE) Biolegend, San Diego, CA, USA 
Taq polymerase  Peqlab, Erlangen, Germany 
Tigecyclin Sigma-Aldrich, St. Louis, MO, USA now: Merck, 
Kenilworth, NJ, USA 
Torin 1 Hölzel Diagnostika GmbH, Köln, Germany 
TRIS AppliChem, Darmstadt, Germany  
Triton X-100 (Fluka)  Sigma-Aldrich, St. Louis, MO, USA now: Merck, 
Kenilworth, NJ, USA 
Trizol LS reagent Life Technologies, Carlsbad, CA, USA 
Trypan Blue Carl Roth, Arlesheim, Switzerland 
Volvic, Water Danone Waters, Frankfurt, Germany 
 
1.2 Buffers and Media  
Agarosegel (1%) 
 Agarose 1.5 g 
TAE (1x) 150 mL 
  Ethidiumbromid 
 H2O 7,44 mL 
Ethidiumbromid (1%) 650 µL 
  Cell Transfer Buffer 
 DMEM 
 HEPES 10mM 
  CFSE/CTV staining medium 
 
C Material and Methods 
24 
PBS (1x) 
 BSA 0.1% 
  
DMEM (pH 7.0) 
 H2O add up to 1 L 
DMEM (w/v) 
 Natriumhydrogencarbonat 3.7 g 
HEPES 10 mL 
BSA 50 mL out of 20% 
  Doxycyclin (20 mg/mL) 
 H2O (Volvic) add up to 50 mL 
Doxycyclin 1 g 
  FACS-Medium 
 DMEM 
 HEPES 10 mM 
BSA (w/v) 1% 
  GeneRuler 
 Marker 100 µL 
1x TAE 700 µL 
Loading buffer (6x) 200 µL 
  DNA isolation buffer (10x) 
 H2O 
 TRIS, pH 8,8 670 mM 
(NH4)2SO4 166 mM 
MgCl2 65 mM 
Gelatin 0.1% 
  Loading Buffer (6x) 
 Orange G 250 mg 
Glycerin (30%) 30 mL 
H2O 70 mL 
  MACS Buffer 
 PBS (1x) 
 BSA (w/v) 0.5% 
EDTA 1mM 
  Paraformaldehyde pH 7.4 (4%) 
 H2O add up to 100 mL 
Paraformaldehyde 4g 
PBS (10x) 10 mL 
  PCR Mastermix 
 H2O   
PCR Buffer 1x 
PCR Enhancer 0.5x 
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Oligonucleotide 1 0.5 µM 
Oligonucleotide 2 0.5 µM 
dNTPs 0.2 mM 
Taq polymerase 0.026 U/µL 
  PBS (1x) 
 H2O add up to 1 L 
PBS (10x) 100 mL 
  PBS (10x) 
 H2O add up to 1 L 
NaCl 90 g 
Na2HPO4x2H2O 14.33 g 
KH2PO4 2.17 g 
  TAE (1x) 
 H2O add up to 1 L 
TAE (50x) 20 mL 
  TAE (50x) 
 H2O add up to 1 L 
TRIS Base 242 g 
Acetic acid (99%) 57.1mL 
EDTA, pH8 (0.5 M) 100 mL 
  Tissue digestion buffer 
 H2O 
 DNA isolation buffer 1x 
Triton-X-100 0.5% 
Proteinase K 0.3 mg/mL 
  TE 
 H2O 
 TRIS, pH 7,6 10mM 
EDTA 1mM 
  T cell medium / RPMI Full 
 RPMI 1680 GlutaMAX 
 FCS (w/v) heat inactivated 0.1% 
Antibiotic/Antimycotic (100x) 1x 
2-Mercaptoethanol 5 µM 
  
  Trypan Blue Solution (10x) 
 PBS 
 Trypan Blue (w/v) 0.05% 
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1.3 Oligonucleotides 
Oligonucleotides for mice genotyping were purchased from Eurofins MWG Operon, 
Ebersberg, Germany. 
Target Primer name Sequences (5' - 3') 
OT-I RO459 CAGCAGCAGGTGAGACAAAGT 
 RO460 GGCTTTATAATTAGCTTGGTCC 
 
CD45.1 RO489 CATGGGGTTTAGATGCAGGA 
 RO490 GCAAGGCAGGATGCTAGAAA 
 
CD45.2 RO484 GAGCCTGTATCTAAACCTGAGT 
 RO487 GGCAACATGCCCCTTAACT 
 
Ii-rTA RO281 GTCTCAGAAGTGGGGGCATA 
 RO282 GGACAGGCATCATACCCACT 
 
TIM RO235 CTCATCTCAAACAAGAGCCA 
 RO236 CACTGCTTACTTCCTGTACC 
 
TSO RO267 TGTAAGCTCTTGGGGAATGG 
 RO268 TGGAGGGTGTCGGAATAGAC 
 
KRAB 
 
RO405 GAGTGGAAGCTGCTGGACAC 
 RO406 CAGGATGGGTCTCTTGGTGA 
Raptor RO291 ATGGTAGCAGGCACACTCTTCATG 
 RO292 GCTAAACATTCAGTCCCTAATC 
 
Rictor RO293 TTATTAACTGTGTGTGGGTTG 
 RO294 CGTCTTAGTGTTGCTGTCTAG 
 
CD4-cre RO289 TGTGGCTGATGATCCGAATA 
 RO290 GCTTGCATGATCTCCGGTAT 
 
NR4 RO445 CGGGTCAGAAAGAATGGTGT 
 RO446 CAGTTTCAGTCCCCATCCTC 
R26 RO599 AAGACCGCAAGAGTTTGTC 
 RO600 AAAGTCGCTCTGAGTTGTTAT 
 RO601 GGAGCGGGAGAAATGGATATG 
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1.4 Antibodies 
specificity conjugate species Isotype Clone Company 
CD3 purified arm. 
hamster 
IgG1 145-2C11 BioXcell, West Lebanon, 
NH, USA 
CD4 bio rat IgG2a, κ RM4-5 Biolegend, San Diego, 
CA, USA 
CD4 PE rat IgG2a, κ RM4-5 eBioscience, San Diego, 
CA, USA now: Thermo 
Fischer Scientific, 
Waltham, MA, USA 
CD4 Al647 rat IgG2b, κ Gk1.5 eBioscience, San Diego, 
CA, USA now: Thermo 
Fischer Scientific, 
Waltham, MA, USA 
CD4 Al647 rat IgG2a, κ RM4-5 Biolegend, San Diego, 
CA, USA 
CD8a Al647 rat IgG2a, κ 53-6.7 Biolegend, San Diego, 
CA, USA 
CD8a PerCP rat IgG2a, κ 53-6.7 Biolegend, San Diego, 
CA, USA 
CD8a bio rat IgG2a, κ 53-6.7 Biolegend, San Diego, 
CA, USA 
CD11b bio rat IgG2b, κ M1/70 Biolegend, San Diego, 
CA, USA 
CD11c bio arm. 
hamster 
IgG N418 Biolegend, San Diego, 
CA, USA 
CD16/32  
(Fc-block) 
purified rat IgG2a, λ 93 eBioscience, San Diego, 
CA, USA now: Thermo 
Fischer Scientific, 
Waltham, MA, USA 
CD28 purified syrian 
hamster 
IgG2 37.51 BioXcell, West Lebanon, 
NH, USA 
      
CD40 purified rat IgG2a FGK4.5 BioXcell, West Lebanon, 
NH, USA 
CD44 PE-Cy7 rat IgG2b, κ IM7 eBioscience, San Diego, 
CA, USA now: Thermo 
Fischer Scientific, 
Waltham, MA, USA 
CD45.1 PE-Cy7 mouse IgG2a, κ A20 Biolegend, San Diego, 
CA, USA 
CD45.1 PerCP/Cy5.5 mouse IgG2a, κ A20 Biolegend, San Diego, 
CA, USA 
CD45.2 APC mouse IgG2a, κ 104 Biolegend, San Diego, 
CA, USA 
CD45R bio rat IgG2a, κ RA3-6B2 Biolegend, San Diego, 
CA, USA 
CD49b bio rat IgM, κ DX5 Biolegend, San Diego, 
CA, USA 
CD62L PE rat IgG2a, κ MEL-14 Biolegend, San Diego, 
CA, USA 
CD69 PE arm. 
Hamster 
IgG H1.2F3 
 
Biolegend, San Diego, 
CA, USA 
CD73 PE rat IgG1, κ TY/11.8 iolegend, San Diego, CA, 
USA 
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CD71 PE rat IgG2a, κ RI7217 Biolegend, San Diego, 
CA, USA 
CD90.1 Al647 mouse IgG1, κ OX-7 Biolegend, San Diego, 
CA, USA 
CD127 PE rat IgG2a, κ A7R34 eBioscience, San Diego, 
CA, USA now: Thermo 
Fischer Scientific, 
Waltham, MA, USA 
CD183 
(CXCR3) 
PE arm. 
Hamster 
IgG CXCR3-
173 
Biolegend, San Diego, 
CA, USA 
CD279 (PD-
1) 
     
Histone H3-P 
(Ser28) 
Al488 rat IgG2a, κ HTA28 Biolegend, San Diego, 
CA, USA 
IFNγ APC rat IgG1, κ XMG1.2 eBioscience, San Diego, 
CA, USA now: Thermo 
Fischer Scientific, 
Waltham, MA, USA 
Isotype 
control 
Al488 rat IgG2a, κ RTK2758 Biolegend, San Diego, 
CA, USA 
Isotype 
control 
Al488 rabbit IgG  DA1E eBioscience, San Diego, 
CA, USA now: Thermo 
Fischer Scientific, 
Waltham, MA, USA 
Ly6C FITC rat IgM, κ AL-21 eBioscience, San Diego, 
CA, USA now: Thermo 
Fischer Scientific, 
Waltham, MA, USA 
LY6G/LY6C  
(GR-1) 
bio rat IgG2b, κ RB6-85C Biolegend, San Diego, 
CA, USA 
p-S6 Al488 rabbit IgG 2F9 eBioscience, San Diego, 
CA, USA now: Thermo 
Fischer Scientific, 
Waltham, MA, USA 
phospho-Rb 
(pS807/pS81
1) 
Al488 mouse IgG2a, κ J112-9060 eBioscience, San Diego, 
CA, USA now: Thermo 
Fischer Scientific, 
Waltham, MA, USA 
Strepatvidin Pe    eBioscience, San Diego, 
CA, USA now: Thermo 
Fischer Scientific, 
Waltham, MA, USA 
Ter119 bio rat IgG2b, κ TER-119 Biolegend, San Diego, 
CA, USA 
TNFα FITC rat IgG1, κ MP6-XT22 Biolegend, San Diego, 
CA, USA 
Vα2 FITC rat IgG2a, λ B20.1 Biolegend, San Diego, 
CA, USA 
Vβ3 FITC arm. 
hamster 
IgG2, κ Kj25 Benoist, Mathis 
1.5 Cytokines 
rhuIL-2 PeproTech, Rocky Hill, NJ, USA 
rmIL-7 Immunotools, Friesoythe, Germany 
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1.6 Enzymes 
Proteinase K Diagonal, Münster, Germany 
Peg Gold Taq DNA Polymerase Peqlab, Erlangen, Germany 
RNase A Thermo Fischer Scientific, Waltham, MA, USA 
 
1.7 Peptides 
Q4H7 SIIQFEHL peptides & elephants GmbH, Hennigsdorf, Germany 
 
1.7 Consumables 
Casy cups Roche, Basel, Switzerland 
Cell culture plate, 96-well round bottom Sarstedt, Nümbrecht, Germany 
Cell strainer (100 µm, sterile) BD, Franklin Lakes, NJ, USA 
Cover slides (glass) Diagonal, Münster, Germany 
Dissecting scissors WPI-Europe, Hertfordshire, UK 
Ear punch, 10 cm, 2 mm diameter WPI-Europe, Hertfordshire, UK 
Cannulas 23G blue Carl Roth, Arlesheim, Switzerland 
FACS tubes Sarstedt, Nümbrecht, Germany 
Filter tips OneTip, 1-10ul Starlab, Hamburg, Germany 
Filter tips OneTip, 2-20ul Starlab, Hamburg, Germany 
Filter tips, 1000 µL Diagonal, Münster, Germany 
Glaspipette 5 mL Diagonal, Münster, Germany 
Gloves Small Diagonal, Münster, Germany 
Insulin syringes 0.5 mL 0.30 x 8 mm Diagonal, Münster, Germany 
Insulin syringes 1 mL 0.33(29G) x 12.7 mm Diagonal, Münster, Germany 
MACS LS columns Miltenyi, Bergisch-Gladbach, Germany 
Microfine Syringes  BD, Franklin Lakes, NJ, USA 
Omnifix 20 mL syringes Diagonal, Münster, Germany 
Operating scissors WPI-Europe, Hertfordshire, UK 
PCR reaction tubes stripes Diagonal, Münster, Germany 
PCR-plates, 96-well Diagonal, Münster, Germany 
Petri dish 60 mm x 15 mm Diagonal, Münster, Germany 
Pipette tips 20-200 µL, yellow Brand, Wertheim, Germany 
Pipette tips 50-1000 µL, blue Brand, Wertheim, Germany 
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Polyamide-mesh, pore size 150 µm and 89 
µm 
RCT, Heidelberg, Germany 
Reaction tube rack Carl Roth, Arlesheim, Switzerland 
Reaction tubes round-bottom 4 mL and 14 
mL 
BD, Franklin Lakes, NJ, USA 
Reaction tubes Safeseal 1.5 mL Sarstedt, Nümbrecht, Germany 
Reaction tube 50 mL Greiner, Kremsmünster, Austria 
Rotilabo-Abdeckfolien für PCR-Platten Carl Roth, Arlesheim, Switzerland 
Serological pipettes (5mL, 10 mL, 25 mL) Sarstedt, Nümbrecht, Germany 
Steril filter Milex-GP 0.22 µm Diagonal, Münster, Germany 
Synrignes 1 mL Omnifix Diagonal, Münster, Germany 
TPP Bottle-Top-Filter 500 mL, 0.22 µm Sigma-Aldrich, St. Louis, MO, USA now: 
Merck, Kenilworth, NJ, USA 
 
 
1.8 Kits 
CFDA-SE Cell Tracer Kit USA Invitrogen, Carlsbad, CA, USA 
CTV Cell Tracer Kit USA Invitrogen, Carlsbad, CA, USA 
Click-iT HPG Thermo Fischer Scientific, Waltham, MA, USA 
 
1.9 Laboratory Equipment 
BD FACSAriaIII BD, Franklin Lakes, NJ 
BD FACSCalibur BD, Franklin Lakes, NJ 
BD FACSCantoII BD, Franklin Lakes, NJ 
Casy Counter Innovatis/OLS OMNI Life Science GmbH & Co. 
KG, Bremen, Germany 
Centrifuge 5417R Eppendorf, Hamburg, Germany 
Centrifuge 5424 Eppendorf, Hamburg, Germany 
Centrifuge Rotanata 460R Hettich, Tuttlingen, Germany 
Electrophoresis Power supply 
(EPS200) 
Pharmacia Biotech, Upsalla, Sweden 
Fridge, Freezer Liebherr, Bulle, Switzerland 
GelDoc XR+ BioRad, Hercules, CA, USA 
Heatblock Thermomixer 5436 Eppendorf, Hamburg, Germany 
Ice machine Scotsman, Radevormwald, Germany 
Incubator Heraeus, Hanau, Germany 
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Incubator FlowSafe B-[MaxPro]2-
190 
Berner International GmbH, Elmshorn, Germany 
Laminar airlflow cabinet HeraSafe Heraeus, Hanau, Germany 
Microscope Labovert FS Leitz, Wetzlar, Germany 
Microscope Leica  Leica Microsystems GmbH, Wetzlar, Germany 
Microwave DAEWOO, Seoul, South Korea 
Multifuge X3R Heraeus, Hanau, Germany 
Pipette  Brand, Wertheim, Germany 
Pipette 0.2 - 2 µL Eppendorf, Hamburg, Germany 
Pipette 8-channel, 0,1-10 uL Eppendorf, Hamburg, Germany 
Pipette, 12-channel, 20-200 µL Brand, Wertheim, Germany 
Pipettes Brand, Wertheim, Germany 
Thermocycler T1 Biometra, Göttingen, Germany 
Thermocycler TADVANCED Biometra, Göttingen, Germany 
Vortex Genie 2 Bender & Hobein AG, Zurich, Switzerland 
Water bath Lauda, Lauda-Köningshofen, Germany 
 
1.10 Software 
BD cell quest BD, Franklin Lakes, NJ, USA 
Graph Pad Prism 5.0c and 7.0d for Mac GraphPad, La Jolla, CA, USA 
MS Office for Mac Microsoft, Redmont, WA, USA 
FACSDiva BD, Franklin Lakes, NJ, USA 
FlowJo 8.8.7 for Mac Treestar Ashland, OR, USA 
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2 Methods 
2.1. Mice 
Mice were bred and maintained at the animal facility of the Institute for Immunology, 
Ludwig-Maximilians-University Munich in Munich, Germany. All experiments were 
performed in compliance with German federal guidelines. 
Line Name Official Line Name Background MHC Source Reference 
AND x 45.1 Tg(TcrAND)53Hed; 
Ptprca 
B10.BR/IfI H-2k CB, DM (Kaye et al., 
1989) 
AND x 90.1 Tg(TcrAND)53Hed; 
Thy1a 
B10.BR/IfI H-2k CB, DM (Kaye et al., 
1989) 
AND x NR4 Tg(TcrAND)53Hed; 
Tg(Nr4a1-
EGFP/cre)820Khog 
B10.BR/IfI H-2k The 
Jackson 
Laboratory 
(Moran et al., 
2011) 
AND T-Rptor-/- Tg(TcrAND)53Hed 
Tg(Cd4-cre)1Cwi; 
Rptortm1.1Dmsa 
 
B10.BR/Jax H-2k The 
Jackson 
Laboratory 
(Lee et al., 
2001; 
Sengupta et 
al., 2010)  
B10.BR/Jax B10.BR-H2k; H2-
T18a/SgSnJ 5045 
B10.BR/Jax H-2k The 
Jackson 
Laboratory 
(Stimpfling & 
Richardson, 
1965) 
B6 C57BL/6 C57BL/6 H-2b The 
Jackson 
Laboratory 
 
Bm1 H-2Kbm1 C57BL/6 H-2bm1 Veit 
Buchholz 
(McKenzie et 
al., 1977) 
Bm12 H2-Ab1bm12 B6KhEgJ H-2bm12 The 
Jackson 
Laboratory 
(McKenzie et 
al., 1979) 
iMCC Ii-rTAxTIM. Tg(Cd74-
rtTA)#Doi; Tg(tetO-
Cd74/MCC)#Doi 
B10.BR/IfI H-2k CBDM (Obst et al., 
2005; van 
Santen et al., 
2004) 
iOVA Tg(tetO-
Cd74/MCC)#Doi; 
Tg(TetO-OVA)7Obst 
C57BL/6 H-2b Reinhard 
Obst 
(Rabenstein 
et al., 2014) 
iOVA-KRAB Tg(Cd74rtTA)#Doi;Tg
(TetO-
OVA)7Obst;CD11c-
DTR; HPGKtTR-
KRAB 
C57BL/6 H-2b Reinhard 
Obst 
(Barde et al., 
2009; 
Rabenstein et 
al., 2014) 
 
OT-I x 45.1 Tg(TcraTcrb)1100Mjb
; Ptprca 
 
C57BL/6 H-2b Thomas 
Brocker 
(Hogquist et 
al., 1994) 
OT-I x 90.1 Tg(TcraTcrb)1100Mjb
; Thy1a 
 
C57BL/6 H-2b Thomas 
Brocker 
(Hogquist et 
al., 1994) 
OT-I x NR4 Tg(TcraTcrb)1100Mjb
;Tg(Nr4a1-
C57BL/6 H-2b The 
Jackson 
(Moran et al., 
2011) 
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EGFP/cre)820Khog 
 
Laboratory 
OT-I T-Rptor-/- Tg(TcraTcrb)1100M 
jb; Tg(Cd4-cre)1Cwi; 
Rptortm1.1Dmsa   
C57BL/6 H-2b The 
Jackson 
Laboratory 
(Lee et al., 
2001; 
Sengupta et 
al., 2010)  
R26-rtTA-M2 x 
KRAB 
Gt(ROSA)26Sortm1(rtT
A*M2)Jae; HPGKtTR-
KRAB 
C57BL/6 H-2b Vigo 
Heissmeyer 
(Barde et al., 
2009; 
Hochedlinger 
et al., 2005) 
RAG-/- Rag1tm1Mom C57BL/6 H-2b Thomas 
Brocker 
(Mombaerts 
et al., 1992) 
T-Rictor-/- Tg(Cd4-cre)1Cwi; 
Rictortm1.1Klg   
C57BL/6 H-2b The 
Jackson 
Laboratory 
(Lee et al., 
2001; Tang et 
al., 2012) 
T-Rptor-/- Tg(Cd4-cre)1Cwi; 
Rptortm1.1Dmsa   
C57BL/6 H-2b The 
Jackson 
Laboratory 
(Lee et al., 
2001; 
Sengupta et 
al., 2010)  
2.1.1 Wildtype mice 
Wildtype C57/Bl6 (H-2b) and B10.Br/Jax (H-2k) mice were both originally obtained from 
The Jackson Laboratory and bred in the mouse facility of the Institute for Immunology, 
LMU Munich. 
2.1.2 Congenic marker 
In order to identify adoptively transferred T cells, the congenic markers CD45.1 and 
CD90.1 were used. They originally derived from Ptprca and Thy1a mice, respectively. 
Ptprca and Thy1a mice were purchased from The Jackson Laboratory. 
2.1.3 TCR transgenic mice 
AND TCR transgenic mice (Tg(TcrAND)53Hed Tg(Cd4-cre)1Cwi2.1.4) were  received 
from Diane Mathis and Christophe Benoist (Harvard Medical School, Boston, MA, 
USA). The TCR of AND T cells predominantly consists of the Vα11 (clone: AN6.2) and 
Vβ3 chain (clone: 5C.C7) and recognizes a peptide, derived from moth cytochrome c 
(MCC93-103) in the context of H-2Ek. 
OT-I TCR transgenic mice (Tg(TcraTcrb)1100Mjb) were received from Thomas Brocker 
(Ludwig-Maximilians-University Munich, Munich, Germany). The TCR of OT-I T cells 
predominantly consists of the Vα2 and Vβ5 chain (clone: 149.42) and recognize a 
peptide derived from chicken ovalbumin (OVA257-264 /SIINFEKL) in the context of H-2Kb. 
TCR transgenic animals were crossed with mice expressing the congenic marker 
CD45.1 or CD90.1. 
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2.1.4 TCR signaling reporter mice 
To visualize early TCR activity, a mouse strain was used, carrying a BAC-transgene 
consisting of a Nur77-GFP reporter cassette (Tg(Nr4a1-EGFP/cre)820Khog). Mice 
were purchased from The Jackson Laboratory. The expression of Nur77-GFP was 
measured by flow cytometry and is described to be upregulated within hours upon TCR 
stimulation, correlating with the strength of the TCR stimulus. It remains high up to two 
days post-antigen-pulse in vitro (Moran et al., 2011). 
Transgenic mice were crossed with AND and OT-I mice carrying the congenic markers 
CD90.1 and CD45.1 on H-2k or H-2b background, respectively. 
2.1.5 T cell specific mTORC1/2- deficient mice 
T cell specific mTORC1 (Tg(Cd4-cre)1Cwi; Rptortm1.1Dmsa)- and mTORC2 (Tg(Cd4-
cre)1Cwi; Rictortm1.1Klg)-deficient mice were purchased from the Jackson Laboratory 
and bred on B6 background. The Mouse Genome Informatics database gives this 
detail: “Cre recombinase is expressed under the control of mouse Cd4 regulatory 
elements. The Cd4 enhancer, promoter and silencer collectively drive expression at 
sequential stages specifically of CD4+ T cell development.“1 For mTORC1-deficient T 
cells, the Mouse Genome Informatics database reports: “Exon 6 was flanked by 5' and 
3' LoxP sites located 111 bp upstream and 547 bp downstream, respectively, and an 
FRT flanked neo cassette was inserted via homologous recombination. The neo 
cassette was removed by flp mediated recombination.“2 For mTORC2-deficient mice, 
the Mouse Genome Informatics database describes: “A targeting vector was designed 
to insert a loxP site followed by a frt-flanked neomycin resistance (neo) cassette 
upstream of exon 11, and a second loxP site downstream of exon 11. Flp-mediated 
recombination removed the neo cassette and left exon 11 floxed.“3  
Both mice were crossed with OT-I and AND mice carrying the congenic marker CD45.1 
on H-2b and H-2k background, respectively. 
2.1.6 Bm1 and Bm12 mice 
Bm1 mice were received from Dr. Veit Buchholz (Technical University Munich, Munich, 
Germany). The Mouse Genome Informatics database gives this detail: “The bm1 
mutation contains 7 nucleotide differences resulting in amino acid substitutions at 
codon 152 (glutamate to alanine), codon 155 (arginine to tyrosine) and codon 156 
                                                
1 http://www.informatics.jax.org/allele/key/8393; retrieved on 23.11.2018 
2 http://www.informatics.jax.org/allele/key/636375; retrieved on 23.11.2018 
3 http://www.informatics.jax.org/allele/key/822979; retrieved on 23.11.2018 
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(leucine to tyrosine)“4, thus binding and presenting a different repertoire of self-peptides 
in the context of MHC-I. 
Bm12 mice were purchased from The Jackson Laboratory. The Mouse Genome 
Informatics database gives this detail: “Three non-consecutive nucleotide changes 
occurred, resulting in three amino acid substitutions in the beta1 exon. The amino acid 
changes consist of codon 67 (isoleucine to phenylalanine), codon 70 (arginine to 
glutamine) and codon 71 (threonine to lysine). These changes were likely the product 
of gene conversion of H2-Ab1b with sequence from H2-Ebb.“5 Hence, Bm12 mice bind 
and present a different repertoire of self-peptides in the context of MHC-II. 
2.1.7 RAG-deficient mice 
RAG-deficient mice were kindly provided by Thomas Brocker (Ludwig-Maximilians-
University Munich, Munich, Germany). The recombination activation gene 1 (RAG1) is 
essential for the V(D)J recombination in B and T cells. RAG1-deficient mice have small 
lymphoid organs and no mature B and T cells. In these mice a neomycin cassette 
replaced a 1356 bp genomic fragment of the Rag1 gene, encoding the nuclear 
localization signal and the zinc-finger motif. 
Upon adoptive transfer, T cells start to vigorously proliferate in these lymphopenic 
mice. 
2.1.8 Double-transgenic mice 
iMCC double-transgenic (dtg) mice (Ii-rTAxTIM. Tg(Cd74-rtTA)#Doi; Tg(tetO-
Cd74/MCC)#Doi) were provided from Diane Mathis and Christophe Benoist (Harvard 
Medical School, Boston, MA, USA). Ii-rTA mice were crossed with mice carrying the 
tetracycline inducible invariant chain in cooperation with MCC92-103 (TIM) in MHC-II 
positive cells. Mice were bred on the B10.BR background. 
iOVA dtg mice (Tg(TetO-OVA)7Obst) were generated by crossing Ii-rTA mice with mice 
carrying a tetracycline regulated signal sequence in cooperation with OVA257-264 (TSO) 
in MHC-II positive cells in the laboratory of Reinhard Obst (Ludwig-Maximilians-
University Munich, Munich, Germany).  Mice were bred on the C57/Bl6 Background. 
Both recipient mice carry a transgene for the improved S2 mutant of the reverse tet-
transactivator under the control of the invariant chain (Ii) promoter and the H-2Eα 
enhancer element from the pDOI-6 transgene expression vector. The S2 mutant 
consists of a tetracycline binding domain and a transactivator (Urlinger et al., 2000). 
                                                
4 http://www.informatics.jax.org/allele/key/42193; retrieved on 23.11.2018  
5 http://www.informatics.jax.org/allele/key/39181; retrieved on 23.11.2018 
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The expression is regulated via the invariant chain (Ii) promoter and the H-2Eα 
enhancer element derived from pDOI-6 transgene expression vector. 
In iMCC mice, the CLIP region of the Ii was replaced by MCC92-103 and named TIM. 
The expression of TIM is under the control of the CMVcore promoter and seven tet-
operator (tetO) sequences. In addition the efficiency of the transgene expression was 
improved by an intron from rabbit β-globulin, which was inserted downstream of the 
transcription start site. 
In iOVA mice, the TSO transgene encodes a minigene combination of the OVA257-264 
and the H2-Kb signal sequence, which mediates a translation into the endoplasmatic 
reticulum. This fusion is followed by two stop codons and the human growth hormone 
splice substrate required for efficient expression. The expression of the cognate 
antigen of OT-I is independent of proteasomal processing and TAP-transport and 
under the control of an improved tetracycline response element in which an interferon 
response element was removed from the spacers separating the seven tetO 
sequences. In addition the spacer region was shortened so that the tetO sequences 
were separated by 3.5 instead of 4 helical turns, which enabled the transactivator 
molecule to alternatively bind on opposite sites of the DNA. Furthermore, an enhancer 
element was removed from the CMVcore promoter. 
In iMCC mice MCC93-103 is expressed on MHC-II upon doxycycline treatment, iOVA 
mice express OVA257-264 on MHC-I, thus presenting cognate antigen to AND and OT-I T 
cell, respectively. 
iOVA mice were crossed to transgenic mice expressing the tetracycline-dependent 
transrepressor KRAB, generating iOVA-KRAB mice. KRAB is a fusion protein that 
consists of the DNA binding domain of the tetracycline repressor from E. coli and the 
Krüppel-associated box (KRAB) domain of the human Kox1 zinc finger protein 
(Deuschle et al., 1995). It is expressed under the human phosphoglycerate kinase 
promoter and constitutively active in the absence of doxycycline (Barde et al., 2009). 
KRAB domains recruit histone deacetylases and histone methyltransferases and thus 
mediate a reversible transcriptional repression of target genes (Groner et al., 2010; 
Margolin et al., 1994). If bound to doxycycline, the tetracycline-dependent 
transrepressor will be inactivated and in turn the transactivator can bind and induce the 
expression of OVA257-264 on MHC-I.  
2.1.9 R26-rtTA-M2 mice 
The Rosa26 locus is ubiquitously expressed. The Mouse Genome Informatics 
database gives this detail: ” An optimized form of reverse tetracycline controlled 
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transactivator (rtTA-M2) was inserted downstream of the Gt(ROSA)26Sor promoter 
and was followed by a PGK-puro selection cassette. This mutant form of rtTA termed 
M2 has five amino acid substitutions in the tetR moiety of tTA: S12G, E19G, A56P, 
D148E and H179R. This mutated form of transactivator protein has increased 
doxycycline sensitivity. Mice have widespread expression of the rtTA-M2 protein.“6 
R26-rtTA-M2 mice were crossed to KRAB expressing mice. 
2.2 Mice Typing 
2.2.1 Tissue digestion 
DNA was harvested from the tail tip. The tissue was digested in 100 µl tissue digestion 
buffer for 7 hours at 56°C, followed by 10 minutes a 90°C for protein denaturation. The 
lysate was diluted 1:10 in dH2O for PCR. 
2.2.2 Polymerase Chain Reaction 
DNA from digested tissue samples (1 µL) was mixed with 24 µL of the master mix 
described below. DNA was initially denaturated for 5 minutes at 95 °C followed by 35 
cycles of denaturation (30 seconds at 95 °C), primer annealing (45 seconds at 55 °C) 
and DNA elongation (45 seconds at 72 °C). A final elongation period for 5 minutes at 
72 °C and a cooling period for 10 seconds at 20 °C was added. 
PCR master mix 
 PCR H2O 
 PCR Buffer 1x 
PCR Enhancer 0.5x 
Oligonucleotide 1 0.5 µM 
Oligonucleotide 2 0.5 µM 
dNTPs 0.2 mM 
Taq polymerase 0.026 U/µL 
2.2.3 Gel electrophoresis 
For size separation of PCR products, a 1% agarose gel (in 1xTAE buffer with 0.005% 
ethidiumbromide) with a 100 bp ladder marker was used. The PCR products were 
loaded on the gel with loading buffer in a 1:5 ratio. The electrophoresis was performed 
at 120 Volt in a horizontal gel chamber for 25 minutes. The results were visualized in a 
gel documentation system using a UV light source. 
                                                
6 http://www.informatics.jax.org/allele/key/52600; retrieved on 22.11.2018 
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2.3 Cell extraction from mouse organs 
Mice were sacrificed by CO2 exposure in accordance with the German Protection of 
Animals Act. Spleen and lymph nodes (axillary, inguinal, brachial and cervical or 
axillary, inguinal and brachial only from recipients of adoptivly transferred T cells) were 
removed under non-sterile conditions and homogenized in FACS Medium either using 
a sterile cell strainer (150 µm) if intended for cell culture or adoptive T cell transfer or 
glass cover slides for flow cytometry analysis. In order to remove erythrocytes, 
splenocytes were centrifuged through a Ficoll cushion for 10 minutes at 2000 rpm/ 450 
x g and brake set on 5 of 9. The interphase was collected. Single cell suspension was 
pelleted with 350 x g for 5 minutes and resuspended in FACS medium, 1xPBS or 
DMEM. Cell numbers were measured with the Casy Counter. 
2.4 Intra peritoneal injection of anti-CD40 
Mice were treated with 20 or 40 µg anti-CD40 in order to stabilize antigen presentation 
on APCs to T cells. Sterile solutions of anti-CD40 in 1xPBS were prepared and injected 
intraperitoneally with a maximum of 100 µL per mouse. 
2.5 CFSE/CTV labeling of naïve T cells 
A stock of 5 mM CTV or CFSE was used to assess cell proliferation. Both dyes bind to 
proteins and thus get diluted in half with every cell division. The number of divisions 
can be calculated by following: N = log2(CFSE MFIctr/CFSE MFIsample). 
Cell labeling was performed with 20 million cells per mL in prewarmed CFSE/CTV 
labeling medium with 10 µM CFSE or CTV for naïve, not enriched cells and 5µM for 
Magnetic-Activated Cell Sorting purified cells, while gently vortexing. Cells were 
incubated for 10 minutes in a 37 °C warm water bath in the dark with an additional step 
of swirling after 5 minutes. Adding equal amounts of CFSE/CTV labeling medium 
blocked the reaction. 1-3 mL heat-inactivated FCS was underlayed to provide nutrients. 
Cells were centrifuged at 1500 rpm at 4°C for 5 minutes and washed twice with transfer 
medium if cells were used for adoptive transfer or FACS Medium if cells were cultured 
in vitro. 
2.6 Adoptive T cell transfer 
For in vivo stimulation assays, lymphocytes were harvested from lymph nodes (axillary, 
inguinal, brachial) in DMEM without BSA. Cells that were pre-stimulated in vitro before 
transfer were harvested from cell culture and washed with DMEM without BSA to 
remove remaining BSA from T cell medium. If indicated, cells were labeled with CFSE 
or CTV and transferred in a maximum of 100 µL DMEM without BSA intravenously. 
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Cell numbers varied between 0.1 x 106 and 2 x 106 cells per mouse depending on the 
experimental setup. 
2.7 Doxycycline treatment 
Mice were treated with 100 µg/mL doxycycline in water with low divalent cations 
(Volvic, Danone Waters, Frankfurt, Germany), if indicated. 
2.8 Immunization  
2.8.1 Immunization with MVA-Ova 
MVA-encoding OVA (MVA-OVA) SC126 5A 13-13 stock: 9.09 x 109 TC ID50/mL 
(Bavarian Nordic GmbH, Planegg-Martinsried, Germany) was used to induce 
ovalbumin expression on myeloid dendritic cells to generate adoptively transferred 
effector (d8) and memory (d36) OT-I T cells. 5 x 107 TC ID50/mL was injected 
intravenously in 100 µL 1xPBS per mouse on day one before adoptive transfer of TCR 
transgenic OT-I T cells. 
2.8.2 Immunization with MHV-68_OVA 
The murine gamma herpes virus 68_OVA (MHV-68_OVA) bacterial artificial 
chromosome (BAC) was generated in collaboration with Prof. Heiko Adler (Helmholtz 
Center for Environmental Health, Munich). The expression cassette of TSO (described 
in 2.1.8) was inserted into the MHV-68 genome between ORF27 and ORF29b at 
position 46347 (Supplementary figure 12). In the presence of the reverse tetracycline-
transactivator (rtTAM2), OVA257-264 expression can be induced on H2-Kb in virus-infected 
cells. 
For immunization, host mice were injected intravenously with 2 x 105 PFU MHV-
68_OVA in 100 µL 1xPBS per mouse one day after adoptive transfer of TCR 
transgenic OT-I T cells. 
2.9 Magnetic purification of CD4+ and CD8+ T cells 
In order to purify CD4+ or CD8+ T cells, Magnetic-Activated Cell Sorting, a technique 
based on the usage of paramagnetic anti-biotin microbeads to separate cells labeled 
with biotinylated antibodies on a column placed in a strong magnetic field, was used. 
Single cell suspensions of lymph nodes and spleen were prepared as described in 2.3 
and pooled before incubation with biotinylated mAb. Biotinylated mAb were added 
according to the following table in 200 µL FACS medium per donor mouse.  
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CD8+ CD4+  /mouse 
CD4 CD8 T cells 8 µl 
CD45R CD45R B cells 8 µl 
CD49 CD49 NK cells 5 µl 
Gr-1 Gr-1 Granulocytes 5 µl 
CD11b CD11b Macrophages 5 µl 
CD11c CD11c DCs 5 µl 
TER119 TER119 Erythrocytes 5 µl 
 
Cells were incubated for 15 minutes on ice and washed three times in FACS medium 
at 1500 rpm for 5 minutes. The pellet was resuspended in 100 µL FACS Medium per 
mouse, 10 µL anti-biotin-beads were added. Cells were incubated for 20 minutes at 
4°C (swirled after 10 minutes) and washed twice (first step with FACS Medium, second 
step with MACS buffer). For negative selection an LS column was placed in a magnetic 
field and equilibrated with 3 mL MACS buffer. Pellet was resuspended in 2 mL MACS 
buffer per mouse and loaded on the LS columns (maximum of cells from two mice per 
column). Columns were subsequently washed twice with 3 mL MACS buffer. The flow-
through was collected. The obtained cells were centrifuged as indicated. The pellet 
was resuspended in FACS medium and cell number was measured with the Casy 
Counter. 
For quality control an aliquot before and after purification was taken for flow cytometry 
analysis. 
2.10 Stimulation with anti-CD3 and anti-CD28 
In order to coat anti-CD3 and anti-CD28 to cell culture plates, 96-well U-bottom plates 
were incubated with 10 µg/mL anti-CD3 and 10 µg/mL anti-CD28 in 70 µL 1xPBS per 
well for 2 hours at 37°C and 5% CO2. Subsequently, plates were washed twice with 
cold 1xPBS. MACS-purified cells (see 2.9) were adjusted to a concentration of          
0.5 x 106 cells/mL in T cell medium, 5 ng/mL IL-7 was added and 10 ng/mL IL-2 if 
indicated. Cells were cultured in 200 µL per well up to 3 days at 37°C and 5% CO2. 
2.11 Stimulation with PMA and ionomycin 
A single cell suspension from lymph node and spleen was generated as described in 
2.3 and pooled for further treatment. 0.2 x 106 cells were transferred into a 96-well 
plate and stimulated in 200 µL RPMI Full with 10 ng/mL PMA (for stimulation of protein 
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kinase C) and 25 ng/mL Ionomycin (a Ca2+ - ionophore) for 20 minutes to 2 hours at 
37°C and 5% CO2.    
2.12 Inhibitor treatment 
Inhibitors were added with a start concentration as listed below. In twelve steps, 
inhibitors were serially diluted two-fold or four-fold ranging from 1:2 or 1:4 to 1:2048 or 
1:42000000 for actinomycin D, respectively in 100 µl RPMI Full Medium with drug-free 
medium as control. Cells were purified and stimulated as described in 2.9 and 2.10 
with the exception that cells were adjusted to a concentration of 1 x 106 cells/mL with 
IL-7 (10ng/mL). 100 µL of the cell suspension were added to 100 µL inhibitor solution, 
which lead to a final concentration of 0.5 x 106 cells/mL and 5 ng/mL IL-7. Cells were 
incubated for 48 hours in vitro at 37°C and 5% CO2. 
Inhibitor Target Stock conc. 
 
Start conc. 
 
Dilution 
Torin 1 mTORC1 and mTORC2 4 mM 1 µM 1:2 
2-DG Glycolysis 305 mM 2 mM 1:2 
Actinomycin D RNA Polymerase I and II 40 mM 4 µM 1:4 
Quarfloxin RNA Polymerase I 16.5 mM 0.2 µM 1:2 
Tigecyclin Mitochondrial ribosomes 5.11 mM 40 µM 1:2 
2.13 Cell preparation for flow cytometry 
The flow cytometers BD FACSCalibur and FACSCanto II were used for data 
acquisitions and analysis was performed with FlowJo 8. In order to remove aggregates, 
antibody dilutions were centrifuged at 14000 rpm in 1.5 mL reaction tubes for 10 
minutes at 4°C. Staining was performed in 96-well plates in the dark at 4°C for 20 
minutes. Cells were washed once with FACS Medium and filtered through a mesh with 
a pore size of 80 µm before analysis. 
2.13.1 Antibody staining 
Staining and washing was performed in FACS Medium when DAPI or 1xPBS when 
fixable viability dye (FVD eFluor450, eFluor660, eFluor780) was used for dead cell 
discrimination. All antibodies were diluted 1:400, SA-conjugated fluorochromes and 
FVD 1:2000 and DAPI 1:1000. 0.01-1 x 106 cells were washed and pelleted at 1500 
rpm at 4°C for 3 minutes. The pellet was resuspended in 50 µL antibody mix and 
incubated as indicated above. 
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2.13.2 Fixation with 4% PFA 
In order to fix cells, T cells stained for extracellular markers as described in 2.13.1 were 
washed once with 1xPBS at 250xg and 4°C for 3 minutes and subsequently 
resuspended in 100 µL freshly thawed 4% paraformaldehyde. Cells were incubated for 
10 minutes at room temperature protected from light. Subsequently, cells were washed 
twice with 1xPBS at 350 x g for 5 minutes and stored in 100 µL 1xPBS at 4°C in the 
dark or further treated as described in 2.13.3. 
2.13.3 Permeabilization with Perm III Buffer 
Permeabilization of fixed cells was performed using Perm III Buffer (BD, Franklin 
Lakes, NJ, BD Phosphoflow). Cells were resuspended in 100 µL Perm III Buffer and 
incubated for 5 minutes at room temperature, followed by two washing steps with 
1xPBS at 250xg for 5 minutes. 
2.13.4 Intracellular antibody staining for phospho-proteins 
For intracellular staining of phosphorylated proteins, cells were stained for extracellular 
markers, fixed and permeabilized as described under 2.13.1 2.13.2 and 2.13.3. Before, 
intracellular antibody staining was performed, non-specific binding was prevented by 
anti-CD16/CD32 treatment in a dilution of 1:400 in 1xPBS for 15 minutes. 
Subsequently, cells were washed once in 1xPBS for 5 minutes at 350xg and 
resuspended in antibody mix containing anti-phospho antibodies diluted in 1x PBS. In 
addition antibodies, which have been used at the first staining step to discriminate 
extracellular markers were added to the solution. 
mAb dilution 
pS6-Al488 1:100 
H3P-Al488 1:10 
pRb-All488 1:50 
2.13.5 RNA and DNA staining with Pyronin Y and DAPI  
To visualize nucleic acids, DAPI and Pyronin Y were used. While DAPI exclusively 
intercalates into DNA, Pyronin Y can stain both DNA and RNA. To guarantee a specific 
binding only to RNA, Pyronin Y was added after incubation with DAPI to block DNA 
binding sites. Both parameters were acquired on a linear scale.  
Equivalent numbers of enriched CD4+ and/or CD8+ T cells (0.5 to 2 x 106 each) were 
treated together in the same well of a 96-well plate. The cells were washed twice and 
stained for intracellular markers and FVD as indicated in 2.13.1. After one washing 
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step with 1x PBS at 1500 rpm and 4°C for 3 minutes, cells were fixed as described in 
2.13.2. Cells were washed twice with 1xPBS at 250xg for 5 minutes at room 
temperature and could then be stored over night at 4°C. To continue, cells were 
permeabilized with Perm III Buffer (BD, Franklin Lakes, NJ, BD PhosphoflowTM) for 5 
minutes at room temperature, followed by two washing steps with 1xPBS as described 
in 2.13.3. DAPI (stock: 250 mg/mL) was added at a 1:1000 dilution in 100 µL 1xPBS 
per well for 10 minutes at room temperature in the dark. Subsequently Pyronin Y 
(stock: 1 mg/mL) was added in a 1:200 dilution (final dilution 1:400) in 100 µL 1xPBS 
for 10 minutes at room temperature. Cells were pelleted at 350xg for 5 minutes at room 
temperature and resuspended in FACS medium for analysis at BD FACSCanto II. 
DAPI has an excitation maximum at 350 nm and can be detected at 470nm. The 
excitation maximum of Pyronin Y lies at 546 nm and can be detected at 565 nm. 
2.13.6 Intracellular cytokine staining 
The FoxP3 staining kit (eBioscience, San Diego, CA, USA) was used as indicated in 
the manufacturer’s instructions for intracellular staining of transcription factors and 
cytokines. Before fixation and permeabilization, cells were stained with surface 
molecules and FVD in 1xPBS for at least 20 minutes on ice. After fixation in 100 µl 
Fix/Perm, cells were washed twice in 150 µl Perm/Wash per well (cells could now be 
stored at 4°C in Perm/Wash over night). Unspecific antibody binding was blocked by 
anti-CD16/CD32 Fc-receptor blockage in a 1:400 dilution for 15 minutes. Cells were 
washed and stained intracellular for at least 20 minutes in antibody dilutions as 
indicated below. 
Specificity Fluorochrome Dilution 
IFNγ APC 1:400 
TNFα Al488 1:100 
 
2.13.7 Visualization of translational activity 
The Click-iT HPG Alexa Fluor Protein Synthesis Assay Kit was used, in order to 
monitor the translation of proteins at a defined time window of 30’ post-stimulation for 
48 hours. With this approach, the incorporation of the L-methionine analogue L-
homopropargylglycine (L-HPG) containing an alkyne moiety was measured. The 
detection of the incorporated amino acid utilized a chemoselective ligation or click 
reaction between an azide and alkyne, where the alkyne-modified protein was detected 
with Alexa Fluor 488 azide. 
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Cells were treated following the manufacturer’s protocol. 
Thus, all reagents were thawed and warmed to room temperature and Click-iT HPG 
reagent (Component A) was briefly centrifuged to maximize reagent recovery. Next a 
10x stock solution of the Click-iT HPG reaction buffer additive was prepared by adding 
2 mL of deionized water to Component E. Click-iT HPG reaction buffer was diluted 
1:10 in deionized water to prepare a 1x solution. 
Polyclonal T cells were purified and stimulated as described in 2.9 and 2.10. T cell 
Medium was removed and exchanged with 100 µL/well L-Methionine free medium 
containing 50 µM (1:1000 dilution) Component A. Cells were incubated for 30 minutes 
at 37°C and 5% CO2 in the dark. After incubation, the medium containing Click-iT® 
HPG was removed and cells were washed twice with 1xPBS. CD4+ and CD8+ T cells 
were mixed and stained for CD8 (1:400) and viability with FVD780 (1:2000) in 1xPBS 
for 15 minutes on ice in the dark. Cells were washed once with 1xPBS. 1xPBS was 
removed and cells were fixed with 4% PFA for 10 minutes at room temperature in the 
dark. Cells were washed twice with 1xPBS and subsequently permeabilized with Perm 
Buffer III (methanol based permeabilization) at room temperature for 5 minutes in the 
dark. The Click-iT reaction cocktail was prepared according to the protocol provided by 
the company.  
 
Cells were washed twice with 1xPBS. 1xPBS was removed and 100 µl of the reaction 
cocktail were added. Cells were incubated for 30 minutes at room temperature 
protected from light. The reaction cocktail was removed and cells were washed once 
with Click-iT reaction rinse buffer (Component F). Rinse buffer was removed and cells 
were resuspended in 1xPBS and subsequently analyzed by flow cytometry with BD 
FACS Canto II. 
Reaction Component 
Amount needed  
(100 µL/well) 
1x Click-iT HPG reaction buffer  86 µL 
Copper [III] Sulfate [CuSO4] (Component D) 4 µL 
Alexa Fluor 488 azide (Component B) 0.25 µL 
1x Click-iT HPG buffer additive  
(1:10 dilution of 10x Click-iT HPG buffer additive in deionized water) 
10 µL 
Total volume 100 µL 
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2.14 RNase digestion of fixed and permeabilized cells. 
Cells were fixed and permeabilized as described in 2.13.2 and 2.13.3. RNase was 
added in 50 µL 1xPBS with a concentration of 2 mg/mL (stock: 10 mg/mL). Cells were 
incubated for 30 minutes at 37°C in the heatblock. RNase was washed away twice with 
1xPBS for 5 minutes at 350xg and subsequently stained as described in 2.13.5. 
2.15 Total RNA Sequencing 
2.15.1 Cell sorting 
Cells were treated as indicated in 2.9 and 2.10. In order to exclude apoptotic and dead 
cells from total RNA sequencing, between 1.5 and 4 x 106 cells were incubated in 300 
µL antibody solution containing MFG8-GFP in a 1:250 dilution and FVD780 in a 1:1000 
dilution in 1x PBS. MFG8-GFP was kindly provided by Dr. Jan Kranich. Cells were 
incubated for 30 minutes and washed once with 1xPBS and resuspended in 1 mL 
1xPBS. Cell sorting was performed on FACSAriaIII with a 70 micro nozzle, and a 
sheath pressure of 70 by Lisa Richter at the Core Facility for Flow Cytometry of the 
Biomedical Center LMU Munich. Gating strategy is monitored in Supplementary figure 
5. 
2.15.2 Trizol treatment  
Sorted cells were pelleted at 250xg for 3 minutes and resuspended in 250 µL 1xPBS in 
a 1.5 mL reaction tube. 750 µL Trizol-LS was added and the reaction tube was inverted 
5 to 10 times. Cells were incubated for 1 minute at room temperature and subsequently 
stored at -80°C. 
2.15.3 RNA Preparation 
Prepared samples were delivered to vertis Biotechnologie AG for total RNA 
sequencing.  
Total RNA was isolated and purified using RNeasy columns (Qiagen), including DNase 
treatment. The total RNA preparations were examined by capillary electrophoresis 
using Shimadzu MultiNA microchip electrophoresis system and Qubit in order to 
discriminate 18/28S RNA and total RNA amounts, respectively.  
2.15.4 cDNA synthesis 
RNA samples were first fragmented using ultrasound (4 pulses of 30 s each at 4°C). 
Then, an oligonucleotide adapter was ligated to the 3' end of the RNA molecules. First-
strand cDNA synthesis was performed using M-MLV reverse transcriptase and the 3’ 
adapter as primer. The first-strand cDNA was purified and the 5' Illumina TruSeq 
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sequencing adapter was ligated to the 3' end of the antisense cDNA. The resulting 
cDNA was PCR-amplified to about 10-20 ng/µL using a high fidelity DNA polymerase. 
Cycle numbers are indicated in following table. The TruSeq barcode sequences, which 
are part of the 5' and 3' TruSeq sequencing adapters, are included. The cDNA was 
purified using the Agencourt AMPure XP kit (Beckman Coulter Genomics) and was 
analyzed by capillary electrophoresis. 
Sample no.  Barcode i5  Barcode i7  PCR cycles  
1  AGGCTATA  ATTACTCG  12  
2  GCCTCTAT  ATTACTCG  12  
3  AGGATAGG  ATTACTCG  13  
4  TCAGAGCC  ATTACTCG  13  
5  CTTCGCCT  ATTACTCG  12  
6  TAAGATTA  ATTACTCG  12  
7  ACGTCCTG  ATTACTCG  13  
8  GTCAGTAC  ATTACTCG  12  
9  ATAGAGAG  ATTACTCG  12  
10  AGAGGATA  ATTACTCG  13  
11  CTCCTTAC  ATTACTCG  12  
12  TATGCAGT  ATTACTCG  13  
13  TACTCCTT  ATTACTCG  12  
14  AGGCTTAG  ATTACTCG  12  
15  ATTAGACG  TCCGGAGA  12  
16  CGGAGAGA  TCCGGAGA  13  
25  CTAGTCGA  TCCGGAGA  14  
26  CTTAATAG  TCCGGAGA  13  
27  ATAGCCTT  TCCGGAGA  13  
28  TAAGGCTC  TCCGGAGA  12  
29  TCGCATAA  TCCGGAGA  15  
30  AGTCTTCT  TCCGGAGA  13  
31  CATTCGCT  TCCGGAGA  14  
32  TCTACTCT  TCCGGAGA  12  
33  ATCCTGTG  TCCGGAGA  13  
34  TACAGGTC  TCCGGAGA  13  
35  AGTCCAAC  TCCGGAGA  13  
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2.15.5 Pool generation and size fractionation 
For Illumina NextSeq sequencing, the samples were pooled in approximately 
equimolar amounts. The cDNA pool was size fractionated in the size range of 150 - 
500 bp using a preparative agarose gel. An aliquot of the size-fractionated pool was 
analyzed by capillary electrophoresis.  
2.15.6 Description of the cDNA 
The cDNAs have a size of about 150 – 500 bp. The 3’ and 5’ adapters and the primers 
used for PCR amplification were designed for small RNA sequencing according to the 
instructions of Illumina. The following adapter sequences flank the DNA insert:  
 
TruSeq_Sense_primer i5 Barcode 5'-AATGATACGGCGACCACCGAGATCTACAC-
NNNNNNNN-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3’  
TruSeq_Antisense_primer i7 Barcode 5’-CAAGCAGAAGACGGCATACGAGAT-NNNNNNNN-
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3’  
 
The combined length of the flanking sequences is 136 bases.  
2.15.7 Illumina sequencing 
The cDNA pool was sequenced on an Illumina NextSeq 500 system using 75 bp read 
length.  
 
Step 2.15.3 – 2.15.7 were performed by vertis Biotechnologie AG. 
2.15.8 RNA sequencing analysis 
Data generated in 2.15.7 were analyzed in collaboration with Dr. Tobias Straub of the 
Bioinformatics Core Unit, Ludwig-Maximilians-Universität Munich, Biomedical Center. 
 
Adapter sequences were removed using cutadapt (v.1.16) keeping only reads with a 
minimum length of 25bp. Sequences mapping to rRNA sequences with bowtie2 
(v2.2.9) were counted and removed. The remaining sequences were mapped to mouse 
genes (genome version GRCm38, annotation version GRCm38.92) using STAR 
(v2.6.0a, parameters "--outFilterMultimapNmax 200 --winAnchorMultimapNmax 200") 
and expression was estimated using RSEM (v.1.3.0).  
rRNA database contained the sequences of a) rRNA genes extracted from ENSEMBL 
Mus_musculus.GRCm38.92.gtf, b) manually selected sequences from the NCBI 
database (Rn45s (NR_046233.2 and BK000964.1), Rn4.5s (NR_002841.2), n-R5s136 
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(NR_046144.1), Rn5s (NR_030686.1)) c) manually selected blast hits of unaligned 
reads (AH002076.2, AH002077.2, BK000964.3, JQ247698.1, GU372691.1, J00623.1, 
X55996.1, X82564.1, V00849.1, V00850.1, V00851.1, X00525.1, X56974.1, D17318.1, 
D17317.1, D14835.1, D14834.1, D14833.1, D14832.1, X00686.1, X04886.1, 
X71804.1, J01871.1, M27441.1, M27443.1, M57716.1, M57714.1, K01366.1, 
M18066.1, M18065.1, M18064.1, M18063.1, M18062.1, M20154.1, M35283.1, 
M57720.1, M57723.1, K01367.1, M57708.1, K02235.1, M19226.1, M55272.1, 
M27358.1, K01380.1, M31319.1) d) the silva rRNA database for mouse and human 
(arb-silva.de, date stamp 2018-06-16). 
tRNA database contained the sequences obtained from gtrnadb.ucsc.edu (mm10-
tRNAs.fa). Alignment rates were ≤ 0.5%. 
2.16 In vivo killing assay 
To test the capability of TCR transgenic OT-I T cells to kill target cells presenting the 
cognate peptide OVA257-364, congenically marked, peptide pulsed splenocytes from 
C57/Bl6 mice were transferred into recipients of OT-I T cell one day before being 
analyzed. The spleen was dissected from CD45.1.2+ C57/Bl6 mice and homogenized. 
The cell suspension was centrifuged at 1500 rpm for 5 minutes. The pellet was 
resuspended in FACS Medium at a concentration of 2 x 106 cells/mL. 1 µg/mL, 0.01 
µg/mL or no Q4H7 peptide was added to the cell suspension, respectively. Cells were 
incubated for 4 hours at 37 °C and 5% CO2. Splenocytes pulsed with 1 µg/mL peptide 
were labeled with 5 nM CTV and cells pulsed with 0.1 µg/mL with 0.5 nM CTV as 
described under 2.5. Unpulsed cells kept unlabeled. This allows a discrimination of all 
three populations ex vivo. Pulsed and unpulsed cells were mixed in a 1:1:1 ratio with 
the equivalent of 1 x 106 cells per population and transferred in 100 µL DMEM w/o BSA 
into recipient mice of OT-I T cells, 4 or 29 days post-transfer, respectively. Mice were 
sacrificed 16 hours later 
2.17 Statistic analysis 
Statistic analysis was performed on Prism 5.0c and 7.0d. Mean and p-values have 
been generated from unpaired two-tailed student’s t-test, if not indicated otherwise. 
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D Results 
I mTORC1-dependent RNA synthesis in proliferating T cells 
1 mTORC1-dependent physiological changes upon TCR 
stimulation 
Antigen-recognition rapidly induces a series of signals, downstream of the TCR, which 
lead to T cell activation, blast formation and eventual clonal expansion of the cell. 
Besides the transduction of NFAT, Jun, Fos and NFκB to the nucleus, the TCR ligation 
to cognate antigen triggers a PI3K-dependent activation of mTOR in collaboration with 
CD28 (Finlay et al., 2012; Gaud et al., 2018).  
1.1 The phosphorylation of S6 in stimulated T cells is mTORC1-dependent 
The source of the signals that lead to the phosphorylation of mTORC1 downstream 
targets during T cell activation was further investigated. Thus, we tested whether TCR 
signaling alone is sufficient to activate mTORC1 or if co-stimulation via CD28 is 
needed to induce the phosphorylation of downstream targets of mTORC1. Polyclonal 
CD4+ and CD8+ T cells from mouse spleen and lymph nodes were stimulated with 
immobilized anti-CD3, anti-CD28, both antibodies combined (anti-CD3/28) or PMA/IM 
for 2 hours in vitro. The activity of mTORC1 was measured by flow cytometry for the 
presence of phosphorylated S6 ribosomal protein at Ser240/244 (pS6) by S6K1, a 
direct target of mTORC1. Figure D1.1 A and B show an ~80-fold increase of pS6 in 
CD4+ and ~45-fold increase in CD8+ T cells upon stimulation with anti-CD3/28 in 
comparison to unstimulated cells. The omission of CD28 reduced the gMFI of S6 
phosphorylation by ~55% in CD4+ and ~ 70% in CD8+ T cells, indicating the amplifying 
effects of co-stimulation. A treatment by PMA/IM does not directly induce mTORC1 
signaling via PI3K/Akt but rather indirect by a crosstalk via Erk/Tsc1/Rheb (Powell et 
al., 2012). PMA/IM induced an increase in the phosphorylation of S6 up to 45-fold in 
CD4+ and 23-fold in CD8+ T cells. This result is in line with previous data showing anti-
CD3 can induce the phosphorylation of S6 but signaling via CD28 is required to 
stabilize the phosphorylation of S6 at later time points (16 hours) (Yang & Chi, 2013).  
To test the expression of pS6 in Raptor-deficient T cells, T-Rptor-/- and T-WT cells were 
stimulated with PMA/IM for two hours in vitro. Even though mTORC1 was disrupted in 
T-Rptor-/- cells, an induction of S6 phosphorylation was detected, albeit with a 1.5- to 
two-fold lower magnitude than in T-WT cells probably due to mTORC1-independent 
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activation of S6K (Fig. D1.1C, D). Hence, TCR signaling induces a phosphorylation of 
S6, which partially depends on the presence of mTORC1. 
 
 
Figure D1.1: TCR stimulation induces mTORC1 dependent S6 phosphorylation.  
(A) 0.2 x 106 cells pooled from six sub-cutaneous (s.c.) lymph nodes and spleen from 
B6 mice were incubated in 96-well plates for two hours in vitro with immobilized 
antibodies (10 µg/mL) or PMA/IM. The phosphorylation of S6 in T cells was monitored 
by flow cytometry with the rabbit IgG mAb 2F9-Al488 (black) and rabbit IgG-Al488 
isotype control. Results are representative of 6 independent experiments. (B) 
Geometrical mean fluorescence intensities (gMFIs) were quantified and normalized to 
isotype controls. (C) 0.2 x 106 WT and T-Rptor-/- cells pooled from lymph nodes and 
spleen were stimulated as indicated and analyzed two hours later. Stimulated T-WT 
cells are shown in black, T-Rptor-/- cells in blue and the specific isotype control in grey 
(n=6). (D) Geometrical fluorescence intensities were quantified and normalized to 
isotype controls. Statistical analysis was performed using Student‘s t-test with *: 
p<0.05, ** p < 0.01, *** p< 0.001. 
 
1.2 T cell blast formation is delayed in mTORC1-deficient T cells 
In numerous studies, a correlation between mTORC1 activity and cell growth has been 
detected. They demonstrated a reduced blast formation early upon T cell stimulation 
(Pollizzi & Powell, 2015; So et al., 2016; Yang et al., 2013). To test whether mTOR 
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activity affects T cell blast formation not only 24 hours post-stimulation, but also at later 
time points, MACS-purified T-WT, T-Rptor-/- and T-Rictor-/- cells were stimulated with 
anti-CD3/28 for 48 hours in vitro and analyzed by flow cytometry. T cell blast formation 
was measured by the increase of the forward scatter area (FSC-A). The detection 
signal of the FSC-A visualizes the light diffraction of cells and is proportional to the cell 
diameter. Hence, the FSC-A correlates with the size of a cell (Tzur et al., 2011).  
Within 48 hours of stimulation, both CD4+ and CD8+ T cells increased two-fold in size in 
comparison to naïve T cells. T cells deficient in either mTORC1 or mTORC2 were able 
to increase in size to the same degree as T-WT cells could by this time point. T-Rictor-/- 
cells were even slightly bigger than T-WT cells (Fig. D1.2 A and B).  
To investigate changes in cell size over time in vivo, naïve T-WT and T-Rptor-/- AND or 
OT-I TCR transgenic cells specific for MCC93-103 or OVA257-264, were co-transferred into 
iMCC or iOVA mice, respectively and monitored in the spleen. iMCC mice can express 
MCC93-103 on H-2Ek, iOVA mice express OVA257-264 on H-2Kb. Only if orally treated with 
100 µg/mL doxycycline in the drinking water, the tet-responsive transactivator can bind 
to the tet-operator and induce the expression of their respective peptides on either 
MHC-II in iMCC and MHC-I in iOVA mice (Rabenstein et al., 2014). In this experiment, 
antigen-expression was induced one day before transfer by doxycycline and continued 
until the end of the experiment. Both T-WT and T-Rptor-/- cells increased in size upon 
stimulation in vivo. Albeit, T-Rptor-/- cells were slower in comparison to T-WT cells (Fig. 
D1.2 C, D). Thus, T cell blast formation is rather delayed in mTORC1-deficient T cells 
than completely reduced. 
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Figure D1.2: Blast formation of T-Rptor-/- cells is delayed upon TCR stimulation.  
(A) 0.1 x 106 magnetically purified T-WT, T-Rptor-/- and T-Rictor-/- CD4+ and CD8+ T 
cells were incubated with 5 ng/mL IL-7 in the presence or absence of 10 µg/mL 
immobilized anti-CD3/28 antibodies for 48 hours in vitro. The FSC-A was determined 
by flow cytometry. Results are representative of six independent experiments. (B) 
Quantification of the geometrical MFI of the FSC-A. (C) FSC-A of in vivo stimulated 
AND and OT-I T-WT (black) and T-Rptor-/- (blue) cells over time. 1 x 106 naive AND or 
OT-I T-WT and T-Rptor-/- cells were transferred into iMCC and iOVA mice, respectively, 
pre-treated with 40 µg anti-CD40 antibody, respectively and persistently fed with 
doxycycline starting one day before transfer. Same experiment as shown in chapter D 
2.2. (D) Quantification of the data shown in (C). Statistical analysis was performed 
using Student‘s t-test with *: p<0.05, ** p < 0.01, *** p< 0.001. 
 
2 Clonal expansion and survival of T-Rptor-/- cells in vivo 
The successful priming of a T cell results in a population of expanded clones. In 2009, 
Jonathan Powell and others have shown a reduced proliferation rate in mTORC1-
deficient T cells in vitro (Delgoffe et al., 2009b; Yang et al., 2013). To test whether this 
is also the case in vivo, mTORC1-sufficient and deficient T cells were isolated from 
congenically marked mice, labeled with CFSE, and adoptively transferred under 
different conditions.  
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2.1 Impaired GvH response of T-Rptor-/- 
The parent-into-F1 model has been used to study autoimmune diseases such as lupus. 
In this model the transfer of homozygous T cells from the parental generation into non-
irradiated semi-allogeneic F1 mice induces a graft-versus-host (GvH) response. It is 
mediated by naïve T cells that develop into mature effector T cells and start to 
proliferate upon the recognition of allo-antigens (Via, 2010).  
To examine the alloresponse of T-WT and T-Rptor-/- cells, an experimental system for 
graft-versus-host response was used by the adoptive transfer of 10 x106 CFSE-labeled 
bulk naïve cells from lymph node and spleen of an H-2Ab/b CD45.1/1+ mouse into 
CD45.2+ recipients, expressing allogeneic MHC class I (H-2Kb/bm1) or class II (H2-
Ab/bm12). Five days post-transfer, CD4+ and CD8+ T-WT cells started to divide up to 
eight times or more in H2-Ab/bm12 and H2-Kb/bm1 recipient mice, respectively. In contrast, 
T-Rptor-/- cells showed a much lower response (Fig. D2.1 A and B). Furthermore, T-
Rptor-/- cells accumulated 15- to 26-times less in vivo up to day five post-stimulation. 
Thus, either fewer T-Rptor-/- cells can responded to alloantigen or more cells died upon 
proliferation than T-WT cell, resulting in an impaired graft-versus-host response in T-
Rptor-/- cells. 
 
 
Figure D2.1: Reduced proliferation and survival of T-Rptor-/- cells in an allogenic-
mediated GvH response.  
(A) 10 x 106 CFSE-labeled T lymphocytes from pooled lymph nodes and spleen from 
CD45.1+ T-WT and T-Rptor-/- animals were transferred into either B6 (H-2b/b), bm1 
(H2Kb/bm1) or bm12 (H-2Ab/bm12) mice that have been injected with 20 µg anti-CD40 
antibody 24 hours before cell transfer. CFSE dilution of alloresponsive splenic T-WT 
and T-Rptor-/- cells was monitored five days post-adoptive transfer by flow cytometry. 
Results are shown for CD45.1+ donor cells only. Results are representative of five 
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independent experiments. (B) Average division number of proliferative-active 
transferred T cells was calculated as N = log2(gMFIctrl/gMFIsample). (C) The total number 
of transferred T cells was quantified in the spleens of the recipient mice. Statistical 
analysis was performed using Student‘s t-test with *: p<0.05, ** p < 0.01, *** p< 0.001. 
 
2.2 T-Rptor-/- cells proliferate slower and accumulate less in response to antigen 
We next tested an antigen-specific response to cognate antigen by monitoring the 
proliferation of AND CD4+ and OT-I CD8+ TCR transgenic T cells. Purpose of the 
experiment was to analyze proliferation and accumulation of T-WT and T-Rptor-/- cells 
in response to persistent antigen-presentation side by side under similar conditions at 
different time points during clonal expansion. 
Equal numbers of CFSE-labeled AND or OT-I T-WT and T-Rptor-/- cells isolated from 
six lymph nodes were co-transferred into either iMCC or iOVA mice, treated with 20 or 
40 µg anti-CD40 per mouse, respectively one day before transfer and 100 µg/mL 
doxycycline in the drinking water starting 24 hours before transfer until the end of the 
experiment (Fig. D2.2 A and E). Absolute T cell numbers and proliferation by the 
dilution of CFSE was monitored by flow cytometry over time (Fig. D2.2 B and F) and 
translated into average division numbers (Fig. D2.2 C and G). Upon 40 hours post-
transfer T-WT and T-Rptor-/- cells from AND or OT-I have started to proliferate, even 
though not all T-Rptor-/- cells have started their first division, yet. Whereas AND and 
OT-I T-WT cells display an average division number higher than three, T-Rptor-/- cells 
have not divided more than twice. Between 40 and 64 hours post-transfer, a further 
division has been detected every seven hours in AND and eleven hours in OT-I T-WT 
cells. In contrast, the division rate was two-times lower in T-Rptor-/- cells. Six days post-
transfer, T-WT cells have divided eight-times or higher, whereas T-Rptor-/- cells divided 
five-times in average. Moreover, the total number of transferred T-Rptor-/- cells per 
spleen was 50 to 90-fold reduced (Fig. 2.2 D and H).  
In summary, not only the first cell cycle entry in T-Rptor-/- cells appears to be delayed 
but also later divisions. In total, all T-Rptor-/- cells were able to divide, albeit slower, but 
show a hampered accumulation due to cell death.  
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Figure D2.2: Reduced proliferation rate and survival of TCR transgenic T-Rptor-/- 
cells in an antigen-specific response.  
(A, E) 1 x 106 CFSE-labeled AND (A-D) or OT-I T-WT and T-Rptor-/- cells from bulk 
lymph node cells were co-transferred into iMCC (A-D) or iOVA mice that have been 
treated with 40µg anti-CD40 antibody one day before transfer, respectively. The 
respective antigen-expression was induced by 100 µg/mL doxycycline in the drinking 
water from one day before transfer on until the end of the experiment. (B, F) CFSE 
dilution of transferred control (A) naïve (gray) AND T cells or  (E) OTI-/- as well as OT-
I+/+ T-WT (black) and T-Rptor-/- (blue) cells was monitored over time in the spleen by 
flow cytometry. Results are representative of three independent experiments. (C, G) 
Average division number of transferred T cells was calculated as N = 
log2(gMFIctrl/gMFIsample). (D,H) Total number of transferred T cells was quantified in the 
recipient spleen. Statistical analysis was performed using Student‘s test with *: p<0.05, 
** p < 0.01, *** p< 0.001. 
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2.3 T-Rptor-/- OT-I T cells expand less in response to transient TCR stimulation 
It has been published that a short antigen pulse is sufficient to induce clonal expansion 
of CD8+ T cells (Rabenstein et al., 2014). We asked if mTOR-deficient TCR transgenic 
OT-I T cells proliferate upon a transient TCR stimulus to the same extent as T-WT 
cells. Thus, naïve CD8+ T-WT, T-Rptor-/- and T-Rictor-/- cells were magnetically purified 
and primed in vitro for 48 hours and subsequently labeled with CFSE and separately 
transferred into B6 hosts. As positive control, in vitro primed OT-I T-WT cells were 
transferred into iOVA mice. Proliferation in the context of CFSE dilution was monitored 
three days later by flow cytometry (Figure D2.3 A). Upon stimulation, T-WT and T-
Rictor-/- cells divided up to five-times independent of antigen persistence. However, T-
Rptor-/- cells divided up to two-times upon transient TCR stimulation, indicating a 
reduced antigen-independent expansion in T-Rptor-/- cells (Figure D2.3 B, C). 
 
 
Figure D2.3: Impaired response to a transient antigen stimulus in OT-I T-Rptor-/- 
cells.  
(A) Experimental outline. Magnetically sorted CD45.1.1+ T-WT, T-Rictor-/- and T-Rptor-/- 
cells were cultured in the absence (condition 1) or presence of anti-CD3/CD28 for 48 
hours and subsequently labeled with CFSE. 2 x 106 cells were transferred into 
CD45.2.2+, cognate Ag-free (condition 1 and 2) or -expressing (condition 3) recipients 
and analyzed three days later. (B) Representative histograms of the CFSE dilution of 
congenically identified splenic AND and OT-I T cells. (C) The average division number 
N is calculated as N = log2(CFSE MFIctr/CFSE MFIsample). Results are representative of 
3-18 independent experiments. Statistical analysis was performed using Student‘s t-
test with *: p<0.05, ** p < 0.01, *** p< 0.001. 
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2.4 T-Rptor-/- cells expand and persist less in response to an infection with MVA-
OVA 
To investigate whether additional signals, such as virus-induced cytokine expression 
might benefit a proliferation in mTORC1-deficient T cells, the same numbers of OT-I T-
WT and T-Rptor-/- cells were co-transferred in recipient mice that had subsequently 
been infected with OVA-expressing Modified Vaccinia Ankara Virus (MVA-OVA) (Fig. 
D2.4 A). The expansion of T-WT and T-Rptor-/- cells was monitored side by side under 
equal conditions. MVA is known to preferentially target dendritic cells, with viral life 
cycle arrest before late gene expression, limiting the presentation of antigen to the 
turnover of the infected DCs and thus induced a short antigen pulse only. Furthermore, 
an infection with MVA-OVA is reported to induce CD8+ T cell activation and a 
differentiation into cytotoxicity T lymphocytes (Liu et al., 2008).  
By eight days post-infection, OT-I T-WT cells had expanded up to 38-fold in 
comparison to naïve OT-I cells transferred into uninfected mice. Also OT-I T-Rptor-/- 
cells had expanded, however three times less than T-WT cells. Five weeks post-
infection, OT-I T-Rptor-/- cells were only detected in half of all recipient mice. The 
accumulation was nine-fold reduced in mice that still had T-Rptor-/- cells. T-Rptor-/- cells 
showed a reduced response to MVA-OVA early and late after infection. Thus, the 
expansion and survival of T-Rptor-/- cells is impaired in response to an MVA-OVA 
infection. 
 
 
Figure D2.4: Reduced antigen-driven and homeostatic expansion and 
accumulation in response to MVA-OVA in OT-I T-Rptor-/- cells.  
(A) 0.1 x 106 OT-I T-WT and T-Rptor-/- cells were co-transferred (d-1) into B6 mice that 
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were infected with 5x107 TC ID50 i.v. 24 hours later (d0). (B) The total number of 
transferred T cells was quantified in the recipient lymph nodes on day 8 and day 36 
post-infection. Results are representative of three independent experiments, of which 
one was done without uninfected recipient mice. Statistical analysis was performed 
using Student‘s t-test with *: p<0.05, ** p < 0.01, *** p< 0.001. 
2.5 Lymphopenic-driven expansion is diminished in T-Rptor-/- cells 
It has been reported that T cells rapidly divide and persist in lymphopenic mice (Bell et 
al., 1987; Bruno et al., 1996; Kieper et al., 2001; McDonagh & Bell, 1995; Pereira & 
Rocha, 1991; Rocha et al., 1989; Sprent et al., 1991). We next tested the proliferative 
capacity of T-Rptor-/- cells under homeostatic conditions.  CFSE-labeled T-WT and T-
Rptor-/- cells were co-transferred into lymphopenic, RAG1-deficient hosts. RAG1-
deficient mice are not able to perform V(D)J recombination and thus B and T cell 
differentiation arrests at an early stage (Mombaerts et al., 1992). 
Five days post-transfer around 50% of all CD8+ T-WT but only 8% T-Rptor-/- cells have 
started to proliferate in the lymph nodes of the recipient mouse (Fig. D2.4). Hence 
demonstrating reduced proliferation capacity of T-Rptor-/- cells under homeostatic 
conditions in vivo. In agreement with Yang et al., 2013, T-Rptor-/- cells responded less 
to non-infectious, homeostasis-induced signals. Nevertheless, also T-WT cells only 
divided up to four-times in RAG1-/- mice, which is less than previously described. This 
could be due to environmental conditions in the animal facility of the Biomedical Center 
at the LMU, Munich. In agreement with others, we found diminished lymphopenic 
proliferation in T-Rptor-/- cells (Li et al., 2011; Rathmell et al., 2001; Yang et al., 2013). 
 
 
Figure D2.5: T-Rptor-/- cells proliferate less in RAG1-/- mice.  
(A) Co-transfer of 2 x 106 CFSE-labeled CD8+ T-WT (black) and T-Rptor-/- (blue) cells 
into RAG1-sufficient or deficient (black, blue) mice. CFSE dilution was monitored by 
flow cytometry five days post-transfer in the lymph nodes of the recipient mice. Results 
are representative of four independent experiments (B) The percentage of proliferating 
cells was quantified. Statistical analysis was performed using Student‘s t-test with *: 
p<0.05, ** p < 0.01, *** p< 0.001. 
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3 rRNA expression limits T cell proliferation 
In a proliferating cell, the biosynthetic demands are expected to be very high. It has 
been estimated that around 80% of the energy consumption is used for the synthesis 
of Ribosomes (Moss et al., 2007; Warner, 2001). Also in yeast, around 80% of 
nucleolar transcription is dedicated to the assembly of the translational machinery, in 
mammalian cell lines around 50% (Moss & Stefanovsky, 2002). Two studies in tumor 
cell lines have shown that the transcription of ribosomal DNA is regulated via an 
mTORC1-dependent phosphorylation of RNA Polymerase I specific transcription 
factors TIF-IA (Rrn3) and Ubf by S6K1 (Hannan et al., 2003; Mayer & Grummt, 2006). 
The aim of the following experiments was to establish a link between mTORC1-
dependent expression of RNA with clonal expansion in T cells. 
3.1 The expression of RNA Polymerase I subunits is mTORC1-dependent 
In 2017, Chi and colleagues performed total and phospho-proteomic experiments of in 
vitro stimulated T-WT and T-Rptor-/- cells (Tan et al., 2017a). To determine the 
expression of RNA Polymerase I subunits on protein level, the data generated in Chi’s 
lab were re-analyzed in this study in collaboration with Prof. Axel Imhof at the BMC. 
Upon stimulation with anti-CD3/28, an increase of the expression of RNA Polymerase I 
subunits was detected, while the expression of RNA Polymerase II subunits was high 
and independent of TCR stimulation. Furthermore, the expression of RNA Polymerase 
II subunits did not rely on mTORC1-signaling. In contrast, T-Rptor-/- cells showed lower 
expression levels of RNA Polymerase I subunits (Fig. D3.1). Thus, the increased 
expression of RNA Polymerase I subunits upon TCR stimulation was partially 
dependent on the activity of mTORC1. 
 
Figure D3.1: mTORC1-dependent increase of expression of RNA Polymerase I 
subunits.  
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Proteomic analysis of in vitro stimulated (anti-CD3/CD28) T cells at indicated time 
points. Data were retrieved from Tan et al., 2017 and analyzed by Prof. Axel Imhof, 
Core Facility Proteomics, Biomedical Center, Munich. Statistical analysis was 
performed using Student‘s t-test with *: p<0.05, ** p < 0.01, *** p< 0.001. 
 
3.2 TCR induced expression of total and ribosomal RNA is mTORC1 dependent -
quantity versus specificity 
To explore whether mTORC1 activity affects RNA Polymerase I mediated expression 
of rDNA only or also other RNA species, total RNA sequencing was performed as 
previously described (Westermann et al., 2016). MACS-purified CD4+ and CD8+ T-WT 
and T-Rptor-/- cells were stimulated with anti-CD3/28 in vitro for 48 hours and 
subsequently sorted to remove dead cells from the suspension (Gating strategy 
Supplementary Figure 4). Viable cells were discriminated as FVD780- and MFG8-GFP- 
and lysed in Trizol to purify RNA using RNeasy columns (Qiagen), including DNase 
treatment. A quantification of total RNA and 28S rRNA was performed by Dr. Fritz 
Thümmler at Vertis Biotechnology AG by two different methods and compared with 
sorter-determined cell numbers.  
The amount of RNA per cell increased 44-times in CD4+ and 26-times in CD8+ T-WT 
cells upon stimulation. T-Rptor-/- cells showed a 23-fold increase in RNA expression in 
CD4+ T cells and a 10-fold increase in CD8+ T cells, which was 2.6 to 2.8-times lower 
than in T-WT cells (Fig. 3.2 A). The amount of 28S rRNA was detected on quite similar 
levels as global RNA expression at around 0.5 µg per 105 cells, which indicates 
ribosomal RNA being the most common of all RNA species in the cell. Also among 
rRNA species, activated T-Rptor-/- cells show an approximately 2.5-fold reduced 
upregulation in comparison to T-WT cells (Fig. D2.3 B).  
cDNA libraries were generated from fragmented RNA and total RNA sequencing 
performed. Figure D3.2 C, D and Table 1 show the percentage distribution of all 
mappable RNA species. With around 83% of the mappable RNA reads belong to 45S 
and 5S ribosomal RNA in naïve CD4+ and CD8+ T-WT cells. Even though the amount 
of global and ribosomal RNA species increased upon stimulation, the relative amounts 
of the RNA species remained mostly unchanged. However, the proportion of mRNA 
increased slightly two-fold upon stimulation in CD8+ T-WT cells. In turn snoRNA 
dropped accordingly.  
In general, the reduced RNA expression following the activation of T-Rptor-/- cells 
observed before affected all RNA species to a similar extend.  
Ribosomes consist of 28S, 18S, 5.8S and 5S rRNA and approximately 92 proteins. 
First three rRNAs are processed from a common 47S precursor, which is expressed 
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from hundreds of genes by RNA Polymerase I, whereas 5S rRNA is synthesized by 
RNA Polymerase III (Moss et al., 2007; Warner, 2001). To compare 47S rRNA 
processing in activated T-WT and T-Rptor-/- cells, the expression levels of 28S, 18S 
and 5.8S rRNA were analyzed. No strong difference has been detected in T-WT and T-
Rptor-/- as well as T-Rictor-/- cells, hence showing no detectable influence of mTORC1 
and 2 activities on 47S rRNA processing (Fig. D3.2 E). However, the number of reads 
across the 47S rRNA is highly variable across the sequence, likely due to secondary 
structures interfering with primer ligation during cDNA synthesis. In addition, the spread 
within ETS and ITS is higher than within the 28S, 18S and 5.8S rRNA itself, indicating 
a higher variation in total 47S rRNA synthesis but not in processing of the ribosomal 
subunits (Fig. D3.2 E).  
Worth to mention, tRNA could not be mapped within this assay probably also due to 
secondary structures. Thus, other than RNA Polymerase I and II activity, RNA 
Polymerase III activity can hardly be accessed with this method. 
 
Number of mappable reads: 
 
Table D1: RNA type distribution in activated T-WT versus T-Rptor-/- cells.  
MACS-purified CD4+ and CD8+ T-WT or T-Rptor-/- cells were incubated in 96-well 
plates in vitro with 5 ng/mL IL-7 in the presence or absence of 10 µg/mL anti-CD3/28 
mAbs for 48 hours. Viable (FVD780-, MFG8-GFP-) cells were sorted and resuspended 
in Trizol. Total RNA was purified and fragmented using ultrasound. cDNA was 
synthesized and amplified with 12-15 PCR cycles. Illumina NextSeq sequencing was 
done of three independent experiments. Relative percentage of all detected RNA 
species with standard deviation are shown.  
 
 
stimulation 
T-WT T-Rptor-/- 
CD4+ CD8+ CD4+ CD8+ 
- + - + - + - + 
rRNA 83.300 ± 1.21 85.800 ± 2.68 84.300 ± 0.04 85.400 ± 1.56 82.700 ± 1.05 86.600 ± 0.87 83.900 ± 0.56 86.400 ± 1.10 
protein_coding 6.040 ± 1.23 7.900 ± 3.21 4.560 ± 0.61 8.360 ± 1.73 5.490 ± 1.24 5.570 ± 1.33 4.240 ± 1.02 6.040 ± 1.73 
snoRNA 3.770 ± 1.72 2.280 ± 0.51 5.390 ± 0.79 2.150 ± 0.72 4.410 ± 0.39 2.920 ± 0.51 5.600 ± 0.66 2.920 ± 0.65 
Mt_rRNA 3.530 ± 0.36 1.510 ± 0.18 2.380 ± 0.10 1.370 ± 0.22 3.120 ± 0.70 1.900 ± 0.28 2.070 ± 0.52 1.920 ± 0.50 
snRNA 1.880 ± 0.80 1.380 ± 0.25 2.100 ± 0.27 1.390 ± 0.23 2.890 ± 1.00 1.890 ± 0.28 2.840 ± 1.16 1.420 ± 0.33 
lincRNA 0.432 ± 0.03 0.534 ± 0.11 0.444 ± 0.00 0.777 ± 0.07 0.416 ± 0.07 0.497 ± 0,04 0.416 ± 0.03 0.659 ± 0.11 
misc_RNA 0.475 ± 0.03 0.230 ± 0.04 0.385 ± 0.04 0.242 ± 0.01 0.408 ± 0.09 0.276 ± 0.02 0.415 ± 0.07 0.291 ± 0.05 
miRNA 0.127 ± 0.03 0.124 ± 0.04 0.103 ± 0.01 0.116 ± 0.02 0.131 ± 0.05 0.131 ± 0.04 0.130 ± 0.07 0.142 ± 0.03 
scaRNA 0.237 ± 0.00 0.041 ± 0.01 0.226 ± 0.01 0.037 ± 0.00 0.232 ± 0.02 0.077 ± 0.01 0.250 ± 0.04 0.067 ± 0.00 
processed_transcript 0.035 ± 0.00 0.059 ± 0.01 0.028 ± 0.00 0.060 ± 0.00 0.035 ± 0.01 0.046 ± 0.00 0.029 ± 0.00 0.050 ± 0.00 
TEC 0.062 ± 0.02 0.026 ± 0.01 0.043 ± 0.01 0.026 ± 0.00 0.054 ± 0.01 0.037 ± 0.01 0.042 ± 0.00 0.035 ± 0.01 
antisense 0.046 ± 0.01 0.030 ± 0.01 0.033 ± 0.00 0.028 ± 0.00 0.041 ± 0.01 0.026 ± 0.00 0.032 ± 0.01 0.030 ± 0.01 
Mt_tRNA 0.009 ± 0.00  0.023 ± 0.01 0.011 ± 0.00 0.021 ± 0.00 0.012 ± 0.00 0.017 ± 0.00 0.011 ± 0.01 0.019 ± 0.01 
processed_pseudogene 0.019 ± 0.01 0.019 ± 0.01 0.014 ± 0.00 0.020 ± 0.01 0.018 ± 0.00 0.020 ± 0.01 0.017 ± 0.00 0.022 ± 0.01 
sense_intronic 0.007 ± 0.00  0.002 ± 0.00 0.005 ± 0.00 0.002 ± 0.00 0.006 ± 0.00 0.004 ± 0.00 0.004 ± 0.00 0.004 ± 0.00 
TR (V, D, J, C) 0.013 ± 0.00  0.007 ± 0.00 0.008 ± 0.00 0.007 ± 0.00 0.015 ± 0.00 0.006 ± 0.00 0.009 ± 0.00 0.005 ± 0.00 
D Results 
62 
 
Figure D3.2: Total RNA sequencing in activated T-WT versus T-Rptor-/- cells 
shows reduced global RNA expression in T-Rptor-/- cells.  
(A-D) MACS-purified CD4+ and CD8+ T-WT or T-Rptor-/- cells were incubated in 96-well 
plates in vitro with 5 ng/mL IL-7 in the presence or absence of 10 µg/mL anti-CD3/28 
antibodies for 48 hours. Viable (FVD780-, MFG8-GFP-) cells were sorted and 
resuspended in Trizol. Total RNA was purified and measured by (A) Qubit and (B) 
Shimadzu MultiNA microchip electrophoresis; n=1-4. (C, D) The RNA was fragmented 
using ultrasound, synthesized to cDNA and amplified with 12-15 PCR cycles. Illumina 
NextSeq sequencing was performed for three independent experiments. Relative 
percentage of all detected RNA species was plotted. (E) Expression level of processed 
45S rRNA (18S, 5.8S, 28S) was measured in stimulated T-WT (green), T-Rptor-/- (red) 
and T-Rictor-/- cells relative to unstimulated T cells. Statistical analysis was performed 
using Student‘s t-test with *: p<0.05, ** p < 0.01, *** p< 0.001. 
 
3.3 Visualization of RNA synthesis by flow cytometry  
To further analyze the expression of RNA in T-WT, T-Rptor-/- and T-Rictor-/- cells on a 
single cell level, a staining strategy for flow cytometry was established. RNA content 
was visualized in fixed and permeabilized cells applying the fluorescent xanthene dye 
Pyronin Y. It intercalates into double stranded nucleic acids, thus binding not only RNA 
but also enhances DNA staining. The interaction with DNA can be blocked by prior 
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staining with Hoechst, a dye only intercalating into DNA (Shapiro, 1981). In this thesis, 
the application of 4′,6-diamidino-2-phenylindole (DAPI) was used instead of Hoechst.  
DAPI allows assessing the cell cycle phases G0/G1, S and G2/M. 
Figure D3.3 A shows CD8+ T-WT cells cultured for 48h in vitro, subsequently PFA-fixed 
and methanol permeabilized and stained with Pyronin Y and DAPI. The Pyronin Y 
staining of naïve cells was very low. Upon stimulation with anti-CD3/28, the level of 
Pyronin Y increased 12-fold in comparison to unstimulated cells.  
To test whether Pyronin Y exclusively stained RNA and not DNA in this experimental 
setup, fixed and permeabilized cells were treated with RNAse before RNA and DNA 
staining. A treatment with RNAse had no effect on DNA staining levels, but remarkably 
reduced the level of Pyronin Y to a basal level (Fig D 3.3 A-C).  
To investigate the expression of RNA in vivo, TCR transgenic AND and OT-I T cells 
were either transferred into iMCC or iOVA mice treated with doxycycline. Cells from 
lymph node and spleen of the recipient mice were pooled 48 hours post-transfer and 
magnetically purified for either CD4+ or CD8+ T-WT cells in order to enrich the cells of 
interest for Pyronin Y staining. A staining with Pyronin Y increased five-fold in activated 
AND and OT-I T cells in comparison to cells transferred into antigen-free hosts. Thus, 
Pyronin Y can be used to assess RNA expression on a single cell level by flow 
cytometry in naïve and stimulated T cells (Fig D3.3 D, E).   
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Figure D3.3: RNA expression in single cells with Pyronin Y in vitro and in vivo.  
(A-C) MACS-purified CD8+ T cells were incubated in 96-well plates in vitro with IL-7 in 
the presence or absence of 10 µg/mL anti-CD3/28 antibodies for 48 hours. Fixed and 
permeabilized cells were treated with (C) or without (A, B) RNAse for 30 minutes at 
37°C. Cells were stained with DAPI (250 µg/mL) and Pyronin Y (625 µg/mL). Results 
are representative of 2-6 independent experiments (D, E) 1 x 106 congenically marked 
TCR transgenic AND and OT-I T cells were transferred into either iMCC or iOVA mice 
that have been pre-treated with 20 or 40 µg anti-CD40 mAb, respectively. Two days 
post-transfer, cells from lymph node and spleen were pooled and magnetically 
separated for either CD4+ or CD8+ T cells. The fixed and permeabilized CD4+ and CD8+ 
T cells were stained with DAPI and Pyronin Y in the same reaction tube and analyzed 
by flow cytometry. (B, E) The expression of Pyronin Y was quantified by the gMFI for 4-
6 independent experiments. Statistical analysis was performed using Student‘s t-test 
with *: p<0.05, ** p < 0.01, *** p< 0.001. 
 
3.4 RNA expression in T cells correlates with cell cycle entry – kinetics 
To further investigate the kinetics of RNA expression in T-WT cells, AND and OT-I T 
cells were stimulated in vitro for different periods of time and analyzed by flow 
cytometry. Even though TCR signaling was already seen four hours post-stimulation as 
visualized by the expression of Nur77-GFP (Moran et al., 2011) (Fig. D3.4 B), RNA 
expression was first detected after 24 hours, whereby OT-I T cells increased RNA 
levels up to 104-fold and AND T cells 74-fold (1.4 times lower than in OT-I T cells) in 
comparison to unstimulated cells. The RNA expression levels further increased up to 
48 hours and 72 hours post-stimulation in AND T cells and plateaued on a very high 
level in OT-I T cells. Cell cycle entry was determined as percentage of cells that had 
entered S/G2/M-phases. 24 hours post-stimulation less than 0.1% AND and ~20% OT-I 
T cells had entered the cell cycle. The number further increased upon ongoing 
stimulation up to half of the cells being found in S/G2/M-phases 72 hours post-
stimulation (Fig. D3.4 A and B). Cell cycle entry directly correlated with RNA 
expression patterns (Fig. D3.4 A). In addition, AND and OT-I T cells started to form 
blasts and upregulated the transferrin receptor CD71 regulated by the activity of 
mTORC1 (Zheng et al., 2007), with comparable kinetics (Fig. D3.4 B). Thus, RNA 
expression upon TCR stimulation correlates with cell blasting, cell cycle entry and 
mTORC1 activity in vitro. Since CD4+ and CD8+ T cells were different at their activation 
status 24 hours post-stimulation, further experiments were performed at 48 hours. 
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Figure D3.4: RNA expression in activated T cells over time.  
(A) MACS-purified CD4+ and CD8+ T cells were incubated in 96-well plates in vitro with 
5 ng/mL IL-7 in the presence or absence of 10 µg/mL anti-CD3/28 antibodies over 
time. After 48 hours of stimulation anti-CD3/28 was replaced by 10 ng/mL IL-2 in fresh 
T cell medium. Cells were incubated for further 24 hours. Fixed and permeabilized. 
CD4+ and CD8+ T cells were stained with DAPI (250 µg/mL) and Pyronin Y (625 
µg/mL) in the same reaction tube and analyzed by flow cytometry. Results are 
representative of three independent experiments. (B) The increase of FSC-A, Nur77-
GFP, Pyronin Y, DAPI and CD73 in unstimulated (gray) and stimulated (black) T cells 
plotted in histograms and (C) quantified as percentage of cells in the indicated gate or 
relative to naïve control for 3 independent experiments. Statistical analysis was 
performed using Student‘s t-test with *: p<0.05, ** p < 0.01, *** p< 0.001. 
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3.5 RNA expression in activated T-WT versus T-Rptor-/- and T-Rictor-/- cells 
The in this study established staining method with Pyronin Y was next used to visualize 
RNA expression in T-Rptor-/- and T-Rictor-/- cells. Magnetically purified CD4+ and CD8+ 
T-WT, T-Rptor-/- and T-Rictor-/- cells were stimulated with anti-CD3/28 in vitro for 48 
hours. CD4+ and CD8+ T cells were subsequently stained with Pyronin Y and DAPI 
together in the same tube. Upon stimulation CD4+ T-WT cells upregulated RNA 
expression up to 9-fold, CD8+ T-WT cells up to 12-fold in comparison to unstimulated 
cells. Accordingly, 45% of T-WT cells were detected in S/G2/M-phases. T-Rptor-/- cells 
showed a 2-fold lower upregulation of RNA. Nevertheless, 17% of CD4+ and 31% of 
CD8+ T-Rptor-/- cells were found in the S/G2/M stages. T-Rictor-/- cells even showed a 
~1.5 times higher expression of RNA than T-WT cells, with comparable if not slightly 
more cells in S/G2/M-phases (Fig. D3.5). In agreement with observations described in 
2.2, showing that TCR transgenic T-Rptor-/- cells could proliferate albeit slower upon 
transfer into antigen-presenting mice, T-Rptor-/- cells were able to enter cell cycle upon 
in vitro stimulation for 48 hours, but with a lower extend than T-WT cells. Furthermore, 
T-Rptor-/- cells were not able to upregulate RNA expression to the same extend as T-
WT cells. This indicates a defect in RNA upregulation in T-Rptor-/- but not T-Rictor-/- 
cells, which results in less cells in S/G2/M-phases. 
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Figure D3.5: RNA expression in activated T-WT versus T-Rptor-/- and T-Rictor-/- 
cells. 
(A) MACS-purified CD4+ and CD8+ T cells were incubated in 96-well plates in vitro with 
5ng/mL IL-7 in the presence or absence of 10 µg/mL anti-CD3/28 antibodies for 48 
hours. Fixed and permeabilized CD4+ and CD8+ T cells were stained with DAPI (250 
µg/mL) and Pyronin Y (625 µg/mL) in the same reaction tube and analyzed by flow 
cytometry. Results are representative of 3-6 independent experiments. (B) 
Quantification of gMFI or (C) percentage was calculated for 3-6 independent 
experiments. Statistical analysis was performed using Student‘s t-test with *: p<0.05, ** 
p < 0.01, *** p< 0.001. 
 
3.6 Differential translational activity in mTORC1-deficient T cells 
It is published that mTORC1 is crucial for the translation of a specific group of mRNAs, 
the 5’ TOP mRNA. 5’ TOP mRNAs mainly encode for proteins involved into RNA and 
protein synthesis as well as ribosomal assembly (Araki et al., 2017; Hukelmann et al., 
2016; Iadevaia et al., 2012; Tan et al., 2017a; Thoreen et al., 2012). In this study we 
found a significantly reduced expression of global and ribosomal RNA in T-Rptor-/- 
cells. We further tested whether this has an impact on the translational activity of 
activated T-Rptor-/- cells. 
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CD4+ T-WT and T-Rptor-/- were stimulated with anti-CD3/28 for 48 hours in vitro and 
metabolically labeled with the fluorescence-tagged methionine analogue L-
homopropargylglycine (L-HPG) for 30 minutes (Fig. D3.6 A). At this particular time 
point, a lack of mTORC1 did show a significant reduction of the translational activity in 
CD4+ T-Rptor-/- cells. Nevertheless, both T-WT and T-Rptor-/- cells increased their 
translational activity up to 80-fold and 70-fold upon stimulation, respectively. Thus, 
translational activity was not completely diminished but significantly reduced in 
mTORC1-deficient CD4+ T cells. This reduction can be due to the impaired translation 
of 5’ TOP mRNAs. The translational activity over time needs to be further investigated 
in CD4+ and CD8+ T cells.  Moreover, the effect on the abundance of total protein is not 
tested so far.  
 
 
Figure D3.6: Differential translational activity in CD4+ T-Rptor-/- cells.  
(A) Magnetically purified CD4+ T-WT (black) or T-Rptor-/- (blue) cells were incubated 
with 5 ng/mL IL-7 in the presence (black, blue) or absence (gray) of 10 µg/mL anti-
CD3/28 antibodies for 48 hours in vitro. The medium was replaced by L-Methionine 
free medium and incubated with Click-iT L-HPG for 30 minutes. Incorporated L-HPG 
was detected in fixed and permeabilized cells by chemoselective ligation (also known 
as click reaction) between azide and alkyne, where the alkyne-modified protein is 
detected with Alexa Fluor 488. (B) Incorporated Click-iT L-HPG –Al488 in unstimulated 
(gray) or stimulated WT (black) or T-Rptor-/- (blue) cells measured by flow cytometry. 
Results are representative of three independent experiments. (C) Geometrical 
intensities were quantified and normalized to the intensities of Al-488 in cells treated 
without Click iT L-HPG. Statistical analysis was performed using Student‘s t-test with *: 
p<0.05, ** p < 0.01, *** p< 0.001. 
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3.7 Drug-induced inhibition of RNA Polymerase I reduces the expression of RNA 
and limits cell cycle entry in vitro 
To further dissect which downstream targets of mTORC1 contribute to proliferation in T 
cells, an inhibition of RNA expression was induced with drugs interfering with the 
mTORC1-signaling pathway. Torin 1 is a very potent inhibitor of mTOR selectively 
inhibiting kinase activities of mTORC1 and 2 (Liu et al., 2012). Together with 2-deoxy-
D-glucose (2-DG), a glucose analogue which terminates glycolysis, it functioned as a 
positive control inducing a similar phenotype observed in T-Rptor-/- cells (Cham et al., 
2008). Tigecycline binds to 30S ribosomal subunits and therefore inhibits the activity of 
mitochondrial ribosomes (Skrtic et al., 2011). To inhibit the activity of RNA 
Polymerases I and II, actinomycin D and quarfloxin (CX-5343) were used (Bywater et 
al., 2012; Drygin et al., 2011; Perry & Kelley, 1970). Quarfloxin exclusively inhibits RNA 
Polymerase I and thus the synthesis of 47S RNA and actinomycin D the activity of both 
Polymerases in a dose dependent manner. Magnetically enriched CD4+ and CD8+ T-
WT cells were stimulated with anti-CD3/28 for 48h in the absence or presence of the 
named inhibitors with increasing doses. With very high doses of torin 1 and 2-DG, not 
only cell cycle entry and proliferation were blocked but also a ten- to twenty-fold 
reduction of RNA contends were detected in comparison to untreated activated T cells 
(Fig. D3.7 A and B). Furthermore, cell cycle entry, RNA expression, T cell blasting and 
proliferation were affected in a dose-dependent manner (Fig. D3.7 C-F). An inhibition 
with actinomycin D has shown similar patterns as torin 1 and 2-DG: a dose-dependent 
reduction of cell cycle entry, RNA expression, blasting and proliferation resulting in 
completely blocking of clonal expansion with very high doses. An inhibition of RNA 
Polymerase I activity alone with very high doses of quarfloxin, was also able to block 
proliferation and cell cycle entry but to a lesser extent than torin 1, 2-DG and 
actinomycin D. Furthermore, the highest inhibitor dose possible, merely showed a four-
fold reduction of RNA expression in comparison to untreated cells in CD4+ and a two-
fold reduction in CD8+ T cells, being in line with RNA expression levels in T-Rptor-/- 
cells (Fig. D3.7 A-F). Thus, an exclusive inhibition of RNA Polymerase I dependent 
rRNA synthesis by quarfloxin, was enough to phenocopy the RNA expression and cell 
cycle progression patterns of T-Rptor-/- cells. In contrast, even very high doses of 
tigecycline had no effect on global RNA expression and proliferation in stimulated T 
cells, as expected, since it only targets mitochondrial ribosomal RNA expression. Of 
note, CD4+ T cells were more susceptible to torin 1, 2-DG, actinomycin D and 
quarfloxin.   
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Figure D3.7: RNA Polymerase I inhibition in T-WT cells is sufficient to phenocopy 
RNA expression and proliferation patterns from T-Rptor-/- cells.  
(A-F) MACS-purified CD4+ and CD8+ T-WT cells were CTV-labeled and incubated in 
96-well plates in vitro with 5ng/mL IL-7 in the presence or absence of 10µg/mL anti-
CD3/28 antibodies for 48 hours with increasing levels of torin 1, 2-DG, actinomycin D, 
quarfloxin and tigecycline. Fixed and permeabilized CD4+ and CD8+ T cells were 
stained with DAPI (250 µg/mL), Pyronin Y (625 µg/mL) and for CD71 in the same 
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reaction tube and analyzed by flow cytometry. Pyronin Y was plotted against CTV (A) 
and DAPI (B) with (blue) or without (black) inhibitors in indicated concentrations. 
Results are representative of 3 independent experiments (C-F) Percentage of cells in 
S/G2/M-phases (C) gMFI of Pyronin Y (D) and FSC-A (E) as well as the average cell 
division number defined as N = log2(gMFIctrl/gMFIsample) (F) were monitored in CD4+ 
(line) and CD8+ (dashed) T cells; x-axes shown in log2 scale. Statistical analysis was 
performed using paired Student‘s t-test with *: p<0.05, ** p < 0.01, *** p< 0.001. 
 
4 Persistent RNA synthesis is required for T cell proliferation 
A previously published study by Yang and colleagues demonstrated that mTORC1 
activity is critical for the transition from quiescent G0 to S phase and becomes less 
important after cell cycle entry (Yang et al., 2013). The next experiment addressed the 
question if this is also true for RNA Polymerase I activity or if ongoing rRNA synthesis 
is required for cell cycle progression.  
To address this question, CD4+ and CD8+ T-WT cell were stimulated in vitro for 24 
hours (Fig. D4 A). Within this period, both cell types increased two-fold in size and 
showed a 6-fold upregulation of global RNA expression, indicating an exit from 
quiescence into G1 phase. Nevertheless, no proliferation was detected in CD4+ and 
CD8+ T cells 24 hours post-stimulation (Fig. D4 B, C). Next, 0.2 µM quarfloxin was 
added to stimulated cells for two more days (Fig D4 A). As shown in figure D3.7, an 
inhibition of RNA Polymerase I by quarfloxin was sufficient to fully diminish RNA 
expression and cell cycle progression, when added to the T cells at the time of 
activation. If administered 24 hours after an initial stimulation, global RNA expression 
and cell size was hardly affected in CD4+ and CD8+ T-WT cells. Nevertheless, 
proliferation was fully blocked in quarfloxin treated T-WT cells, whereas untreated cells 
were able to divide up to three-times within 72 hours. This indicates that other than 
mTORC1 activity, RNA Polymerase I induced rRNA expression is not only required 
early upon activation but also for continuous T cell proliferation.  
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Figure D4: Persistent RNA synthesis is required for T cell proliferation.  
(A) MACS-purified CD4+ and CD8+ T-WT cells were labeled with CTV and incubated in 
96-well plates in vitro with 5 ng/mL IL-7 in the presence or absence of 10 µg/mL anti-
CD3/28 antibodies for 72 hours. If indicated 0.2 µM CX-5343 was added 24 hours post-
stimulation. (B) Fixed and permeabilized CD4+ and CD8+ T cells were stained with 
Pyronin Y (625 µg/mL) in the same reaction tube and analyzed by flow cytometry. 
Results are representative of three independent experiments. (C) The gMFI of FSC-A 
and Pyronin Y as well as the average cell division number defined as N = 
log2(gMFIctrl/gMFIsample) was calculated. Statistical analysis was performed using 
Student‘s t-test with *: p<0.05, ** p < 0.01, *** p< 0.001. 
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5 T-Rptor-/- cells show a lower cell cycle progression with 
changed cell abundance in G0- and S-phase 
Cell cycle analysis was performed to dissect which cell phase was slowed down in T-
Rptor-/- cells. As described in 3.3, a DNA staining with DAPI can distinguish between 
G0/G1, S and G2/M-phase (Fig. D5 A). To clearly separate cells in G0 from cells that 
already have entered G1-phase an antibody specific for phosphorylated retinoblastoma 
protein at Serine 780 (pRb) was used. When phosphorylated, Rb induces G0 to G1 
transition. The detection of phosphorylated Histone H3 with fluorescently labeled anti-
H3P allows distinction of cells specifically in M but not G2 phase (Fig. D5 B). 
As already described in Figure D3.3, less T-Rptor-/- than T-WT cells have entered cell 
cycle upon in vitro stimulation with anti-CD3/28 for 48h (Fig. D3.3; Fig D5 A). With 40% 
CD4+ and 12% CD8+ T-Rptor-/- cells being detected in G0, half as many cells have left 
G0 in comparison to T-WT cells upon stimulation (Fig. D5 C). In contrast, similar levels 
of T-WT and T-Rptor-/- cells were detected in G1-phase. Between 40% and 50% of all 
stimulated cells can be found in this cell cycle phase. Furthermore, only minor but 
detectable differences have been observed in G2 and M phases. A significant 
disadvantage of T-Rptor-/- cells was observed in the S-phase of the cell cycle with three 
times less CD4+ (6.2%) and twice less CD8+ (11.6%) T cells in S-phase in comparison 
to T-WT cells. Hence, T-Rptor-/- cells showed a disadvantage in transitioning from G0 to 
G1 and G1 into S phase.  
 
 
Figure D5: Lower cell cycle progression in G0- and S-phase in T-Rptor-/- cells.  
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(A-C) MACS-purified CD4+ and CD8+ T-WT cells were incubated in 96-well plates in 
vitro with 5 ng/mL IL-7 in the presence or absence of 10 µg/mL anti-CD3/28 antibodies 
for 48 hours. Fixed and permeabilized cells were stained with DAPI (250 µg/mL) (A) 
and either pRb or H3P (B) and analyzed by flow cytometry. Results are representative 
of 3-6 independent experiments. (C) Percentage of cells in G0, G1, S, G2 and M were 
calculated as indicated in (B). Statistical analysis was performed using Student‘s t-test 
with *: p<0.05, ** p < 0.01, *** p< 0.001. 
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II Development of a mouse system to investigate CD8+ T cell 
development upon acute and chronic antigen presentation 
under sterile conditions 
1 Improved performance of iOVA by the Tet-repressor KRAB 
In order to improve the tools for the analysis of T cell responses to acute and chronic 
antigen-presentation under sterile conditions, a mouse system was developed that 
allowed inducing or withdrawing antigen-expression on MHC-I at defined time points. In 
the past, the termination of antigen-presentation could only be investigated in systems 
of bacterial infections by antibiotic treatment (Corbin & Harty, 2004; Williams & Bevan, 
2004). Furthermore, studies with chronic and acute strains of the lymphocytic 
choriomenengitis virus (LCMV) were performed to analyze the duration of antigen 
presentation on T cell development (Wherry et al., 2007). In these systems, a 
separation of the antigen stimulus from general inflammation is not necessarily 
possible. Thus in this work a doxycycline-inducible antigen expression system was 
developed that allowed a tuning of antigen-presentation on APCs and a separation of 
antigen-stimulus from inflammation.  
Previously, a doxycycline-inducible antigen expression system of an MHC-I restricted T 
cell antigen was developed in this laboratory (Rabenstein et al., 2014). Upon 
doxycycline treatment (100 µg/mL in drinking water), the tetracycline-transactivator 
converts into an active state and induces the expression of OVA257-264 in the context of 
H-2Kb. Adoptively transferred OT-I T cells recognize the peptide-MHC complex on 
APCs and start to expand (Fig. D6.1 A).  
As shown in figure D1 C and published in Rabenstein et al., 2014, CFSE-labeled OT-I 
T cells were able to proliferate extensively three days post-transfer into iOVA mice 
independent of doxycycline and the expression of the rtTAS2 (Rabenstein et al., 2014).  
To abolish this leakiness, iOVA mice were crossed to transgenic mice expressing the 
tetracycline-dependent repressor KRAB, generating iOVA-KRAB mice. KRAB is a 
fusion protein of the DNA binding domain of the tetracycline repressor from E. coli and 
the Krüppel-associated box (KRAB) domain of the human Kox1 zinc finger protein 
(Deuschle et al., 1995). It is expressed under the human phosphoglycerate kinase 
promoter and constitutively active in the absence of doxycycline (Barde et al., 2009). 
KRAB domains recruit histone deacetylases and histone methyltransferases and thus 
mediate a reversible transcriptional repression of target genes (Groner et al., 2010; 
Margolin et al., 1994). In the presence of doxycycline, the tetracycline-dependent 
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transrepressor will be inactivated and in turn the transactivator can bind and induce the 
expression of OVA257-264 on MHC-I (Fig. D6.1 B). The tight expression of the target 
antigen is demonstrated in figure D1 C by a five-fold reduction of OT-I T cells 
responding to peptide-MHC expression in the presence of KRAB. 
To further analyze the kinetics and time courses in which antigen-presentation can be 
turned on and off, 1 x 106 CFSE-labeled OT-I T cells were transferred into iOVA-KRAB 
mice. The administration of doxycycline (100 µg/mL) in the drinking water was started 
and stopped at different time points. T cell responses were monitored three days post-
transfer by the dilution of CFSE. Figure D1 D shows that a pre-treatment with 
doxycycline for one week was not enough to induce OT-I T cell proliferation. Rather a 
treatment of at least 14 days before transfer was necessary to induce proliferation in 
OT-I T cells. On the other hand, ten days were sufficient to withdraw antigen-
presentation in APCs and thus proliferation of OT-I T cells. This resulted in an 
experimental setup further described in figure D6.3. 
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Figure D6.1: The tet-repressor KRAB improves the performance of TSO 
expression. 
(A) Scheme of double transgenics for tetracycline-inducible epitope expression. To 
generate mice with controllable presentation of the H-2Kb/OVA257–264 complex, a 
transcriptional unit consisting of a signal sequence, the epitope, stop codons and a 
splicing substrate was put under the control of tet-responsive regulatory elements 
(TSO) and introduced into the germ line of B6 animals. This minigene targets the 
OVA257–264 peptide directly to the ER in a proteasome- and TAP- independent fashion 
and excludes indirect presentation of transferred OVA protein by other APCs. TSO+ 
founder animals were bred to the Ii-rTA line. iOVA offsprings displayed dox-inducible 
OVA257–264 presentation in vivo as evidenced by proliferation of CFSE-labeled OT-I TCR 
transgenic T cells. (B) The repressor KRAB (hPGK-tTRKRAB), which induces DNA 
methylation and H3K9me3 via KAP1 was crossed into iOVA mice, to diminish a dox-
independent expression of OVA257-264 on H-2Kb in iOVA mice. (C) 1 x 106 CFSE-labeled 
CD45.1.1+ OT-I TCR transgenic T cells were transferred into CD45.2.2+ iOVA recipient 
mice with genotypes as indicated. Responsiveness of T cells was measured by CFSE-
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dilution three days post-transfer. (D) Inducibility and leak tightness of the expression of 
the H-2Kb/OVA257–264 complex was tested. 1 x 106 naive CFSE-labeled OT-I T cells 
were transferred into iOVA-KRAB recipient mice treated with 100 µg/mL (gray box) or 
without (white box) doxycycline at time points and frames as indicated. CFSE dilution 
was detected by flow cytometry on three days post-transfer. 
 
2 Effector T cell generation in iOVA-KRAB mice 
We next tested if antigen-presentation in iOVA-KRAB mice is sufficient to induce 
effector cell development in OT-I T cells. Thus, 1 x 106 OT-I T cells were adoptively 
transferred into iMCC-KRAB mice pre-treated with 40 µg/mL anti-CD40 one day before 
transfer and tested five days later. The oral exposure of doxycycline to iOVA-KRAB 
mice started at least 14 days before cell transfer with doxycycline-containing food and 
was switched to 100 µg/mL doxycycline in the drinking water until the end of the 
experiment at the day of transfer. As negative control, OT-I T cells were transferred 
into antigen-free B6 hosts. To test the proliferation of OT-I T cells, cells were labeled 
with CFSE before transfer. Upon antigen-exposure in iOVA-KRAB mice, OT-I T cells 
divided approximately six times within five days. IFNγ and granzyme B expression was 
measured in OT-I T cells after restimulation with PMA and ionomycin in vitro. The 
expression of IFNγ was around twice as high in comparison to naïve OT-I T cells, the 
expression of granzyme B was only slightly increased. Furthermore, the killing capacity 
of OT-I T cells was tested. Splenocytes from B6 mice were pulsed with a high and low 
dose of Q4H7 peptide and subsequently labeled with different doses of CFSE and 
transferred into either B6 or iOVA-KRAB mice five days after OT-I T cells were injected. 
The clearance of antigen-pulsed APCs was analyzes one day later. Antigen-exposed 
OT-I T cells were able to remove APCs pulsed with high concentrations of antigen (1 
µg/mL) nearly completely and approximately one third of APCs pulsed with low doses 
of antigen were killed. Thus, OT-I T cells are able to develop into cytotoxic effector T 
cells in doxycycline-treated iOVA-KRAB mice. 
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Figure D6.2: Effector T cell generation in iOVA-KRAB mice. 
(A) 1 x 106 CD45.1.1+ OT-I TCR transgenic T cells were transferred into either 
CD45.2.2+ B6 mice or with doxycycline-treated (100 µg/mL in drinking water) iOVA-
KRAB mice. CFSE dilution, IFNγ and granzyme B expression were displayed by flow 
cytometry five days later. To test killing capacity of OT-I T cells five days post-transfer 
1 x 106 antigen presenting cells from spleen were pulsed with either 0.1 µg/mL, 1 
µg/mL or none Q4H7 peptide in vitro and labeled with medium, high or no dose of cell 
trace violet. Same amount of CD45.1.2+ pulsed cells were transferred into recipient 
mice. Killing capacity was measured one day after challenge with peptide-pulsed 
APCs. (B) Average division number of transferred T cells was calculated as N = 
log2(gMFIctrl/gMFIsample). Fold change of the geometrical MFI of cells stained for the 
specific antigen against isotype control was measured for IFNγ and granzyme B. The 
relative survival rate of peptide pulsed APCs was calculated. APCs transferred into B6 
mice are shown in black, those transferred in iOVA-KRAB mice in red. Survival rate 
was calculated in relation to the abundance of unpulsed APCs. 
 
3 Persistent antigen-exposure compromises memory formation 
in OT-I T cells  
To further investigate the effect of transient and persistent antigen exposure to OT-I T 
cells on memory formation, 1 x 106 OT-I T cells were adoptively transferred into 
recipient mice under three different conditions and analyzed four weeks later. Recipient 
mice were pre-treated with anti-CD40 (40 µg/mouse) one day before transfer. In 
condition one, OT-I T cells were transferred into antigen-free B6 mice not treated with 
doxycycline. In condition two, cells were transferred into iOVA-KRAB recipients treated 
with doxycycline-containing food for at least 14 days before transfer until the day of 
transfer and in condition 3 iOVA-KRAB recipient mice were additionally exposed to 
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doxycycline in the drinking water (100 µg/mL) until the end of the experiment starting 
on the day before transfer (Fig. D6.3 A). The surface expression of several activation 
markers was tested. A differential expression pattern was detected between transiently 
and persistently antigen-exposed OT-I T cells. 
Even though CD44 expression was comparably high in transiently and persistently 
treated OT-I T cells, the expression of CD62L was significantly reduced six-fold in 
persistently treated animals. Furthermore, the expression of Ly6C was reduced by half, 
CXCR3 six-fold and CD127 four-fold on persistently treated OT-I T cells. In addition 
CD73 expression decreased two- to three-fold. On the other hand persistently treated 
OT-I T cells monitored a significantly ten-times higher expression of CD69 and an 
approximately six-fold increased expression of PD-1 (Fig. D6.3 B). Next, cytokine 
expression was tested after restimulation with PMA and ionomycin in vitro. In OT-I T 
cells persistently exposed to antigen, the expression of IFNγ and TNFα were reduced 
five- and three-times, respectively (Fig. D6.3 C). In contrast to that, killing capacity was 
even slightly improved in persistently stimulated OT-I T cells (Fig. D6.3 D). Only slight 
differences in absolute T cell numbers were detected. This indicates, that a persistent 
antigen-exposure to OT-I T cells under sterile conditions can only partly compromise 
memory formation. 
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Figure D6.3 Persistent antigen-exposure to T cells partly compromises memory 
formation. 
(A) 1 x 106 CD45.1.1+ OT-I TCR transgenic T cells were transferred into either 
CD45.2.2+ B6 mice (naïve) or iOVA-KRAB mice treated with doxycycline (100 µg/mL) 
for at least 14 days before transfer (transient) or for at least 14 days post-transfer and 
beyond (persistent). Recipient mice were injected with 40 µg anti-CD40 i.p. one day 
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before transfer. (B) The expression of surface markers was displayed on day 30 post-
transfer in naïve (gray) transiently (blue) and persistently (red) stimulated OT-I T cells 
by flow cytometry. The fold change of the geometrical MFIs of antigen-treated against 
naïve OT-I T cells was calculated for CD44, CD62L, CXCR3, CD127 and PD-1 and for 
markers with a non-homogenous expression, the percentage of positively gated cells 
was determined (Ly6C, CD69 and CD73).  (C) On day 30 post-transfer, OT-I T cells 
were extracted from spleen and restimulated with PMA (10 ng/mL) and ionomycin (0.5 
µg/mL) in vitro and subsequently stained for IFNγ and TNFα (black) or their respective 
isotype controls (gray). Fold change was calculated by dividing the geometrical MFIs of 
the specific antibody to isotype control. (D) To test killing capacity of OT-I T cells 30 
days post-transfer 1 x 106 antigen presenting cells from spleen were pulsed with either 
0.1 µg/mL, 1 µg/mL or none Q4H7 peptide in vitro and labeled with medium, high or no 
dose of cell trace violet. Same amount of CD45.1.2+ pulsed cells were transferred into 
recipient mice. Killing capacity was measured one day after challenge with pepide-
pulsed APCs. The relative survival rate of peptide pulsed APCs was calculated. APCs 
transferred into transiently stimulated mice are shown in blue, those transferred in 
persistently treated mice in red. Survival rate was calculated in relation to the 
abundance of unpulsed APCs. Statistical analysis was performed using paired 
Student‘s t-test with *: p<0.05, ** p < 0.01, *** p< 0.001 
4 Establishment of an antigen-inducible latent virus in mice 
Gamma herpes viruses such as the Epstein bar virus (EBV) and the Karposi’s sarcoma 
virus (KSHV) can cause severe infections and are associated with lymphomas in 
immunocompromised patients. In healthy patients on the other hand these viruses can 
be found in B cells in a latent state, with having no effect on the host (Ganem, 1997; 
Schulz, 1998). Since OT-I T cells were only incompletely impaired in iOVA-KRAB mice 
upon persistent antigen-exposure, MHV-68 was tested with the future perspective of 
comparing it to iOVA-KRAB mice but under inflammatory conditions. The murine 
gamma herpes virus 68 (MHV-68) was developed as animal model of gamma herpes 
virus pathogenesis. Prof. Heiko Adler and colleagues cloned the MHV-68 genome as a 
bacterial artificial chromosome (BAC) in E. coli (Adler et al., 2000). In collaboration with 
his lab, a version of MHV-68 was developed carrying the sequence for OVA257-264 
under the control of the tet-operator, MHV-68_OVA. Upon the infection of mice 
expressing the tet-transactivator, ovalbumin can be expressed on MHC-I of infected 
cells. R26-rtTA x KRAB mice were tested as hosts under different conditions. In these 
mice, the reverse tet-transactivator (rtTAM2) gene locus is ubiquitously expressed under 
the Rosa 26 promoter (Hochedlinger et al., 2005). If treated with doxycycline, rtTAM2 
converts into its active form and induced the expression of genes under the control of 
the tet-operator (Fig. D6.4 A). 
In this experimental setup, 1 x 106 naïve OT-I T cells were labeled with CFSE and 
subsequently transferred into R26-rtTA mice, either carrying the Rosa-26-rtTA locus as 
one (R26wt/ki) or two (R26ki/ki) alleles or into mice negative for the transgene (R26wt/wt). 
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Host mice were infected with 2 x 105 PFU MHV-68_OVA one day later. Proliferation 
was tested three days after infection. No proliferation of OT-I T cells was detected in 
uninfected R26wt/wt mice. Upon infection, OT-I T cell proliferation was induced 
independent of the presence of doxycycline. This effect could be reduced by almost 
half in infected heterozygous R26wt/ki mice that additionally expressed the tet-
transrepressor KRAB. KRAB alone was not able to reduce the induction in R26ki/ki mice 
to the same extent, indicating that KRAB can only repress the expression of the 
peptide in the presence of low levels of rtTAM2. If treated with 100 µg/mL doxycycline in 
the drinking water from day 14 before infection on, a proliferation was induced in 
R26wt/ki as well as in R26ki/ki mice to an expand of approximately 80%. Thus, OVA257-264 
expression can be controlled by doxycycline in heterozygous R26-rtTA x KRAB mice 
infected with MHV-68_OVA, creating an inducible virus mouse model for challenging 
OT-I T cells, in vivo (Fig. D6.4 B). In the future, this virus can be used to study the 
effect of transient and persistent antigen-presentation on TCR transgenic OT-I T cells 
under inflammatory conditions side by side. So far this question could only be 
addressed by using different strains of the same virus such as the chronic and acute 
LCMV clone 13 and Armstrong in different doses (Wherry et al., 2003; Zajac et al., 
1998).  
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Figure D6.4 KRAB improves MHV-68_OVA performance in R26-rtTA-M2 x KRAB 
mice. 
(A) Scheme of MHV-68_OVA infected R26-rtTA-M2 x KRAB mice. In the presence of 
doxycycline, the ubiquitously expressed tet-transactivator can bind to the tet-operator 
on MHV-68_OVA and induce the expression of OVA257-263. In the absence of 
doxycycline, the tet-repressor KRAB binds to the tet-operator and inhibits the synthesis 
of OVA257-264. (B) 1 x 106 CFSE-labeled OT-I T cells were transferred into R26-rtTA-M2 
mice with different copy numbers of the tet-transactivator gene, positive or negative for 
KRAB. Mice were treated with doxycycline if indicated. One day later, mice were 
intravenously injected with 2 x 105 PFU MHV-68_OVA. CFSE-dilution of OT-I T cells 
was measured on day 3 post-infection. Gate was set on proliferating T cells.  
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E Discussion 
This study has shown a direct correlation between RNA Polymerase I activity and 
proliferation in T cells in an mTORC1 dependent manner. The upregulation of global 
and ribosomal RNA as well as proliferation was compromised in mTORC1-deficient T 
cells. In the course of this work, new techniques as well as in vitro and in vivo test 
systems were developed. 
1 TCR signaling increases mTORC1 activity 
The ligation of co-stimulatory receptors besides TCR triggering on a T cell is 
prerequisite for T cell activation. A lack of such signals results in anergy and thus 
dysfunction of a T cell (Jenkins, 1992; Schwartz, 2003). In several studies, mTORC1 
signaling became known as mediator of secondary signals necessary for productive T 
cell activation. mTORC1 is activated by the kinase Akt which in turn gets activated by 
PI3K. The activation of PI3K relies on co-stimulatory signals generated by CD28 and 
other amplifying signals such as IL-2 receptor signaling (Inoki et al., 2003b; Pollizzi & 
Powell, 2015; Tee et al., 2003; Zoncu et al., 2011). One of the described targets 
downstream of mTORC1 is S6 kinase beta-1 (S6K1). When phosphorylated and thus 
activated by mTORC1, it mediates the phosphorylation of the ribosomal protein S6 
(pS6). It has been shown that the stimulation of the TCR with anti-CD3/28 in vitro 
induces the phosphorylation of S6by S6K1 (Choo et al., 2008). In addition, the 
induction of mTORC1 signaling in response to weak TCR signals, e.g. in T cells 
deficient for the TCR signaling molecule Lck, was reduced, which points out that TCR 
signal strength directly corresponds to mTORC1 signaling (Tan et al., 2017b). Even 
though the phosphorylation of S6 is not required for T cell development, growth and 
antigen-dependent proliferation and differentiation, it is a reliable indicator of mTORC1 
activity (Salmond et al., 2015).  
In agreement with the current literature, our data showed an increased phosphorylation 
of S6 in T cells two hours after stimulation in vitro (Fig. D1.1A). Stimulation with anti-
CD3 or anti-CD28 alone was not sufficient to induce the same amount of response as 
both antibodies did in combination. This indicates two things: First, co-stimulation via 
CD28 alone is not sufficient to induce mTORC1 signaling and second, CD28 signaling 
has an amplifying effect on the signaling via the TCR. Yang et al. reported similar 
results: Two hours of stimulation with anti-CD3 alone were sufficient to induce pS6, but 
CD28 engagement was needed to remain this signal high at later time points such as 
E Discussion 
86 
four hours post-stimulation (Yang et al., 2013). Furthermore, the role of co-stimulation 
on a transcriptional level during T cell activation was investigated in in vitro stimulated 
CD4+ T cells in the absence or presence of co-stimulatory molecules such as CD28. 
Also in this study, CD28 signaling had merely an enhancing effect on gene expression 
in T cells induced by TCR signaling (Wakamatsu et al., 2013). To further investigate 
the supportive effect of co-stimulation on mTORC1 signaling, experiments with 
different doses of anti-CD28 together with anti-CD3 at different time points during early 
T cell activation need to be performed. Multiple receptors signal via mTORC1, among 
them is the IL-2 receptor (Rollings et al., 2018; Ross & Cantrell, 2018; Waickman & 
Powell, 2012). If mTORC1 activity is directly regulated by TCR signaling or also 
indirectly induced by IL-2 needs to be tested in further experiments using blocking 
antibodies against IL-2, IL-2R or in gene-ablated animals. 
In summary, TCR signals, in combination with co-stimulatory signaling via CD28 
affects the phosphorylation of targets downstream of mTORC1. 
 
We further tested S6 phosphorylation in mTORC1-deficient T cells. mTORC1 can be 
activated either directly via PI3K signaling or indirectly by Erk, Tsc1 and Rheb. 
Stimulation via Erk can be induced by PMA and ionomycin. In response to PMA and 
ionomycin, T-Rptor-/- cells display a reduced signaling (Fig. D1.1C). Nevertheless, the 
phosphorylation of S6 was not completely erased. Similar results were detected in 
iNKT cells, thymocytes and T cells by other groups (Shin et al., 2014; Yang et al., 
2013). It is likely that other pathways are responsible for the phosphorylation of S6 in 
Raptor-deficient T cells. Two candidates are the kinases Pim-1 and Pim-2. Both are 
described to mediate resistance to low-dose rapamycin treatment in T cells in vitro 
(Fox et al., 2005). Furthermore, a rapamycin-resistant S6 phosphorylation at S240/244 
induced by serum factors in a cell-cycle dependent manner in fibroblasts was reported 
(Rosner & Hengstschlager, 2010). 
In conclusion, mTORC1 activity, measured by the phosphorylation of S6, is 
significantly reduced in Raptor-deficient T cells. Residual pS6 could be detected, which 
is probably due to alternative pathways upstream of S6K1. 
2 Cell size increase is delayed in T-Rptor-/- cells 
When a T cell gets stimulated in vitro, it starts to increase in size within 24 hours, 
known as blast formation (Fig D3.4). As potent inhibitor of mTORC1 in mammalian 
cells, rapamycin is described to impair blast formation of T cells early upon activation 
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with anti-CD3/28 or cognate peptide. Similar findings were reported for T cells deficient 
for Raptor and thus mTORC1 activity and in wing cells of Drosophila (Pollizzi et al., 
2015; So et al., 2016; Terada et al., 1995; Yang et al., 2013; Zhang et al., 2000).  
In this thesis, T cells were activated in vitro with anti-CD3/28 for 48 hours and relative 
cell size was measured by flow cytometry using forward scatter as a surrogate 
parameter (Tzur et al., 2011).  We found that mTORC1-deficient T cells increased their 
size as mTORC1-sufficient T cells did at this time point (Fig. D1.2 A). Since most of the 
cell size measurements of other studies were performed 24 hours post-stimulation, and 
thus 24 hours earlier than done here, it is likely that the increase in cell size is not 
generally disrupted but delayed in mTORC1-deficient T cells: T-WT and T-Rptor-/- cells 
showed differential FSC-A patterns 16 hours post-transfer in an antigen-dependent 
GvH response in vivo (Fig. D1.2 C). 24 hours later, this difference was undetectable, 
with T-WT and T-Rptor-/- cells showing the same forward scatter. This is consistent with 
data showing that rapamycin-treatment was responsible for a delayed cell size 
increase in human T cells, measured by the presence of β-Tubulin and a delayed 
cyclin A expression, highly expressed in the G1/S-phase (Gelfand et al., 1995; Terada 
et al., 1995). Similar results were also obtained in S. cerevisiae (Barbet et al., 1996) 
and in mouse embryonic fibroblast (MEF) cells deficient for the transcription initiation 
factor IA (TIF-IA), a downstream target of mTORC1 regulating ribosomal RNA 
synthesis (Mayer et al., 2004). However, Yang and colleagues detected a lower size of 
T-Rptor-/- cells three days after transfer into mice that have been treated with peptide 
(Fox et al., 2005; Tan et al., 2017a; Yang et al., 2013). Nevertheless, the dose of 
peptide injected was not discussed in this study. Thus, lower doses of antigen could 
potentially lead to a higher delay in cell size increase, which could be overcome with 
high antigen-doses in T-Rptor-/- cells. Further experiments need to be performed testing 
the kinetic of blast formation in Raptor-deficient T cells. Also other methods to define 
the size of a cell need to be used to corroborate our results. Besides microscopy, the 
Coulter Counter is widely used to measure the cell size directly (Tzur et al., 2011). 
In summary, T cell blast formation was impaired upon T cell stimulation transiently in 
mTORC1-deficient T cells, indicating that mTORC1 regulates rapid cell size increase of 
T cells following stimulation. 
3 Proliferation of T-Rptor-/- cells is compromised in vivo  
Upon T cell activation, T cells must proliferate rapidly. Within this expansion phase, T 
cells show a high biosynthetic activity in which they have to replicate DNA, produce 
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proteins and generate membranes. mTORC1 is a mediator of these highly anabolic 
processes and thus profoundly associated with the proliferative capacity of T cells 
(Delgoffe & Powell, 2015) 
In this thesis, five different experimental setups were used to explore the role of 
mTORC1 in T cell proliferation.  
First, T-WT and T-Rptor-/- cells were adoptively transferred into H2-Kb/bm1 or H2-Ab/bm12 
heterozygous recipients to follow T-Rptor-/- cells in a graft-versus-host response. 
Alloreactive mTORC1-deficient T cells were not able to expand to the same degree as 
T-WT cells and fewer alloreactive (CFSElow) cells could be retrieved on day five after 
transfer. The responsive cells had divided 1.9 to 4.6 times on an average compared to 
approximately eight divisions of T-WT cells (Fig D2.1). In addition the mutant cells were 
lost due to apoptosis. These data are in agreement with another study performed with 
alloresponsive T cells from mice on the H-2b background. If transferred into either mice 
from H-2d or H-2b/d background, rapamycin treatment led to lower GvHD scores in all 
organs tested, lower serum cytokine levels and less glycolysis, allowing a correlation 
between mTORC1 activity and alloresponse but no direct causation. The same was 
true in Raptor- but not Rictor-deficient T cells (Nguyen et al., 2016). Nevertheless, no 
proliferation assays such as CFSE-dilutions were performed in this study. A second 
study addressed rapamycin-induced changes in Treg-mediated suppression of graft 
rejection. Upon transplantation of human internal mammary artery into immunodeficient 
BALB/c Rag2-/- Il2rg-/- mice injected with allogenic human PBMCs together with ex vivo 
expanded Treg cells, it was shown that rapamycin increased a Treg-mediated effect of 
less graft rejection by alloresponsive T cells (Hester et al., 2012). Similar results have 
been obtained after inhibition of Akt, which acts upstream of mTORC1 (Herrero-
Sanchez et al., 2016). In conclusion, the alloresponse of Raptor-deficient T cells was 
impaired due to less cell proliferation and accumulation upon activation. 
 
In a second experiment, polyclonal CD8+ T-WT and T-Rptor-/- cells were stimulated in 
vitro for 48 hours and subsequently transferred into antigen-free hosts. It has been 
reported that a short antigen pulse in a time frame of 48 hours is sufficient to fully 
activate CD8+ T cells and to induce proliferation even if antigen presentation does not 
continue (Rabenstein et al., 2014). In this study, T-Rptor-/- cells were not able to induce 
antigen-independent proliferation in CD8+ T cells (Fig D2.2, D2.1). This indicates an 
essential role for mTORC1 in maintaining proliferation in CD8+ T cells when antigen is 
cleared. 
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Next, antigen-specific proliferation of adoptively transferred AND and OT-I TCR 
transgenic T cell was tested in mice expressing MCC93-103 on MHC-II and OVA257-264 on 
MHC-I, respectively. Yang and colleagues had suggested that mTORC1 was only 
needed for leaving quiescence upon TCR stimulation or in other words that mTORC1 
activity is only needed for the first but not any further divisions. They tested it by 
stimulating T cells in vitro with anti-CD3/28 and added rapamycin at different time 
points after stimulation. If added 24 hours or later post-stimulation, cell cycle was not 
impaired as measured by BrdU incorporation and the DNA dye 7-AAD (Yang et al., 
2013). In vivo we found, T-Rptor-/- cells were not only delayed in cell cycle entry, but 
subsequent rounds of division were slowed down from approximately three to one 
divisions per day (Fig D2.3, D2.2). Furthermore, cell cycle analysis in activated T cells 
with the DNA staining dye DAPI and two antibodies binding pRb and H3P, 
phosphorylated in cells that have entered G1- or M-phases, respectively, confirmed this 
finding (Fig. D5). We detected that T-Rptor-/- cells are enriched in G0-phase and 
depleted in the S-phase of the cell cycle, whereas the percentage of cells in G1-, G2- 
and M-phases remained unchanged. We also found that the RNA Polymerase I 
inhibitor quarfloxin not only blocks cell cycle entry if added at the beginning of 
stimulation, but also at later time points, indicating that RNA Polymerase I activity, just 
like mTORC1, is necessary not only for the first cell division but also later on (Fig. D4).  
In summary, our data indicate that a constant activity of mTORC1 and its downstream 
target RNA Polymerase I are necessary for T cell proliferation, in vivo and in vitro. 
 
We next investigated how mTORC1 sufficient and deficient T cells respond to a viral 
infection. OT-I TCR transgenic T cells were adoptively transferred into mice that were 
subsequently infected with a Modified Vaccinia Ankara virus expressing Ovalbumin 
(MVA-Ova). MVA-OVA preferentially infects dendritic cells with viral life cycle arrest 
before late gene expression, limiting the presentation of antigen to the turnover of the 
infected DCs and thus induces a short antigen pulse only (Liu et al., 2008). 
The response to MVA-OVA was reduced in mTORC1-deficient T cells, which resulted 
in lower effector and memory T cell numbers (Fig. D2.4). Thus, an additional cytokine 
induction by the infected environment could not improve a T cell response to antigen in 
comparison to antigen-presentation alone. These results are in agreement with data 
demonstrating that T cells deficient for the mTORC1-activator Rheb proliferated less in 
response to Vaccinia infection in vivo (Delgoffe et al., 2011). Nevertheless, a short 
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inhibition of mTORC1 by low-dose rapamycin could improve memory formation in CD8+ 
T cells and induce iTreg cell differentiation in CD4+ T cells, indicating a differential 
outcome of partial and transient mTORC1 inhibition (Araki et al., 2009; Haxhinasto et 
al., 2008; Nguyen et al., 2016). In conclusion, mTORC1-deficient T cells expand less in 
response to MVA-OVA. 
We also found that on day 36 post-transfer, T-Rptor-/- cells were lost in half of the 
uninfected recipient mice under steady-state conditions, indicating a defect in 
homeostatic survival (Fig. D2.4).  
 
To further address homeostatic expansion of mTORC1-deficient T cells, a fifth 
experimental setup was used. Polyclonal T-WT and T-Rptor-/- cells were transferred 
into lymphopenic RAG1-deficient hosts to monitor lymphopenic proliferation. No 
proliferation was detected in mTORC1-deficient T cells (Fig D2.5). Similar results were 
reported on Raptor-deficient cells transferred into lethally irradiated mice (Li et al., 
2011; Rathmell et al., 2001; Yang et al., 2013). Whether the signals inducing 
mTORC1-dependent proliferation in lymphopenic mice and  in homeostasis are the 
same, was not investigated so far. However, it is known that the two cytokines IL-7 and 
IL-15 are important for homeostatic survival of memory cells under non-inflammatory 
conditions. Both are reported to induce mTORC1 signaling and thus could be essential 
for lymphopenic proliferation (Ali et al., 2015; Li et al., 2011; Marzec et al., 2008; 
Rathmell et al., 2001; Sowell et al., 2017). IL-7 is essential for lymphopenic proliferation 
of effector cells, as tested in IL-7-deficient OT-I T cells (Schluns et al., 2000). Further 
experiments in IL-15R or IL-7R deficient T cells need to be performed to test whether 
these signaling pathways are connected to mTORC1 and thus proliferation. 
In summary, proliferation of mTORC1-deficient T cells was impaired in lymphopenic 
hosts. 
 
Taken together, mTORC1 signaling was found to be essential for T cells to proliferate 
in vivo under five conditions: GvH reactions, responses to transient and persistent TCR 
stimuli, a viral infection and in lymphopenic hosts. 
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4 RNA Polymerase I-induced rRNA expression can be linked 
with T cell proliferation 
4.1 mTORC1 controls RNA Polymerase I expression 
The synthesis of rRNA is likely to put the highest energetic demands on proliferating T 
cells (Moss et al., 2007; Warner, 2001). mTORC1 is described to regulate the 
phosphorylation and thus activation of two transcription factors associated with RNA 
polymerase I, which catalyzes the synthesis of ribosomal DNA (Hannan et al., 2003; 
Mayer & Grummt, 2006). An analysis of data published by the laboratory of Hongbo 
Chi revealed an mTORC1-dependent upregulation of RNA Polymerase I subunits on 
protein level, which are necessary for the transcription of ribosomal RNA upon TCR 
stimulation (Fig. D3.1 and Tan et al., 2017). The data also show that ribosome 
biogenesis and translation heavily depend on mTORC1 (Tan et al., 2017a). mTORC1 
regulates the activity of RNA Polymerase I but also II and III, which mediate the 
transcription of mRNA and tRNA, respectively (Iadevaia et al., 2012).  
Nevertheless, a direct effect of mTORC1 on RNA Polymerase II subunit expression 
was not shown so far (Fig. D3.1). Thus, it is more likely that the effect of mTORC1 is 
mediated via the translation of specialized mRNAs, the so-called 5’ TOP mRNAs, 
encoding ribosome biogenesis genes. Moreover, a disruption of upstream signals of 
mTORC1 such as glucose uptake, had no effect on RNA Polymerase II recruitment to 
DNA, indicating that mTORC1 does not regulate RNA Polymerase II activity via the 
influx of metabolites such as glucose (Finlay et al., 2012). The regulatory effect of 
mTOR on RNA Polymerase III was only tested in S. cerevisiea, worms, flies and tumor 
cell lines so far (Filer et al., 2017; Kantidakis et al., 2010; Mayer et al., 2006). Mayer 
and colleagues pointed out in more detail that mTOR regulates TIFIIIB, a transcription 
initiation factor binding to RNA Polymerase III (Mayer & Grummt, 2006; Mayer et al., 
2006). 
It is described that the regulatory effect of mTORC1 on RNA Polymerase I operates at 
least via the activation of TIF-IA and upstream binding factor (UBF), two transcription 
factors associated with the activity of RNA Polymerase I. Furthermore, rapamycin 
treatment of activated T cells altered the phosphorylation of TIF-IA. The consequences 
were lower pre-RNA levels but not necessarily 28S RNA, which indicates that RNA 
processing might not be affected (Claypool et al., 2004; Hannan et al., 2003; Hardwick 
et al., 1999; Mahajan, 1994; Mayer et al., 2004; Zaragoza et al., 1998). Furthermore, 
the phosphorylation of the CDK2-Cyclin E complex, which kinase activities induces the 
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phosphorylation of TIF-IA at Ser44 during G1 to S-phase transition, was altered. Thus, it 
is likely that mTORC1 regulates TIF-IA via this cyclin complex (Mayer et al., 2004). 
In summary, mTORC1 signaling is necessary for the upregulation of RNA polymerase I 
on protein levels as well as proteins associated with ribosomal biogenesis upon 
stimulation of the TCR, which affects the translational activity in T cells. 
4.2 mTORC1 is necessary for global RNA upregulation 
To further address the question of how mTORC1 shapes total and ribosomal RNA 
expression, the composition of all RNA species, except tRNA and thus RNA 
polymerase III activity, in activated T cells was measured by total RNA sequencing. 
Due to secondary structures formed by tRNAs the accessibility of the linker sequence 
was blocked, which interfered with cDNA synthesis. In a second approach, global RNA 
expression was detected on the single cell level by flow cytometry. In combination, 
both techniques showed a reduced expression of all RNA species in mTORC1-
deficient T cells (Fig. D3.2, Fig. D3.5).  
Total RNA sequencing revealed that 83-87% of all RNA species of a T cell could be 
assigned to rRNA, independent of stimulation or mTORC1 activity. Furthermore, 
mTORC1 deficiency did not cause any changes in the abundance of other RNA 
species. This indicates high activity of RNA polymerase I on the one hand and 
mTORC1 as regulator not only of the expression of RNA polymerase I transcribed 
rRNA but also RNA species expressed by RNA polymerase II on the other hand. 
Nonetheless, mRNA levels were slightly reduced in mTORC1-deficient activated T 
cells (Fig. D3.2). The major demand RNA Polymerase I activity puts on T cells can be 
assessed by the high abundance of its product, the rRNA in comparison to mRNA 
(4.8%). 
We further tested whether mTORC1-disruption affects rRNA synthesis only or also 
processing or rRNA to functional ribosomes. A previous study showed that different 
inhibitors of signaling molecules involved in rRNA synthesis can either interrupt rRNA 
transcription or 47S RNA processing (Burger et al., 2010). For instance actinomycin D, 
an inhibitor of RNA Polymerase I at low concentrations and II activity at high 
concentrations, was rather responsible for a reduced rRNA synthesis in human 
sarcoma cell lines instead of 47S rRNA processing (Bensaude, 2011; Burger et al., 
2010). The same effect was reported upon rapamycin treatment (Burger et al., 2010). 
In this thesis, no differential expression of 28S, 18S and 5.8S rRNA was detected in 
WT and mTORC1-deficient T cells, indicating that mTORC1 likely regulates the 
expression of pre-rRNA by RNA Polymerase I instead of inducing its processing (Fig. 
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D3.2 E). In addition, direct inhibition of RNA Polymerase I with quarfloxin and 
actinomycin D interfered with RNA expression and proliferation of activated T cells, 
pointing towards a direct correlation between RNA Polymerase I activity, rRNA 
synthesis and T cell expansion. Since pre-rRNA processing was not affected in 
mTORC1-deficient T cells, formation of fully functional ribosomes should be possible. 
Further investigation regarding the translation in mTORC1-deficient T cells has to be 
performed. 
Taken together, we found that mTORC1 disruption affects RNA polymerase I and II-
dependent transcription, while 47S rRNA processing was not impaired in mTORC1-
deficient T cells. 
4.3 T cell proliferation can be linked to RNA synthesis 
The biosynthesis of ribosomes is essential to sustain and duplicate translational activity 
in a proliferating cell. This highly energy-demanding process is described to be 
regulated by mTORC1 at least via its downstream targets TIF-IA and Ubf, two 
transcription factors required to be phosphorylated for the activity of RNA polymerase I 
and thus rRNA synthesis (Claypool et al., 2004; Hannan et al., 2003; Mayer et al., 
2004; Tan et al., 2017a). Furthermore, it is known that mTORC1 signaling is crucial for 
T cell proliferation (Delgoffe et al., 2009a; Delgoffe et al., 2009b; Delgoffe et al., 2011; 
He et al., 2011; Tan et al., 2017a; Tan et al., 2017b; Yang et al., 2013; Zeng et al., 
2013; Zhang et al., 2011). We found that T-Rptor-/- cells proliferate slower and are more 
prone to die in vivo (Fig. D2.2). In addition, inhibitors of RNA Polymerase I were used 
to document their effect on proliferation and RNA synthesis. We detected that not only 
the direct inhibitor of mTOR, Torin 1 or the inhibition of glycolysis by 2-DG affected T 
cell proliferation upon in vitro stimulation with anti-CD3/28, but also the inhibition of 
mRNA and rRNA synthesis by quarfloxin and actinomycin D. We found that an 
inhibition of RNA polymerase I by quarfloxin and thus rRNA synthesis exclusively was 
sufficient to block T cell proliferation in vitro (Fig. D3.7). In addition, RNA expression 
levels as well as blast formation and cell cycle entry was impaired to comparable levels 
as detected in mTORC1-deficient T cells, indicating that RNA polymerase I inhibition 
could phenocopy the effect of mTORC1-deficiency in these parameters (Fig D3.5, 
D3.7). An inhibition of mTOR or glycolysis as well as of RNA polymerase I and II 
showed more drastic effects on cell cycle entry and proliferation than mTORC1-
deficiency and inhibition of RNA polymerase I alone (Fig. D3.5, D3.7). This could 
indicate, that T cell proliferation is not exclusively regulated by mTORC1 and rRNA 
expression but also other signaling pathways associated with mTOR fuel into potent T 
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cell expansion. It is likely that mTORC1 and RNA synthesis regulate the division speed 
and cell survival in proliferating T cells, not only for quiescence exit but also for ongoing 
proliferation, as discussed in detail in chapter E 3. If there is a direct correlation 
between mTORC1 signaling via TIF-IA and UBF, rRNA synthesis and proliferation has 
not been investigated so far in T cells.  
 
In addition we saw that DNA synthesis was not fully impaired by mTORC1 disruption, 
indicating that low levels of newly synthesized RNA are enough to induce entry into the 
cell cycle (Fig. D3.5). Whether a T cell needs to reach a certain threshold of RNA 
content to start proliferating or if the signal generated by RNA expression is 
proportional to T cell proliferation is not clear. We found that T-WT cells that have been 
treated with inhibitors against mTORC1 signaling components show a direct correlation 
between RNA expression and cell cycle progression, suggesting direct correlation 
between RNA expression and proliferation (Fig. D3.7). Cao and colleagues have 
published a similar connection in T cells treated with 2-DG, an inhibitor of glycolysis 
(Cao et al., 2014). In summary, we found a direct correlation between T cell 
proliferation and RNA expression. 
 
We next tested whether lower levels of rRNA due to mTORC1-deficiency had not only 
an effect on T cell proliferation but also translation. It was recently published that the 
translation of 5’ TOP mRNA is enhanced in an mTORC1-dependent manner in T cells 
(Araki et al., 2017). 5’ TOP mRNAs mainly encode for proteins associated with 
ribosome formation and translational initiation as well as T cell effector function 
(Thoreen et al., 2012). Furthermore, rapamycin has an impact on overall protein 
synthesis and specifically the translation of 5’ TOP mRNAs is affected by mTORC1 
inhibition (Iadevaia et al., 2012; Terada et al., 1995). We found that the translational 
activity was impaired in mTORC1-deficient CD4+ T cells 48 hours post-stimulation in 
vitro. Further experiments need to be performed addressing the translation activity in 
CD8+ T cells. Data on the kinetics of the translational initiation and activity need to be 
generated in vitro and in vivo to provide clear interpretations for the role of mTORC1 on 
both. 
In summary, we have described a direct effect of RNA Polymerase I inhibition on T cell 
proliferation comparable to observations made in mTORC1-deficient T cells. 
Consequently, the translational activity in mTORC1-deficient T cells was impaired in 
vitro.  
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Ribosomal RNA has additional functions besides translating mRNA into protein. Newly 
synthesized rRNA is organized in subnuclear structures called nucleoli, providing a 
niche for several regulatory molecules to bind. This study showed that a persistent 
synthesis of rRNA is needed to maintain proliferation in T cells, since T cells treated 
with the RNA polymerase I inhibitor quarfloxin 24 hours post-initial stimulation were not 
able to enter the cell cycle and start to proliferate (Fig. D4). Impaired mTORC1 activity 
led to an enrichment of T-Rptor-/- cells in G0 and to fewer cells in S-Phase after 48 
hours of in vitro stimulation with anti-CD3/28 (Fig. D5). Similar results were reported on 
TIF-IA-deficient cells, a downstream target of mTORC1, that regulates RNA 
Polymerase I activity (Yuan et al., 2005). The cell cycle is regulated by the up- and 
downregulation of different cyclins. TIF-IA depleted cells have decreased levels of 
cyclin A and E, but not D1 and p27. On the other hand p130, which is highly expressed 
in quiescent cells and a known inhibitor of RNA polymerase I and p21, an inhibitor of 
cyclin dependent kinases, is increased (Ciarmatori et al., 2001; Rubbi & Milner, 2003; 
Yuan et al., 2005). This indicates that T cells impaired in rRNA expression are not able 
to leave quiescence properly and if so die upon failed transition into S-Phase. A major 
apoptotic inducer is the tumor suppressor p53. Previous studies demonstrated that 
TIF-IA inactivation leads to an interaction of MDM2, a negative regulator of p53, with 
ribosomal proteins such as L11 instead of binding to rRNA in the nucleolus, thus 
disrupting its inhibitory function. Hence, p53 is stabilized and genes involved in 
apoptosis could be activated (Yuan et al., 2005). In this study, rRNA expression had a 
direct effect on the cell cycle of T cells. Several questions still remain to be clarified. It 
is not clear yet whether RNA Polymerase I has a direct effect on cyclin expression or if 
they are regulated via the nucleolus exclusively. Furthermore, the relation between 
RNA and DNA synthesis has to be investigated. In activated T-WT cells, DNA and 
RNA are synthesized in direct proportion to one another in cells in S-phase and the 
transition to S-Phase requires RNA Polymerase I release from DNA (Smirnov et al., 
2016). Thus, an inhibition of RNA Polymerase I can have different outcomes 
depending on which cell cycle phase a cell is in.  
Taken together, we have found a direct correlation between ongoing RNA Polymerase 
I activity and thus rRNA synthesis and T cell proliferation after in vitro stimulation. This 
process relies on mTORC1 and has either a direct or indirect effect on the expression 
of all other RNA species detectable in our experimental setup.  
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5 Differences between CD4+ and CD8+ T cells 
Even though developed side by side in the thymus, antigen-recognition, diversity and 
effector functions are very different in CD4+ and CD8+ T cells. Our lab has recently 
shown that besides above-mentioned differences, CD4+ and CD8+ T cells depend 
differently on persistent antigen presentation with CD4+ T cells only being able to 
proliferate when antigen is presented continuously (Rabenstein et al., 2014). 
In this thesis, we found that CD4+ and CD8+ T cells show different kinetics regarding 
their increase in size, RNA expression and cell cycle entry upon in vitro stimulation, 
whereby CD4+ T cells appear to be slower in all three points. Among CD8+ T cells, a 
peak of RNA expression was reached by 24 hours post-stimulation. In CD4+ T cells it 
was delayed to 48 hours post-stimulation. The same was true for blast formation and 
cell cycle entry (Fig. D3.4). In addition, CD4+ T cells tend to show a reduced division 
velocity in vitro but not in vivo (Fig D3.7; Fig. D2.2). Previously published microarray 
analysis of in vitro stimulated CD4+ and CD8+ T cells showed only few differences in 
their protein-coding RNA, despite their obvious functional differences (Mingueneau et 
al., 2013; Rabenstein et al., 2014), indicating that rather translation than transcription 
may be differentially regulated in CD4+ and CD8+ T cells. The group of Rafi Ahmed 
showed that translation is actively regulated in an mTORC1-dependent manner by the 
content of polysomes and monosomes. They described that effector gene mRNAs and 
5’ TOP mRNAs are mainly bound by polysomes, during CD8+ effector T cell 
differentiation (Araki et al., 2017). Whether CD4+ and CD8+ T cells harbor a differential 
content of monosomes and polysomes needs to be tested in further experiments, in 
order to clarify differential translational activities in those two cell subsets.  
Moreover, in experiments using increasing doses of inhibitors interfering with the 
mTORC1 signaling pathways we found that CD4+ T cells are more susceptible to 
metabolic inhibitors and are more affected regarding their cell cycle entry, increase in 
size and RNA expression by mTORC1-deficiency, thus indicating a higher dependence 
on mTORC1 signaling (Fig. D3.7, Fig. D3.5) (Cao et al., 2014). Nevertheless, in vivo 
proliferation assays were not able to support these findings, indicating that the 
differences found in vitro are potentially harder to detect in vivo. To overcome this 
problem, changes in medium as well as the addition of cytokines such as IL-2 need to 
be tested regarding proliferation and cell survival. This might reveal the influence of 
signal strength on cell survival in mTORC1-compromised T cells (Fig. D3.5). 
Taken together, differences observed between CD4+ and CD8+ T cells regarding RNA 
expression, blast formation, cell cycle entry, proliferation and susceptibility to metabolic 
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inhibitors might be induced by suboptimal stimulation conditions in vitro and could not 
corroborate in vivo.  
6 Role of mTORC2 on RNA synthesis, stability and T cell 
proliferation 
The role of mTORC2 in proliferating T cells is not very well established. It was shown 
that mTORC2 binds to actively translating ribosomes (Oh et al., 2010). If this directly 
regulates RNA synthesis as well as proliferation is unknown. If anything, in vitro 
stimulated mTORC2-deficient T cells showed a higher expression of global RNA (Fig. 
D3.5). This could point to a direction that mTORC2 acts as a negative regulator on 
RNA synthesis and thus proliferation.  
7 Technical challenges and benefits 
7.1 Pyronin Y in flow cytometry 
RNA synthesis is a major component of biosynthesis in activated T cells. mTORC1 is 
described to regulate rRNA synthesis, which makes approximately 83-87% of a T cells 
RNA. At least in yeast and tumor cell lines, ribosome synthesis has been described as 
being essential for translational activity and expansion (Claypool et al., 2004; Hannan 
et al., 2003; Mayer et al., 2004).  
Thus, assessing RNA content in T cells is important for studying cell growth and 
differentiation. In the early eighties Pyronin Y was first used to visualize RNA content 
by flow cytometry. Plotted against the DNA dye Hoechst it enabled the analysis of 
mainly the G0- and G1-phases of the cell cycle (Kim & Sederstrom, 2015; Shapiro, 
1981). Since than Pyronin y was frequently used to study cell cycle in proliferating T 
cells (Behbehani et al., 2012; Challen et al., 2009; Crissman et al., 1985; Cui et al., 
2003; Janumyan et al., 2003; Nakamura-Ishizu et al., 2014; Qiu et al., 2013; Schmid et 
al., 2000). In more recent studies, Pyronin Y was used to measure total RNA 
abundance in thymocytes (Mingueneau et al., 2013).  
Several challenges had to be overcome regarding the usage of Pyronin Y. Since 
Pyronin Y intercalates into double stranded nucleic acid it thus not only stains RNA but 
also DNA. To fully avoid a staining of DNA by Pyronin Y, all DNA binding sites were 
saturated by previous incubation with the DNA-only binding dye DAPI. In order to avoid 
technically induced differences between samples, the same amount of cells was 
stained in the same reaction tube if possible (Fig. D3.3).  
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With this technique we found a nine- and twelve-fold increase of global RNA 
expression in CD4+ and CD8+ T-WT cells upon stimulation in vitro for 48 hours, 
respectively, which was two-fold reduced in mTORC1-deficient T cells (Fig. D3.5). A 
second way to measure RNA concentrations is based on fluorescence, since RNA has 
an absorption maximum at a wavelength of 260nm. Like RNA measurements based on 
gel electrophoresis (detecting 28S and 18S rRNA), no evaluation on a single cell level 
is possible. Both techniques were performed in this thesis. Purified RNA from in vitro 
stimulated T cells was measured with the Qubit RNA HS Assay from thermofisher 
(fluorescence-based) and Shimadzu MultiNA microchip electrophoresis 
(electrophoresis-based). With both techniques a higher increase in RNA content upon 
stimulation was detected in T cells upon stimulation (44-fold in CD4+ and 26-fold in 
CD8+ T cells), which was 2.6-fold reduced in Raptor-deficient T cells (Fig. D3.2). There 
is a discrepancy in comparison to data generated with Pyronin Y. This can be due to a 
lower accessibility of RNA to Pyronin Y dye in fixed cells compared to absorption by 
quantified RNA in a buffer. The reduced amount of RNA in mutant cells was 
nevertheless detectable.  
Pyronin Y allowed the visualization and measurement of relative RNA expression on a 
single cell level in small, unstimulated versus stimulated T cells. The detected RNA 
mostly visualized ribosomal RNA, since in T cells, 83-87% of RNA belonged to this 
species (Fig. D3.2). It allowed studying the effect of drugs interfering with TCR and 
mTOR signaling on RNA expression in the context of the cell cycle with promising 
applications in the future.  
7.2 mTORC1 signaling inhibitors  
mTOR was first discovered in yeast as target of the toxin rapamycin an antifungal and 
antibiotic product by Streptomyces hygroscopicus. It was described to block the 
transition from G1 to S phase in fungi (Heitman et al., 1991; Singh et al., 1979). Since 
than, many inhibitors interfering with mTOR signaling have been successfully tested as 
cancer treatment drugs. Nevertheless, many of them showed low success in the clinic 
(Saxton & Sabatini, 2017).  
In this study, in vitro application of the inhibitors 2-DG (target: glycolysis), quarfloxin 
(CX-5461) (target: RNA Polymerase I), torin 1 (target: mTORC1 and mTORC2), 
actinomycin D (target: RNA Polymerase I and II) and tigecycline (target: mitochondrial 
ribosome synthesis) were used to further dissect signaling molecules involved in 
mTORC1 signaling, that are essential for RNA synthesis and proliferation. By this, the 
selective RNA polymerase I inhibitor quarfloxin resulted in reduced RNA content and 
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impaired cell cycle entry, which was found to resemble the phenotype described in 
mTORC1-deficient T cells (Fig. D3.7).  
Nevertheless, results obtained from in vitro drug treatment of stimulated T cells have 
their limits regarding their comparability to mTORC1-deficiency. One example is the 
conclusion drawn in several studies regarding the role of mTORC1 in T cell memory 
development. Results from transiently treated T cells with low-dose rapamycin 
(mTORC1-inhibitor) in vitro, showed a beneficial differentiation to memory T cells (Araki 
et al., 2009; Pearce et al., 2009; Rao et al., 2010). In this thesis we found that long-
term accumulation was impaired in mTORC1-deficient T cells upon viral infections (Fig. 
D2.4). Similar results were obtained in vaccine-induced CD8+ T cells treated 
persistently with high doses of rapamycin (Li et al., 2012).  
Since mTOR is a highly conserved molecule in diverse cells of multiple organisms, a 
treatment with mTORC1 signaling inhibitor drugs has systemic effects on plethora of 
immune cells (Saxton & Sabatini, 2017). Nevertheless, many inhibitors of the mTORC1 
pathway, such as quarfloxin already found usage in clinical studies to impair cancer 
cell proliferation (Bywater et al., 2012; Cargnello et al., 2015). In vivo applications of 
this inhibitor in mice can be used to study possible side effects in human cancer 
treatment. Our results raise concerns regarding quarfloxin since adaptive immune 
responses would be transiently hampered. 
Furthermore, in vitro experiments using mTORC1-inhibitors in different doses can be 
used to allow a very broad screening of many targets of the mTORC1 signaling 
cascade, to give a first insight into key players responsible for physiological changes in 
T cells. This allows a more efficient selection of interesting targets to study in 
conditional knock-out mice in vivo. 
In conclusion, combined studies of mTORC1-deficient T cells and inhibitor-treated WT 
T cells are necessary to fully reveal the mechanism underlying mTORC1-dependent 
RNA synthesis and proliferation. 
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8 KRAB in a tet-inducible system 
Comparative studies performed in 2014 by Rabenstein et al. used tetracycline-
inducible antigen-expression systems to directly compare antigen-dependency in CD4+ 
and CD8+ T cells. One limitation faced was a residual OVA257-264-MHC-I expression in 
iOVA mice: OT-I T cells did not only proliferate in doxycycline-treated recipients but 
also in untreated mice (Fig. D6.1) (Rabenstein et al., 2014). To overcome “leakiness” in 
their study, T cell priming was performed in vitro before a transfer into either antigen-
free or antigen-expressing hosts (Rabenstein et al., 2014). In this thesis, the use of on 
additional transgenic tetracycline-dependent repressor carrying the Krüppel-associated 
box (KRAB) in iOVA transgenic mice was investigated to develop a system, which 
allowed for in vivo priming of TCR transgenic OT-I T cells with transient and persistent 
antigen-presentation. The KRAB zinc finger protein acts as transcriptional repressors. 
In 1995, a fusion protein consisting of the KRAB domain of human Kox1 and the tet-
repressor from Tn10 of E. coli was developed (tTR-KRAB). This fusion protein could 
bind to the tet-operator in the absence of doxycycline and repress gene transcription by 
inducing histone modifications via the KRAB-associated protein 1 (KAP1). It was 
shown in HeLa cells that KRAB was released within two days of doxycycline treatment 
(Deuschle et al., 1995). The same was shown in HEK293T cells transduced with a tTR-
KRAB-carrying lentivirus (Barde et al., 2009). The same lentivirus was used to 
generate mice transgenic for an ubiquitously expressed tTR to transduce KRAB-
expression in mice an thus repression of gene expression, but only two conditions 
were tested in mice up to that point: doxycycline-treatment from the same time point of 
transduction on or no doxycycline-treatment at all. In this course they showed that 
doxycycline treatment induced the expression of a reporter gene under the control of 
the tet-operator (Barde et al., 2009).  
In mouse cell lines it was shown that KRAB activity was not reversible if active during 
embryonic development (Wiznerowicz et al., 2007). We thus wanted to know whether 
the same is true in iOVA mice. Therefore, iOVA mice were crossed to rTA-KRAB 
expressing mice generated in Barde et al., 2009 (Barde et al., 2009). Breedings were 
treated with doxycycline-containing food to avoid irreversible binding of KRAB to the 
tet-operator controlled expression cassette of OVA257-264. This thesis demonstrated that 
other than in HeLA and HEK293T cells, KRAB release from the tet-operator takes at 
least two weeks (versus two days in cell lines) of doxycycline treatment in the drinking 
water. Thus the expression of tet-operator controlled genes is slower in mice than in 
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cell lines. Nevertheless, if doxycycline treatment was started at least two weeks before 
transfer of OT-T cells, T cell priming was successful (Fig. D6.1). 
Turning off antigen-expression in iOVA-KRAB mice took at least ten days of treatment 
with doxycycline-free water and food (Fig. D6.1). In iMCC mice, in which the 
expression of MCC93-103 is regulated within the tet-operator and induced via doxycycline 
treatment, it has been shown that the half-life of doxycycline is around 24 hours. 
Antigen-expression in this system is blocked within at least 48 hours (Obst et al., 
2005). Thus it is likely that not doxycycline availability but rather epigenetic changes 
mediated by the KRAB domain are the reason for the extended time of reversibility of 
KRAB inhibition in iOVA-KRAB mice. The reversible activity of KRAB in iOVA mice 
allowed a comparative analysis of antigen-persistence versus antigen-withdrawal after 
in vivo priming. We found that the introduction of KRAB and thus a transient antigen-
exposure to OT-I T cells allowed for the expression of memory-associated surface 
molecules such as CD127, CXCR3 and Ly6C 30 days post-transfer (Fig D6.3). The 
expression of these molecules was reduced by persistent antigen-presentation in mice 
constantly treated with doxycycline (Fig. D6.3). Thus, an introduction of KRAB into 
iOVA mice could improve the performance of controlled antigen-expression in a 
doxycycline-dependent manner. 
In a second approach an MHV-68 virus variant expressing OVA257-264 under the control 
of the tet-operator was developed in collaboration with the group of Prof. Heiko Adler at 
the Helmholtz Research Center for Environmental Health. MHV-68 is a latent gamma 
herpes virus infecting mainly B cells in mice. In this study MHV-68_OVA was tested in 
R26-rtTA mice, which constitutively and ubiquitously express the reverse tet-
transactivator. If treated with doxycycline, rtTA can bind to the tet-operator and induce 
gene expression of any reporter locus (Hochedlinger et al., 2005). If infected with MHV-
68_OVA, viral antigen-expression was detected by the proliferative response of 
transferred OT-I T cells independent of the expression of the rtTA or doxycycline. To 
improve the controllability of this system, the KRAB transgene mentioned before was 
crossed into the R26-rtTA mouse line. In the presence of KRAB, the “leaky” expression 
of OVA257-264 could be reduced by half in mice heterozygous for the R26-rtTA locus. 
Thus in the course of this thesis a doxycycline-inducible peptide-expressing virus was 
generated which enables cognate antigen-expression to OT-I mice in vivo.  
Taken together, the expression of the tetracycline-controllable transrepressor KRAB 
could enable a controllable expression of OVA257-264 not only in iOVA mice but also in 
MHV-68_OVA and thus improve a doxycycline-dependent antigen expressing system 
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in mice and on a recombinant, latent virus. With this approach, it was shown that 
persistent antigen-presentation compromises memory development in CD8+ T cells. 
 
9 Outlook 
This study showed a direct correlation between ribosomal RNA expression and 
proliferation in activated T cells in an mTORC1-dependent manner.  
It is still unclear which signaling molecules downstream of mTORC1 initiate RNA 
Polymerase I activity. It is likely that the two transcription factors UBF and TIF-IA are 
inducing RNA Polymerase I activity. Whether S6 and/or 4E-BP1, two targets of 
mTORC1, are regulators of those transcription factors still needs to be tested. 
Conditional knockout mice, lacking these four molecules in combination with 
techniques developed in this thesis, could allow a further insight into their role on RNA 
expression as well as proliferation.  
Additionally, gain-of function experiments with lentiviral vectors expressing RNA 
Polymerase I subunits, can be used to test if a phenotype of reduced RNA expression 
and proliferation can be reversed in mTORC1-deficient T cells in vitro.  
Moreover, pulse-chase experiments could give answer to the question at which phase 
of the cell cycle mTORC1 is essential. The two nucleotide analogues EdU and BrdU 
can be used to test this. Both can be integrated into DNA during the S-phase of the cell 
cycle. Applied at two different time points after in vitro stimulation of T cells, the 
duration of cell cycle progression can be measured in WT and mTORC1-deficient cells 
(Weber et al., 2014; Clarke et al., 2017).  
Since the nucleolus of T cells plays a major role in regulating cell cycle and survival, a 
visualization of this sub-compartment could give information of differences in size and 
shape in relation to cell size in WT and mTORC1-deficient T cells. Antibodies against 
the nucleoli-associated protein fibrillarin could be used to image nucleoli (Quin et al., 
2016).  
 
Furthermore, the background expression of OVA257-264 in iOVA mice as well as on the 
virus MHV-68_OVA could be abrogated by the expression KRAB. This approach can 
be used to further investigate the effect of persistent and transient antigen-expression 
on memory T cell development under non-inflammatory conditions in direct comparison 
to viral infections.  
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F Abbreviations 
  
2-DG 2-deoxy-D-glucose  
4E-BP1 Eukaryotic translation initiation factor E4 
5’ TOP 5' terminal oligopyrimidine tract 
AMP Adenosin monophosphate 
AMPK AMP-activated protein kinase 
APC Antigen presenting cell 
ATP Adenosine triphosphate 
BAC Bacterial artificial chromosome  
Bcl6 B-cell lymphoma 6 protein 
BrdU Bromodesoxyuridine 
CD Cluster of differentiation 
CDK Cycline-dependent kinases 
CFSE Carboxyfluorescein succinimidyl ester 
CLIP Class II-associated invariant chain peptide 
CMV  Cytomegalovirus 
Cre Causes recombination 
cTEC Cortical thymus epithelial cell 
CTL Cytotoxic T Lymphocyte 
CTLA-4 Cytotoxic T-lymphocyte-associated-protein 4 
CTV Cell trace violet 
DAPI 4′,6-diamidino-2-phenylindole  
DC Dendritic cell 
DEPTOR DEP-domain containing mTOR-interacting protein 
DFC Dense fibrillar centers 
DN Double negative 
DNA Desoxyribonucleic acid 
dNTPs Deoxynucleotide 
DP Double positive 
e.g. Exempli gratia - for example 
EBV  Epstein-Barr virus 
EDTA Ethylenediaminetetraacetic acid 
EdU 5-ethynyl-2-deoxyuridine 
eIF  Elongation initiation factor 
ER Endoplasmatic reticulum 
FACS Fluorescence-activated cell scanning 
FAO Fatty acid oxidation 
FC Fibrillar centers 
FCS Foetal calf serum 
FLCN Folliculin 
Flp  Flippase 
FNIP FLCN-interacting protein 
FoxP3 Forkhead box P3 
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Frt  Flippase recognition target 
FSC-A Forward scatter area 
FVD Fixable viable dye 
GAP GTPase-activating protein 
GC Grnular components 
GEF Guanosine triphosphate exchange factor 
gMFI Geometrical mean fluorescence intensity 
GTP Guanosine triphosphate 
GTP   Guanosine-5’-triphosphate 
GvHD  Graft-versus-Host Disease 
H3 Histone 3 
HLA Human leukocyte antigen 
IFN Interferon 
Ig Immunoglobulin 
Ii  Invariant chain 
IL Interleukin 
ITAM Immunoreceptor tyrosine based activating motif 
KAP1 KRAB-associated protein 1 
Kox1 Zinc finger protein 10 
KRAB Kruppel associated box 
KSHV  Kaposi’s sarcoma-associated herpesvirus 
L-HPG L-Homopropargylglycine 
LAG-3 Lymphocyte-activation gene 3 
LAT Linker of Activated T cells 
LCK Lymphocyte-specific protein tyrosine kinase 
LCMV Lymphocytic choriomeningitis virus 
loxP  Locus of X-over P1 
M-Phase Mitose phase 
mAb Monoclonal antibody 
MAPK Mitogen activated protein-kinase 
MCC Moth cytochrome c 
MEF Mouse embryonic fibroblasts 
MFI Mean fluorescence intensity 
mg  Milligram 
MHC Major Histocompatibility Complex 
MHV-68 Murin Gammaherpesvirus 68 
mL Milliliter 
mLST8 Mammalian lethal with SEC13 protein 8 
mM  Millimolar 
MPEC Memory precursor effector cell 
mRNA messengerRNA 
mSin1 Mammalian stress-activated protein kinase [SAPK]-interacting protein 
mTEC Medullar thymus epithelial cell 
mTOR mammalian/mechanistic target of rapamycin 
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mTORC1 mammalian/mechanistic target of rapamycin complex 1 
mTORC2 mammalian/mechanistic target of rapamycin complex 2 
MVA Modified vaccinia ankara 
NFAT Nuclear factor of activated T-cells 
NFkB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
ng  Nanogram 
NK cells Natural Killer cells 
NKT Natural killer T cell 
OVA Ovalbumin 
OXPHOS Oxidative Phosphorylation 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PDCD4  Programmed cell death protein 4 
PDK1 Phosphoinositide-dependent kinase-1 
PFA  Paraformaldehyd 
PI3K Phosphoinoside 3-kinase 
Pim-1/-2 Proto-oncogene serine/threonine-protein kinase 
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
PKB Protein kinase B 
pMHC Peptide bound to MHC 
PRAS40  Proline-rich AKT substrate 1 
PRR Pattern recognition receptor 
R26 Rosa-26 
RAG Recombination-activating gene 
Raptor Regulatory-associated protein of mTOR 
Rb Retinoblastoma protein 
rDNA Ribosomal DNA 
RHEB Ras homolog enriched in brain 
Rictor Rapamycin-insensitive companion of mammalian target of rapamycin 
RNA Ribonucleic acid 
Rorγ RAR-related orphan receptor gamma 
ROS Reactive oxygen species 
Rrn3 RNA polymerase I-specific transcription initiation factor 3 
rRNA Ribosomal RNA 
rtTA Reverse tetracycline-responsive transactivator 
rtTA  Reverse tetracycline-controlled transcriptional activation 
S-Phase Synthesis phase 
S6K1 p70 S6 kinase 1 
SLC38A9 Sodium-coupled neutral amino acid transporter 9 
SLEC Short-lived effector cells 
SREBP  Sterol regulatory element-binding protein 
T-bet T-box transcription factor 
TAE Tris-acetate-EDTA 
TAP Transporter associated with antigen processing 
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TAP  Transporter associated with antigen processing 
TCR T cell receptor 
tet Tetracycline 
tetO Tetracycline operator 
tetR Tetracycline repressor 
Texh Exhausted T cell 
TFEB Transcription factor EB 
Tfh T follicular helper cell 
TGF Tumor Growth Factor 
Th cell T helper cell 
Thr Threonine 
TIF-IA Transcription initiation factor IA 
TIFIIIB Transcription initiation factor IIIB 
Tmem Memory T cell 
TNF Tumor necrosis factor 
Treg Regulatory T cell 
TRIS Tris(hydroxymethyl)aminomethane 
tRNA Transfer-RNA 
TSC Tuberous sclerosis 
tTA Tetracycline-controlled transcriptional activation 
UBF Upstream binding factor 
ULK1  Unc-51 like autophagy activating kinase 
UV Ultra violet 
Wnt  Wingless/integrated 
WT  Wildtype 
ZAP70 Zeta-chain-associated protein kinase 70 
µg  Microgram 
µl  Microliter 
µM  Micromolar 
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I Gating strategies 
 
Supplimentary figure 1: Gating Strategie Figure D1.1  
 
 
Supplementary figure 2: Gating strategy Figure D1.1, D1.2, D3.2, D3.3A, D3.4, D3.5, 
D3.6, D3.7, D4, D5  
Pre-stimulation with anti-CD3/28 (A) Activity. (B) MACS purity 
 
 
Supplementary figure 3: Gating strategy Figure D1.1, D1.2, D3.3A, D3.4, D3.5, D3.6, 
D3.7, D4, D5 
Post-stimulation with anti-CD3/28  
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Supplementary figure 4: Gating Strategy Figure D3.3B 
Pyronin Y staining ex vivo (A) pre-transfer Day 0 (B) post-transfer and MACS 
purification Day 2 
 
 
Supplementary figure 5: Gating Strategy Cell Sort Figure D3.2. 
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Supplementary figure 6: Gating Strategie Figure D2.1 
(A) Pre-transfer; (B) Day 5 post-transfer 
 
 
Supplementary figure 7: Gating strategy Figure D2.2. 
Pre-transfer activity and TCR (A) AND; (B) OTI 
Day 5 post-transfer (C) AND; (D) OTI 
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Supplementary figure 8: Gating strategy Figure D2.3. 
(A) Pre-transfer; activity and TCR  (B) Day 8/36 post-transfer  
 
 
Supplementary figure 9: Gating strategy Figure D2.4. 
(A) Pre-transfer activity; (B) Day 5 post-transfer 
 
 
Supplementary figure 10: Gating Strategie Figure D6.1, D6.2, D6.3, D6.4 
(A) Pre-transfer; (B) Post-transfer 
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Supplementary figure 11: Gating Strategie Figure D6.2, D6.3 
Killing assay 
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II MHV-68_OVA 
 
Supplementary figure 12: MHV-68_OVA. 
Schematic map of the MHV-68_OVA genome with TSO expression cassette inserted 
at 46 kb between ORF27 and ORF29b. TSO encodes a minigene combination of 
OVA257-264 and the signal sequence of H2-Kb, which mediates a translation into the 
endoplasmatic reticulum. This fusion is followed by two stop codons and the human 
growth hormone splice substrate, required for efficient expression. The expression of 
OVA257-264 is under the control of an improved tetracycline response element, which 
allows the transactivator molecule to bind on opposite sites of the DNA. 
 
0        10       20       30      40       50       60       70      80       90      100     110       kb       
46 
ORF27 ORF29b 
7 tetO / CMVshort 
ORF27 ORF29b TSO 
ss 
OVA257-264 (H-2Kb) 
hGH 
